var title_f24_57_25488="Pancoast tumor MRI III";
var content_f24_57_25488=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F75753&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F75753&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pancoast tumor on MRI",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 314px; height: 337px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Coronal T1-weighted image shows a right-sided Pancoast tumor with vertebral destruction (arrow).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_57_25488=[""].join("\n");
var outline_f24_57_25488=null;
var title_f24_57_25489="Patient information: Tuberculosis (The Basics)";
var content_f24_57_25489=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?38/35/39475\">",
"         Patient information: Tuberculosis (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Tuberculosis (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/tuberculosis-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H537472211\">",
"      <span class=\"h1\">",
"       What is tuberculosis?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Tuberculosis is an infection that usually affects the lungs. It is not very common in the United States. But in other parts of the world, tuberculosis is still a serious problem. Tuberculosis is sometimes called &ldquo;TB.&rdquo;",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H537472218\">",
"      <span class=\"h1\">",
"       How does TB spread?",
"      </span>",
"      &nbsp;&mdash;&nbsp;You can catch tuberculosis from anyone who is sick with TB. The germ that causes TB can travel in the tiny drops of fluid that spray when a person coughs or sneezes. If you inhale those drops, you can get infected.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H537472225\">",
"      <span class=\"h1\">",
"       What happens if I get infected with TB?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If you get infected with TB, you probably will not get sick right away. Instead one of two things might happen:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Your body's infection fighting system, called the immune system, might kill off the germs that cause TB. If that happens, you will not get sick with TB.",
"       </li>",
"       <li>",
"        Your body's immune system might be able to control the germs but not completely kill them off. This is called &ldquo;latent TB.&rdquo; People with latent TB do not get sick right away, but they can get sick later on. People who are sick with TB have what doctors call &ldquo;active TB.&rdquo;",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H537472232\">",
"      <span class=\"h1\">",
"       What are the symptoms of active TB?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The symptoms of active TB can include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        A cough that lasts a long time",
"       </li>",
"       <li>",
"        Fever",
"       </li>",
"       <li>",
"        Sweating at night",
"       </li>",
"       <li>",
"        Losing weight without trying to",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H537472239\">",
"      <span class=\"h1\">",
"       Should I see a doctor or nurse?",
"      </span>",
"      &nbsp;&mdash;&nbsp;See your doctor or nurse if:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        You have been near someone who was sick with TB",
"       </li>",
"       <li>",
"        You have a cough that has lasted longer than 3 or 4 weeks and does not seem to be getting better",
"       </li>",
"       <li>",
"        You have other symptoms of TB, such as fever, sweating at night, and unexpected weight loss",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H537472246\">",
"      <span class=\"h1\">",
"       Is there a test for TB?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. Your doctor or nurse can test you for TB by giving you a shot that contains tiny pieces of the dead TB germ. You will get the shot in the arm. Then, two or three days later, your doctor or nurse will need to look at the spot where you got the shot to see if you form a bump, and to see how big the bump is. Only a doctor or nurse can tell whether the bump from a TB test is positive or negative.",
"     </p>",
"     <p>",
"      There is also a blood test for TB. But that test is not available everywhere.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H537472253\">",
"      <span class=\"h1\">",
"       What if my TB test is positive?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If your TB test is positive, you will probably need treatment. But the treatment will differ depending on whether you are sick.",
"     </p>",
"     <p>",
"      People who are not sick and have latent TB must take medicine every day for 3 to 9 months. People who are sick with active TB must take 4 different medicines every day for at least 2 months. After that, some people can go down to 2 medicines, but all people must keep taking some medicines for another 4 months. That means that treatment for active TB lasts at least 6 months total.",
"     </p>",
"     <p>",
"      If your doctor or nurse gives you medicine to treat TB, it is very important that you take it all. It's hard to take medicine day after day for months. But if you do not take all your medicine, you could get sick with TB, or the medicine could lose its effect. If the medicine loses its effect, the infection can become even harder to treat.",
"     </p>",
"     <p>",
"      TB is a serious disease. It can lead to death. That's why it's so important that you take treatment very seriously.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H537472260\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?38/35/39475?source=see_link\">",
"       Patient information: Tuberculosis (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 14, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?24/57/25489?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 15485 Version 2.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-210.101.131.232-B327878308-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_57_25489=[""].join("\n");
var outline_f24_57_25489=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H537472211\">",
"      What is tuberculosis?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H537472218\">",
"      How does TB spread?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H537472225\">",
"      What happens if I get infected with TB?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H537472232\">",
"      What are the symptoms of active TB?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H537472239\">",
"      Should I see a doctor or nurse?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H537472246\">",
"      Is there a test for TB?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H537472253\">",
"      What if my TB test is positive?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H537472260\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?38/35/39475?source=related_link\">",
"      Patient information: Tuberculosis (Beyond the Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f24_57_25490="Patient information: Diffuse idiopathic skeletal hyperostosis (The Basics)";
var content_f24_57_25490=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/86965\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"UTD.htm?6/21/6485\">",
"         Anatomy of the back",
"        </a>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?7/13/7378\">",
"         Patient information: Dysphagia (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?22/31/23026\">",
"         Patient information: Neck pain (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?39/15/40178\">",
"         Patient information: Nonsteroidal antiinflammatory drugs (NSAIDs) (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?42/3/43058\">",
"         Patient information: Osteoarthritis (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?26/35/27188\">",
"         Patient information: Neck pain (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?2/13/2262\">",
"         Patient information: Nonsteroidal antiinflammatory drugs (NSAIDs) (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?21/29/21975\">",
"         Patient information: Osteoarthritis treatment (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Diffuse idiopathic skeletal hyperostosis (The Basics)",
"    </div>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H55209717\">",
"      <span class=\"h1\">",
"       What is diffuse idiopathic skeletal hyperostosis?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Diffuse idiopathic skeletal hyperostosis, called &ldquo;DISH&rdquo; for short, is a condition that causes bone to form in places where it is not usually found.",
"     </p>",
"     <p>",
"      DISH affects strong bands of tissue that connect bones to other bones in the back. These bands of tissue are called ligaments (",
"      <a class=\"graphic graphic_figure graphicRef86920 \" href=\"UTD.htm?6/21/6485\">",
"       figure 1",
"      </a>",
"      ). New bone growths form on the ligaments. The new bone growths are called bone spurs.",
"     </p>",
"     <p>",
"      Bone spurs can also form in other parts of the body, where ligaments and tendons (strong bands of tissue that connect muscles to bones) attach to bones. This can happen on the ankles, heels, knees, hips, shoulders, elbows, or hands.",
"     </p>",
"     <p>",
"      Doctors don&rsquo;t know what causes DISH.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H55209749\">",
"      <span class=\"h1\">",
"       What are the symptoms of DISH?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Some people have no symptoms from their DISH. They find out they have the condition when they have an X-ray done for another reason.",
"     </p>",
"     <p>",
"      When people have symptoms from their DISH, the most common ones are pain and stiffness in the upper back. People can also have pain in their neck or other joints, depending on where the bone spurs are.",
"     </p>",
"     <p>",
"      Symptoms can also happen when bone spurs press on nearby organs or parts of the body. For example, bone spurs can press on the esophagus (the tube that carries food from the mouth to the stomach) and other structures in the neck. This can cause trouble swallowing, hoarseness, or noisy breathing.",
"     </p>",
"     <p>",
"      Bone spurs in the lower back can press on the bundle of nerves that run down the back. Pressure on these nerves can cause tingling, pain, numbness, or weakness in the legs.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H55209764\">",
"      <span class=\"h1\">",
"       Is there a test for DISH?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. Your doctor or nurse will ask about your symptoms and do an exam. To check for bone spurs, he or she will order X-rays of your back or other parts of your body. Some people have an imaging test called a CT scan. Imaging tests create pictures of the inside of the body.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H55209779\">",
"      <span class=\"h1\">",
"       How is DISH treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;There is no cure for DISH, but different treatments can help reduce pain and stiffness. Treatment usually involves 1 or more of the following:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Physical therapy &ndash; A physical therapist (exercise expert) will teach you exercises and stretches that can help stretch your joints and ease stiffness. He or she can also show you ways to do your daily activities so they don&rsquo;t cause as much pain.",
"       </li>",
"       <li>",
"        Heat &ndash; Heat, especially in the morning, can help reduce pain and stiffness. Do not use heat for longer than 20 minutes at a time. Also, do not use anything too hot that could burn your skin.",
"       </li>",
"       <li>",
"        Pain-relieving medicines &ndash; You can take a pain-relieving medicine, such as",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?19/35/20021?source=see_link\">",
"         acetaminophen",
"        </a>",
"        (sample brand name: Tylenol),",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?14/17/14614?source=see_link\">",
"         ibuprofen",
"        </a>",
"        (sample brand names: Advil, Motrin), or",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?43/35/44597?source=see_link\">",
"         naproxen",
"        </a>",
"        (brand name: Aleve).",
"       </li>",
"       <li>",
"        Shots of steroid medicines into the affected joint &ndash; These steroids are different from the ones athletes take to build muscle. These steroids help reduce pain.",
"       </li>",
"       <li>",
"        Special shoe inserts (called orthotics) &ndash; These can help with walking if you have painful bone spurs on your heels.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      In rare cases, people with DISH are treated with surgery to remove bone spurs. Surgery is done only when the bone spurs cause serious problems.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H60085486\">",
"      <span class=\"h1\">",
"       Is there anything I can do on my own to feel better?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. One of the most important things you can do to feel better is to stay as active as possible. You might want to avoid being active because you are in pain. But this can make your muscles weak and your joints stiffer than they already are.",
"     </p>",
"     <p>",
"      Find physical activities you like to do. If you have not been active for a while, start by doing just a few minutes of activity a few times a week. Then slowly do more. Ask your doctor, nurse, or physical therapist if you need help starting an exercise program.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H56054046\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?22/31/23026?source=see_link\">",
"       Patient information: Neck pain (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?42/3/43058?source=see_link\">",
"       Patient information: Osteoarthritis (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?7/13/7378?source=see_link\">",
"       Patient information: Dysphagia (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?39/15/40178?source=see_link\">",
"       Patient information: Nonsteroidal antiinflammatory drugs (NSAIDs) (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?21/29/21975?source=see_link\">",
"       Patient information: Osteoarthritis treatment (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?26/35/27188?source=see_link\">",
"       Patient information: Neck pain (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?2/13/2262?source=see_link\">",
"       Patient information: Nonsteroidal antiinflammatory drugs (NSAIDs) (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?24/57/25490?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 86965 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-61.234.146.186-E0FBF310BF-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_57_25490=[""].join("\n");
var outline_f24_57_25490=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H55209717\">",
"      What is diffuse idiopathic skeletal hyperostosis?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H55209749\">",
"      What are the symptoms of DISH?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H55209764\">",
"      Is there a test for DISH?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H55209779\">",
"      How is DISH treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H60085486\">",
"      Is there anything I can do on my own to feel better?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H56054046\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/86965\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?6/21/6485\">",
"      Anatomy of the back",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?7/13/7378?source=related_link\">",
"      Patient information: Dysphagia (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?26/35/27188?source=related_link\">",
"      Patient information: Neck pain (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?22/31/23026?source=related_link\">",
"      Patient information: Neck pain (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?2/13/2262?source=related_link\">",
"      Patient information: Nonsteroidal antiinflammatory drugs (NSAIDs) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?39/15/40178?source=related_link\">",
"      Patient information: Nonsteroidal antiinflammatory drugs (NSAIDs) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?42/3/43058?source=related_link\">",
"      Patient information: Osteoarthritis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?21/29/21975?source=related_link\">",
"      Patient information: Osteoarthritis treatment (Beyond the Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f24_57_25491="Scans nasal ethmoid CA";
var content_f24_57_25491=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F50420&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F50420&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 563px\">",
"   <div class=\"ttl\">",
"    Patient with poorly differentiated carcinoma of the nasal cavity and ethmoid sinus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 543px; height: 235px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A) Coronal CT shows mass filling left nasal cavity and sphenoid sinus, with aggressive bone destruction of the anterior skull base and medial wall of the orbit. B) Coronal contrast-enhanced T1 weighted MRI at nearly the same level shows the dura is irregularly thickened and enhances, suggesting dural involvement by tumor.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Parsons JT, Stringer SP, Mancuso AA, Million RR. Nasal vestibule, nasal cavity, and paranasal sinuses. In: Million RR, Cassisi NJ (Eds). Management of Head and Neck Cancer: A Multidisciplinary Approach. Philadelphia: J.B. Lippincott Company, 1994.&nbsp;Copyright &copy; 1994 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_57_25491=[""].join("\n");
var outline_f24_57_25491=null;
var title_f24_57_25492="Folic acid: Patient drug information";
var content_f24_57_25492=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Folic acid: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/61/9174?source=see_link\">",
"     see \"Folic acid: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?21/31/22005?source=see_link\">",
"     see \"Folic acid: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F6813283\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Folacin-800 [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F173692\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Folic&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10019379\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10019381\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691725",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat anemia.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691572",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to help growth and good health.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691412",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to make healthy blood.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692167",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This vitamin is used to aid the diet needs of a pregnant woman or one trying to get pregnant.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10019380\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702156",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to folic acid or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10019385\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10019387\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10019383\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705324",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         All products:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696130",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       To gain the most benefit, do not miss doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705490",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Oral:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694297",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       There is a liquid (solution) if you cannot swallow pills. Shake well before use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696107",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Those who have feeding tubes may also use the liquid. Flush the feeding tube before and after this drug is given.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705429",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Shot:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695979",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into a muscle, under the skin, or into a vein.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696367",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Your doctor will teach you how to give the shot.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696257",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wash your hands before and after use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696118",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Throw away needles in a needle/sharp disposal box and take the box back to your doctor when it is full.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10019384\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10019388\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705564",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Tablet:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2696421",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Liquid:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699340",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature. Do not freeze.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699619",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Throw away any part of the solution not used after 1 month.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705429",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Shot:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699416",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store shot as you have been told by the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10019389\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11370 Version 40.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-61.234.146.186-869C284B9E-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_57_25492=[""].join("\n");
var outline_f24_57_25492=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6813283\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F173692\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019379\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019381\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019380\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019385\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019387\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019383\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019384\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019388\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019389\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?8/61/9174?source=related_link\">",
"      Folic acid: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?21/31/22005?source=related_link\">",
"      Folic acid: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f24_57_25493="SCLC normal CT";
var content_f24_57_25493=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F66186%7EPULM%2F75243&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F66186%7EPULM%2F75243&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    CT negative PET positive Paraneoplastic disease",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 292px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This 71-year-old man presented with a polyneuropathy thought secondary to a paraneoplastic syndrome as he had a high PQ type calcium channel antibody present in serum. CT showing a normal sized hilar node.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    CT negative PET positive Paraneoplastic disease",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 276px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This 71-year-old man presented with a polyneuropathy thought secondary to a paraneoplastic syndrome as he had a high PQ type calcium channel antibody present in serum. PET-CT showing intense metabolic activity in a normal sized left hilar node after CT was negative. Ultrasound guided bronchoscopy sampling revealed small cell lung cancer in this hilar node.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_57_25493=[""].join("\n");
var outline_f24_57_25493=null;
var title_f24_57_25494="Dobutamine: Drug information";
var content_f24_57_25494=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Dobutamine: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?23/35/24115?source=see_link\">",
"    see \"Dobutamine: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?24/48/25348?source=see_link\">",
"    see \"Dobutamine: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F161958\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Dobutamine Injection, USP;",
"     </li>",
"     <li>",
"      Dobutrex&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F162001\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Adrenergic Agonist Agent",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F161962\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Cardiac decompensation: I.V. infusion: 2.5-20 mcg/kg/minute; maximum: 40 mcg/kg/minute, titrate to desired response; see table.",
"    </p>",
"    <table border=\"1\" frame=\"border\" rules=\"all\">",
"     <caption style=\"text-align:center;\">",
"      Infusion Rates of Various Dilutions of Dobutamine",
"     </caption>",
"     <col align=\"center\" width=\"140\">",
"     </col>",
"     <col align=\"center\" width=\"100\">",
"     </col>",
"     <col align=\"center\" width=\"120\">",
"     </col>",
"     <thead valign=\"middle\">",
"      <tr>",
"       <th align=\"center\" rowspan=\"2\">",
"        <p style=\"text-indent:0em;\">",
"         Desired Delivery Rate",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         (mcg/kg/min)",
"        </p>",
"       </th>",
"       <th align=\"center\" colspan=\"2\">",
"        <p style=\"text-indent:0em;\">",
"         <b>",
"          Infusion Rate (mL/kg/min)",
"         </b>",
"        </p>",
"       </th>",
"      </tr>",
"      <tr>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         <b>",
"          500 mcg/mL",
"         </b>",
"        </p>",
"       </th>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         <b>",
"          1000 mcg/mL",
"         </b>",
"        </p>",
"       </th>",
"      </tr>",
"     </thead>",
"     <tbody valign=\"middle\">",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         2.5",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         0.005",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         0.0025",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         5",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         0.01",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         0.005",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         7.5",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         0.015",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         0.0075",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         10",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         0.02",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         0.01",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         12.5",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         0.025",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         0.0125",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         15",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         0.03",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         0.015",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F161981\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?24/48/25348?source=see_link\">",
"      see \"Dobutamine: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Cardiac decompensation: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F161963\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F15804854\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F15804855\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F161937\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Infusion, premixed in D",
"     <sub>",
"      5",
"     </sub>",
"     W, as hydrochloride: 1 mg/mL (250 mL); 2 mg/mL (250 mL); 4 mg/mL (250 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution, as hydrochloride: 12.5 mg/mL (20 mL, 40 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F161922\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F161941\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use infusion device to control rate of flow; administer into large vein. Do not administer through same I.V. line as heparin, hydrocortisone sodium succinate, cefazolin, or penicillin.",
"    </p>",
"   </div>",
"   <div class=\"block uica drugH1Div\" id=\"F14471789\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Usual Infusion Concentrations: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Premixed solutions available.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      I.V. infusion:",
"     </b>",
"     250 mg in 500 mL (concentration: 500",
"     <b>",
"      mcg",
"     </b>",
"     /mL), 500 mg in 250 mL (concentration: 2000",
"     <b>",
"      mcg",
"     </b>",
"     /mL),",
"     <b>",
"      or",
"     </b>",
"     1000 mg in 250 mL (concentration: 4000",
"     <b>",
"      mcg",
"     </b>",
"     /mL) of D",
"     <sub>",
"      5",
"     </sub>",
"     W or NS",
"    </p>",
"   </div>",
"   <div class=\"block uicp drugH1Div\" id=\"F14471790\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Usual Infusion Concentrations: Pediatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Premixed solutions available.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      I.V. infusion:",
"     </b>",
"     1000",
"     <b>",
"      mcg",
"     </b>",
"     /mL, 2000",
"     <b>",
"      mcg",
"     </b>",
"     /mL,",
"     <b>",
"      or",
"     </b>",
"     4000",
"     <b>",
"      mcg",
"     </b>",
"     /mL",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F162007\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Per manufacturer, do not give through same I.V. line as heparin, hydrocortisone sodium succinate, cefazolin, or penicillin.",
"     <b>",
"      Incompatible",
"     </b>",
"     with heparin, cefazolin, penicillin, and in alkaline solutions (sodium bicarbonate).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Stable in D",
"     <sub>",
"      5",
"     </sub>",
"     LR, D",
"     <sub>",
"      5",
"     </sub>",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     W, D",
"     <sub>",
"      10",
"     </sub>",
"     W, LR,",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     NS, NS, mannitol 20%;",
"     <b>",
"      incompatible",
"     </b>",
"     with sodium bicarbonate 5%;",
"     <b>",
"      variable stability (consult detailed reference)",
"     </b>",
"     in peritoneal dialysis solutions.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Alcohol (ethyl), alprostadil, amifostine, amiodarone, anidulafungin, argatroban, atracurium, aztreonam, caffeine citrate, calcium chloride, calcium gluconate, caspofungin, ciprofloxacin, cisatracurium, cladribine, clonidine, dexmedetomidine, diazepam, diltiazem, docetaxel, dopamine, dopamine with lidocaine, dopamine with nitroglycerin, dopamine with nitroprusside, doripenem, doxorubicin liposome, enalaprilat, epinephrine, eptifibatide, etoposide phosphate, famotidine, fenoldopam, fentanyl, fluconazole, gemcitabine, granisetron, haloperidol, hetastarch in lactated electrolyte injection (Hextend&reg;), hydromorphone, inamrinone, insulin (regular), labetalol, levofloxacin, lidocaine, lidocaine with nitroglycerin, lidocaine with nitroprusside, linezolid, lorazepam, magnesium sulfate, meperidine, milrinone, morphine, nicardipine, nitroglycerin, nitroglycerin with nitroprusside, norepinephrine, oxaliplatin, pancuronium, potassium chloride, propofol, ranitidine, remifentanil,  tacrolimus, telavancin, terbutaline, theophylline, thiotepa, tigecycline, tirofiban, vasopressin, vecuronium, verapamil, zidovudine.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Acyclovir, alteplase, aminophylline, amphotericin B cholesteryl sulfate complex, foscarnet, indomethacin, micafungin, pantoprazole, pemetrexed, phytonadione, piperacillin/tazobactam, thiopental, warfarin.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Bivalirudin, cefepime, ceftazidime, drotecogin alfa, furosemide, heparin, midazolam, nesiritide, nitroprusside, pantoprazole, tenecteplase.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Compatibility in syringe: Compatible:",
"     </b>",
"     Caffeine citrate, dimenhydrinate, heparin, ranitidine.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Doxapram, pantoprazole.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F161940\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Short-term management of patients with cardiac decompensation",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F161998\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Positive inotropic agent for use in myocardial dysfunction related to sepsis; stress echocardiography",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F162009\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       DOBUTamine may be confused with DOPamine",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F161999\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Incidence of adverse events is not always reported.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Cardiovascular: Increased heart rate, increased blood pressure, increased ventricular ectopic activity, hypotension, premature ventricular beats (5%, dose related), anginal pain (1% to 3%), nonspecific chest pain (1% to 3%), palpitation (1% to 3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Fever (1% to 3%), headache (1% to 3%), paresthesia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Slight decrease in serum potassium",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Nausea (1% to 3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Thrombocytopenia (isolated cases)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Phlebitis, local inflammatory changes and pain from infiltration, cutaneous necrosis (isolated cases)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Mild leg cramps",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Dyspnea (1% to 3%)",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F161944\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to dobutamine or sulfites (some contain sodium metabisulfate), or any component of the formulation; idiopathic hypertrophic subaortic stenosis (IHSS)",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F161926\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Blood pressure effects: An increase in blood pressure is more common, but occasionally a patient may become hypotensive.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Tachycardia: May increase heart rate.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Ventricular ectopy: May exacerbate ventricular ectopy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Aortic stenosis: Ineffective therapeutically in the presence of mechanical obstruction such as severe aortic stenosis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Atrial fibrillation: Patients with atrial fibrillation may experience an increase in ventricular response.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypovolemia: If needed, correct hypovolemia first to optimize hemodynamics.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Myocardial infarct (post): Use with caution in patients post-MI; can increase myocardial oxygen demand.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Monoamine oxidase inhibitors (MAO-I): Use with extreme caution in patients taking MAO inhibitors; prolong hypertension may result from concurrent use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sodium sulfite: Product may contain sodium sulfite.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Use with caution in the elderly; start at lower end of the dosage range.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Diagnostic testing: Dobutamine in combination with stress echo may be used diagnostically.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299223\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of COMT",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F161931\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AtoMOXetine: May enhance the hypertensive effect of Sympathomimetics. AtoMOXetine may enhance the tachycardic effect of Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Salts: May diminish the therapeutic effect of DOBUTamine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cannabinoids: May enhance the tachycardic effect of Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     COMT Inhibitors: May decrease the metabolism of COMT Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iobenguane I 123: Sympathomimetics may diminish the therapeutic effect of Iobenguane I 123.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Linezolid: May enhance the hypertensive effect of Sympathomimetics. Management: Reduce initial doses of sympathomimetic agents, and closely monitor for enhanced pressor response, in patients receiving linezolid.  Specific dose adjustment recommendations are not presently available.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sympathomimetics: May enhance the adverse/toxic effect of other Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F161933\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F13314045\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events have not been observed in animal reproduction studies.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F161967\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16323116\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (DOBUTamine in D5W Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2 mg/mL (250 mL): $14.15",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F161935\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Blood pressure, ECG, heart rate, CVP, RAP, MAP; serum glucose, renal function; urine output; if pulmonary artery catheter is in place, monitor CI, PCWP, and SVR",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F161947\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Butamine (IL);",
"     </li>",
"     <li>",
"      Cardiject (ID, IN, TH, ZA);",
"     </li>",
"     <li>",
"      Cardiotone (ID);",
"     </li>",
"     <li>",
"      Cardomin (PH);",
"     </li>",
"     <li>",
"      Dobamin (KP);",
"     </li>",
"     <li>",
"      Dobu-Hameln (PE);",
"     </li>",
"     <li>",
"      Dobucard (MY);",
"     </li>",
"     <li>",
"      Dobucor (ES);",
"     </li>",
"     <li>",
"      Dobuject (CZ, DK, FI, ID, IL, KP, MX, NZ, PH, PK, PL, RU, SE, SG, TW);",
"     </li>",
"     <li>",
"      Dobunex (PH);",
"     </li>",
"     <li>",
"      Doburan (ID, PH, VE);",
"     </li>",
"     <li>",
"      Dobusafe (CO);",
"     </li>",
"     <li>",
"      Dobutamin Hexal (DE, HU);",
"     </li>",
"     <li>",
"      Dobutamin-Ratiopharm (DE);",
"     </li>",
"     <li>",
"      Dobutamina Abbott (ES);",
"     </li>",
"     <li>",
"      Dobutamina Inibsa (ES);",
"     </li>",
"     <li>",
"      Dobutamina Rovi (ES);",
"     </li>",
"     <li>",
"      Dobutamine Aguettant (FR);",
"     </li>",
"     <li>",
"      Dobutamine Hydrochloride (GB);",
"     </li>",
"     <li>",
"      Dobutamine Panpharma (FR);",
"     </li>",
"     <li>",
"      Dobutrex (AU, BE, BF, BG, BJ, BR, CH, CI, CL, CZ, DK, ES, ET, FR, GB, GH, GM, GN, HN, HR, HU, IE, IN, IT, KE, KP, LR, MA, ML, MR, MU, MW, MX, MY, NE, NG, NL, NO, RU, SC, SD, SE, SL, SN, TN, TR, TZ, UG, ZM, ZW);",
"     </li>",
"     <li>",
"      Dominic (ID);",
"     </li>",
"     <li>",
"      Doxa (PY);",
"     </li>",
"     <li>",
"      Duvig (AR);",
"     </li>",
"     <li>",
"      Easydobu (TW);",
"     </li>",
"     <li>",
"      Gendobu (TW);",
"     </li>",
"     <li>",
"      Inotop (AT);",
"     </li>",
"     <li>",
"      Inotrex (GR, PT);",
"     </li>",
"     <li>",
"      Inotrop (ID);",
"     </li>",
"     <li>",
"      Myofast (CO);",
"     </li>",
"     <li>",
"      Posiject (GB, IE);",
"     </li>",
"     <li>",
"      Utamine (TW)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F161925\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stimulates beta",
"     <sub>",
"      1",
"     </sub>",
"     -adrenergic receptors, causing increased contractility and heart rate, with little effect on beta",
"     <sub>",
"      2",
"     </sub>",
"     - or alpha-receptors",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F161943\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: I.V.: 1-10 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Peak effect: 10-20 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: In tissues and hepatically to inactive metabolites",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: 2 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (as metabolites)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Bax JJ, Poldermans D, Elhendy A, et al, &ldquo;Improvement of Left Ventricular Ejection Fraction, Heart Failure Symptoms and Prognosis After Revascularization in Patients With Chronic Coronary Artery Disease and Viable Myocardium Detected by Dobutamine Stress Echocardiography,&rdquo;",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 1999, 34(1):163-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/57/25494/abstract-text/10400006/pubmed\" id=\"10400006\" target=\"_blank\">",
"        10400006",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Brierley J, Carcillo JA, Choong K, et al, &ldquo;Clinical Practice Parameters for Hemodynamic Support of Pediatric and Neonatal Septic Shock: 2007 Update from the American College of Critical Care Medicine,&rdquo;",
"      <i>",
"       Crit Care Med",
"      </i>",
"      , 2009, 37(2):666-88.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/57/25494/abstract-text/19325359/pubmed\" id=\"19325359\" target=\"_blank\">",
"        19325359",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dellinger RP, Levy MM, Carlet JM, et al, &ldquo;Surviving Sepsis Campaign: International Guidelines for Management of Severe Sepsis and Septic Shock: 2008,&rdquo; [published correction appears in",
"      <i>",
"       Crit Care Med",
"      </i>",
"      , 2008, 36(4):1394-6],",
"      <i>",
"       Crit Care Med",
"      </i>",
"      , 2008, 36(1):296-327.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/57/25494/abstract-text/18158437/pubmed\" id=\"18158437\" target=\"_blank\">",
"        18158437",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dellinger RP, Levy MM, Rhodes A, et al, &ldquo;Surviving Sepsis Campaign: International Guidelines for Management of Severe Sepsis and Septic Shock, 2012,&rdquo;",
"      <i>",
"       Crit Care Med",
"      </i>",
"      , 2013, 41(2):580-637.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/57/25494/abstract-text/23353941/pubmed\" id=\"23353941\" target=\"_blank\">",
"        23353941",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hollenberg SM, Ahrens TS, Annane D, et al, &ldquo;Practice Parameters for Hemodynamic Support of Sepsis in Adult Patients: 2004 Update,&rdquo;",
"      <i>",
"       Crit Care Med",
"      </i>",
"      , 2004, 32(9):1928-48.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/57/25494/abstract-text/15343024/pubmed\" id=\"15343024\" target=\"_blank\">",
"        15343024",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hunt SA, Abraham WT, Chin MH, et al, &ldquo;2009 Focused Update Incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration With the International Society for Heart and Lung Transplantation,&rdquo;",
"      <i>",
"       CIrculation",
"      </i>",
"      , 2009, 119(14):e391-479.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/57/25494/abstract-text/19324966/pubmed\" id=\"19324966\" target=\"_blank\">",
"        19324966",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Institute for Safe Medication Practice (ISMP) and Vermont Oxford Network, &ldquo;Standard Concentrations of Neonatal Drug Infusions,&rdquo; 2011.  Available at https://www.ismp.org/Tools/PediatricConcentrations.pdf",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Leier CV, Webel J, and Bush CA, &ldquo;The Cardiovascular Effects of the Continuous Infusion of Dobutamine in Patients With Severe Cardiac Failure,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 1977, 56(3):468-72.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/57/25494/abstract-text/884803/pubmed\" id=\"884803\" target=\"_blank\">",
"        884803",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lindenfeld J, Albert NM, Boehmer JP, et al, &ldquo;HFSA 2010 Comprehensive Heart Failure Practice Guideline,&rdquo;",
"      <i>",
"       J Card Fail",
"      </i>",
"      , 2010, 16(6):e1-194.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/57/25494/abstract-text/20610207/pubmed\" id=\"20610207\" target=\"_blank\">",
"        20610207",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Patel MB, Kaplan IV, Patni RN, et al, &ldquo;Sustained Improvement in Flow-Mediated Vasodilation After Short-Term Administration of Dobutamine in Patients With Severe Congestive Heart Failure,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 1999, 99(1):60-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/57/25494/abstract-text/9884380/pubmed\" id=\"9884380\" target=\"_blank\">",
"        9884380",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Paulman PM, Cantral K, Meade JG, et al, &ldquo;Dobutamine Overdose,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 1990, 264(18):2386-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/57/25494/abstract-text/2231992/pubmed\" id=\"2231992\" target=\"_blank\">",
"        2231992",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Phillips MS, &ldquo;Standardizing I.V. Infusion Concentrations: National Survey Results,&rdquo;",
"      <i>",
"       Am J Health Syst Pharm",
"      </i>",
"      , 2011, 68(22):2176-82.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/57/25494/abstract-text/22058104/pubmed\" id=\"22058104\" target=\"_blank\">",
"        22058104",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;Practice Parameters for Hemodynamic Support of Sepsis in Adult Patients in Sepsis. Task Force of the American College of Critical Care Medicine, Society of Critical Care Medicine,&rdquo;",
"      <i>",
"       Crit Care Med",
"      </i>",
"      , 1999, 27(3):639-60. Available at file://www.sccm.org/pdf/Hemodynamic%20Support.pdf",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/57/25494/abstract-text/10199548/pubmed\" id=\"10199548\" target=\"_blank\">",
"        10199548",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rich MN, Woods WL, Davila-Roman VG, et al, &ldquo;A Randomized Comparison of Intravenous Amrinone Versus Dobutamine in Older Patients With Decompensated Congestive Heart Failure,&rdquo;",
"      <i>",
"       J Am Geriatr Soc",
"      </i>",
"      , 1995, 43(3):271-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/57/25494/abstract-text/7884117/pubmed\" id=\"7884117\" target=\"_blank\">",
"        7884117",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rivers E, Nguyen B, Havstad S, et al, &ldquo;Early Goal-Directed Therapy in the Treatment of Severe Sepsis and Septic Shock,\"",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2001, 345(19):1368-77.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/57/25494/abstract-text/11794169/pubmed\" id=\"11794169\" target=\"_blank\">",
"        11794169",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9380 Version 39.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-61.234.146.186-EBC78AF0D7-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_57_25494=[""].join("\n");
var outline_f24_57_25494=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F161958\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F162001\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F161962\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F161981\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F161963\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15804854\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15804855\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F161937\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F161922\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F161941\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14471789\">",
"      Usual Infusion Concentrations: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14471790\">",
"      Usual Infusion Concentrations: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F162007\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F161940\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F161998\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F162009\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F161999\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F161944\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F161926\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299223\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F161931\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F161933\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13314045\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F161967\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16323116\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F161935\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F161947\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F161925\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F161943\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9380\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9380|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?23/35/24115?source=related_link\">",
"      Dobutamine: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?24/48/25348?source=related_link\">",
"      Dobutamine: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f24_57_25495="Treatment of tinnitus";
var content_f24_57_25495=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment of tinnitus",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/57/25495/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/57/25495/contributors\">",
"     Elizabeth A Dinces, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/57/25495/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/57/25495/contributors\">",
"     Daniel G Deschler, MD, FACS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/57/25495/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/57/25495/contributors\">",
"     Fenny H Lin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?24/57/25495/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 4, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tinnitus is a perception of sound in proximity to the head in the absence of an external source. The sound may be a buzzing, ringing, or hissing, although it can also sound like other noises.",
"   </p>",
"   <p>",
"    Tinnitus is most commonly associated with hearing loss, though it may be a presenting symptom of vascular or neurological abnormalities. Once a serious underlying medical condition has been ruled out, treatment should be directed at the symptom itself, which severely interferes with the quality of life in approximately 10 percent of patients with tinnitus [",
"    <a class=\"abstract\" href=\"UTD.htm?24/57/25495/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This topic will review the treatment of tinnitus. The epidemiology, pathogenesis, and diagnosis of tinnitus are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/6/26727?source=see_link\">",
"     \"Etiology and diagnosis of tinnitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment for tinnitus includes correcting identified comorbidities, as well as directly addressing the effects of tinnitus on quality of life. For many patients, tinnitus is a chronic condition; goals of treatment are to lessen its impact and any associated disability, rather than to achieve absolute cure. Several treatment modalities have been studied, including behavioral treatments and medications, but the benefit for most of these interventions has not been conclusively demonstrated in randomized trials [",
"    <a class=\"abstract\" href=\"UTD.htm?24/57/25495/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Associated factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prior to initiating therapy for tinnitus, it is important to address other associated conditions that can exacerbate tinnitus.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Depression",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with depression require appropriate treatment. In a randomized trial, treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/21/30040?source=see_link\">",
"     nortriptyline",
"    </a>",
"    100 mg, compared to placebo, resulted in overall benefit for patients with disabling tinnitus (67 percent versus 40 percent), though tinnitus severity was insignificantly improved [",
"    <a class=\"abstract\" href=\"UTD.htm?24/57/25495/abstract/3\">",
"     3",
"    </a>",
"    ]. Suicidality may be increased in patients with tinnitus, but a cause and effect relationship is uncertain [",
"    <a class=\"abstract\" href=\"UTD.htm?24/57/25495/abstract/4\">",
"     4",
"    </a>",
"    ]. A meta-analysis of six randomized trials of antidepressants for treatment of tinnitus (four evaluating tricyclic antidepressants, one using",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/50/15146?source=see_link\">",
"     paroxetine",
"    </a>",
"    initiated at 10 mg daily, one studying",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/0/24584?source=see_link\">",
"     trazodone",
"    </a>",
"    ) found evidence inconclusive for the effectiveness of antidepressants in this condition [",
"    <a class=\"abstract\" href=\"UTD.htm?24/57/25495/abstract/5\">",
"     5",
"    </a>",
"    ]. There was a suggestion of tinnitus improvement in a patient subgroup that received higher doses of paroxetine (50 mg) in one study [",
"    <a class=\"abstract\" href=\"UTD.htm?24/57/25495/abstract/6\">",
"     6",
"    </a>",
"    ], but this requires further evaluation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Insomnia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with tinnitus who have insomnia should be treated for their sleep disorder with the goal of reducing the severity of tinnitus [",
"    <a class=\"abstract\" href=\"UTD.htm?24/57/25495/abstract/7\">",
"     7",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/62/13290?source=see_link\">",
"     \"Treatment of insomnia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Vascular abnormalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with vascular tinnitus may benefit from a variety of procedures. As examples, a bruit from an AVM, dural AVE, or dehiscent jugular bulb may be treated by ligation or embolization, and glomus tumors can be treated by angiographic embolization and surgical resection.",
"   </p>",
"   <p>",
"    Reassurance for patients with venous hums or benign arterial variants causing pulsatile tinnitus may be helpful and is usually adequate. Rarely, surgical or angiographic ligation of the offending vessel is indicated for patients whose pulsatile tinnitus is so loud that it cannot be adequately treated with masking or other noninvasive treatment strategies and who experience significant impairment in their quality of life.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Presbycusis and other hearing loss",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hearing aids in patients with presbycusis usually result in an improvement in tinnitus symptoms.",
"   </p>",
"   <p>",
"    Patients with conductive hearing loss due to outer ear or middle ear disease may benefit from surgery to correct the conductive defect (",
"    <a class=\"graphic graphic_table graphicRef53903 \" href=\"UTD.htm?4/62/5101\">",
"     table 1",
"    </a>",
"    ). These patients may also derive some benefit from hearing aids if surgery is not an option.",
"   </p>",
"   <p>",
"    Cochlear implantation is a well accepted therapy in adults and children with severe hearing impairment who are not benefiting from hearing aids. Electrical stimulation of the auditory pathway is associated with a loss or reduction of tinnitus in 34 to 93 percent of patients receiving cochlear implants, although some individuals develop tinnitus postoperatively [",
"    <a class=\"abstract\" href=\"UTD.htm?24/57/25495/abstract/8-11\">",
"     8-11",
"    </a>",
"    ]. Cochlear implants are only available for selected patients and a full evaluation for candidacy is required before an implant can be considered.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Drug toxicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tinnitus due to ototoxic effects on the hair cells of the cochlea may be reversible in patients after stopping ototoxic medications (",
"    <a class=\"graphic graphic_table graphicRef68705 \" href=\"UTD.htm?6/55/7036\">",
"     table 2",
"    </a>",
"    ). Often tinnitus is the first sign that ototoxicity is occurring and can herald more severe injury to the inner ear. Discontinuing these medications can prevent progression to hearing loss",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    balance systems dysfunction in some patients even if tinnitus does not resolve.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Other associated factors",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cochlear rescue medications are currently under investigation in patients with chemotherapy-induced tinnitus [",
"      <a class=\"abstract\" href=\"UTD.htm?24/57/25495/abstract/12,13\">",
"       12,13",
"      </a>",
"      ]. Investigational therapies aimed at protecting the inner ear from trauma (noise induced damage) will likely also reduce the incidence of tinnitus seen with such damage [",
"      <a class=\"abstract\" href=\"UTD.htm?24/57/25495/abstract/14-16\">",
"       14-16",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Metabolic and hormone imbalances, if present, should be corrected and may result in resolution of the tinnitus.",
"     </li>",
"     <li>",
"      In patients with myoclonus of the palatal muscles or middle ear structures, treatment with botulinum toxin injections into the palate or sectioning of the tendons with the middle ear usually relieves the symptoms [",
"      <a class=\"abstract\" href=\"UTD.htm?24/57/25495/abstract/17\">",
"       17",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A patulous Eustachian tube can be treated with a variety of agents, including application of mucosal irritants (such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/49/2840?source=see_link\">",
"       tetracycline",
"      </a>",
"      ) to the nasopharynx, which result in swelling or scarring of the Eustachian tube orifice [",
"      <a class=\"abstract\" href=\"UTD.htm?24/57/25495/abstract/18\">",
"       18",
"      </a>",
"      ]. If these treatments fail, surgery may be successful with placement of silicone plugs [",
"      <a class=\"abstract\" href=\"UTD.htm?24/57/25495/abstract/19\">",
"       19",
"      </a>",
"      ] through the middle ear, or various endoscopic techniques to close the nasopharyngeal orifice [",
"      <a class=\"abstract\" href=\"UTD.htm?24/57/25495/abstract/20-22\">",
"       20-22",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Behavioral therapies",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of behavioral treatments have been studied with some success:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Tinnitus retraining therapy (TRT) &nbsp;",
"     </li>",
"     <li>",
"      Biofeedback and stress reduction programs",
"     </li>",
"     <li>",
"      Cognitive-behavioral therapy (CBT)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Multidisciplinary programs at tinnitus centers are available to assist patients with disabling tinnitus. A randomized trial, performed in an audiological referral center, compared a multidisciplinary stepped therapy approach (incorporating TRT and CBT, and involving clinical psychologists, movement therapists, physical therapists, speech therapists, social workers, and audiologists) to usual care for 492 adult patients with tinnitus [",
"    <a class=\"abstract\" href=\"UTD.htm?24/57/25495/abstract/23\">",
"     23",
"    </a>",
"    ]. At 12 months, patients assigned to the stepped therapy had significant improvement in scores reflecting health-related quality of life, tinnitus impairment, and tinnitus severity.",
"   </p>",
"   <p>",
"    Above all, patients should not be discouraged or advised that there are no treatment options.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Tinnitus retraining therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tinnitus retraining therapies (TRT) are based upon bypassing or overriding abnormal auditory cortex neural connections. These therapies are performed at specialized tinnitus centers and in some audiologic practices; techniques vary among practitioners and each center has its own specific rates of success.",
"   </p>",
"   <p>",
"    TRT is based on the principle that all levels of the auditory pathways and several nonauditory systems play essential roles in tinnitus; TRT enhances the role of nonauditory systems in determining the level of tinnitus annoyance [",
"    <a class=\"abstract\" href=\"UTD.htm?24/57/25495/abstract/24\">",
"     24",
"    </a>",
"    ]. TRT involves inducing and facilitating habituation to the tinnitus signal. The goal is to reach a stage in which patients are unaware of their tinnitus unless they specifically and consciously focus on it. Furthermore, even when perceived, tinnitus does not evoke annoyance. Habituation is achieved by directive counseling combined with low-level, broad-band noise generated by wearable generators, and environmental sounds, according to a specific protocol.",
"   </p>",
"   <p>",
"    Significant improvement has been reported in as many as 80 percent of patients with high-pitched tinnitus using TRT with combined counseling and noise generators [",
"    <a class=\"abstract\" href=\"UTD.htm?24/57/25495/abstract/24-27\">",
"     24-27",
"    </a>",
"    ]. The long-term impact may be less reliable [",
"    <a class=\"abstract\" href=\"UTD.htm?24/57/25495/abstract/28\">",
"     28",
"    </a>",
"    ]. TRT can take one to two years before the patient no longer needs the external device.",
"   </p>",
"   <p>",
"    In a systematic review that included only one randomized trial of 123 participants with tinnitus, tinnitus retraining therapy (TRT) was more effective than tinnitus masking in improving symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?24/57/25495/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Biofeedback and stress reduction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Biofeedback is a relaxation technique that teaches people to control certain autonomic body functions. The goal of biofeedback is to help people manage tinnitus-related distress by changing the patient's reaction to it. Many people notice a reduction in tinnitus when they are able to modify their reaction to it [",
"    <a class=\"abstract\" href=\"UTD.htm?24/57/25495/abstract/30\">",
"     30",
"    </a>",
"    ]. Biofeedback was first described as a stand-alone therapy for complex tinnitus in the 1980s and continues to be used as part of a battery of therapy options at many tinnitus centers.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Cognitive-behavioral therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cognitive-behavioral therapy (CBT) is an intervention aimed at motivating patients to learn to alter their psychological response to their tinnitus by identifying and reinforcing coping strategies, distraction skills, and relaxation techniques [",
"    <a class=\"abstract\" href=\"UTD.htm?24/57/25495/abstract/31\">",
"     31",
"    </a>",
"    ]. CBT requires patients to keep diaries and to perform homework. In a meta-analysis of ten randomized trials evaluating different forms of CBT (by therapists and over the internet), CBT improved tinnitus symptoms compared to non-CBT controls [",
"    <a class=\"abstract\" href=\"UTD.htm?24/57/25495/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H504724126\">",
"    <span class=\"h2\">",
"     Medications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some medications may have modest efficacy in the treatment of tinnitus:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Two small placebo-controlled trials of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/41/662?source=see_link\">",
"       misoprostol",
"      </a>",
"      , a prostaglandin E1 analogue, have suggested limited benefit [",
"      <a class=\"abstract\" href=\"UTD.htm?24/57/25495/abstract/32,33\">",
"       32,33",
"      </a>",
"      ], but further studies are needed.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"       Lidocaine",
"      </a>",
"      , either intratympanic or intravenous, has been found in observational studies to be modestly efficacious in reducing symptoms of tinnitus [",
"      <a class=\"abstract\" href=\"UTD.htm?24/57/25495/abstract/34-36\">",
"       34-36",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Benzodiazepines (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?30/31/31224?source=see_link\">",
"       alprazolam",
"      </a>",
"      ) have been found in small trials to be effective in the treatment of tinnitus [",
"      <a class=\"abstract\" href=\"UTD.htm?24/57/25495/abstract/37,38\">",
"       37,38",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Intratympanic medications, such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"       dexamethasone",
"      </a>",
"      , have been used with some success in patients with tinnitus, particularly in those with cochlear disease (eg, sudden hearing loss, autoimmune inner ear disease, M&eacute;ni&egrave;re syndrome) [",
"      <a class=\"abstract\" href=\"UTD.htm?24/57/25495/abstract/39,40\">",
"       39,40",
"      </a>",
"      ]. In a small randomized trial of patients with idiopathic tinnitus of less than three months duration, those who were assigned to combination intratympanic dexamethasone and oral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?30/31/31224?source=see_link\">",
"       alprazolam",
"      </a>",
"      reported greater improvement in tinnitus symptoms, compared to oral alprazolam alone [",
"      <a class=\"abstract\" href=\"UTD.htm?24/57/25495/abstract/41\">",
"       41",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A number of other medications have been studied in patients with tinnitus but have not been found to be effective:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Anticonvulsants do not appear to be effective in improving symptoms of tinnitus. A systematic review and meta-analysis including seven randomized trials of patients with chronic tinnitus found no clinically meaningful effect on symptoms comparing anticonvulsants (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/19/19768?source=see_link\">",
"       gabapentin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/10/25770?source=see_link\">",
"       carbamazepine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/28/6602?source=see_link\">",
"       lamotrigine",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/43/34484?source=see_link\">",
"       flunarizine",
"      </a>",
"      ) to placebo [",
"      <a class=\"abstract\" href=\"UTD.htm?24/57/25495/abstract/42\">",
"       42",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Ginkgo biloba and other bioflavonoids have been advertised to reduce tinnitus, but there is no evidence that ginkgo is effective for the treatment of tinnitus. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/28/11720?source=see_link&amp;anchor=H16#H16\">",
"       \"Clinical use of ginkgo biloba\", section on 'Tinnitus'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Melatonin has also not been found effective in controlled studies of tinnitus therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?24/57/25495/abstract/43\">",
"       43",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Niacin acts as a vasodilator and can potentially improve cochlear blood flow. However, niacin has not demonstrated clinical value in patients with long-standing tinnitus. No controlled studies have shown a significant benefit of niacin or other vitamins for tinnitus therapy.",
"     </li>",
"     <li>",
"      Zinc, copper, and manganese based superoxide dismutases scavenge free radicals in the inner ear [",
"      <a class=\"abstract\" href=\"UTD.htm?24/57/25495/abstract/44\">",
"       44",
"      </a>",
"      ]. Animal models suggest that deficiencies in these enzymes leads to increased death of cochlear hair cells [",
"      <a class=\"abstract\" href=\"UTD.htm?24/57/25495/abstract/45,46\">",
"       45,46",
"      </a>",
"      ]. Studies correlating zinc levels with tinnitus in humans, as well as randomized, controlled trials of zinc therapy for tinnitus have had inconsistent results [",
"      <a class=\"abstract\" href=\"UTD.htm?24/57/25495/abstract/47-50\">",
"       47-50",
"      </a>",
"      ]. Current evidence does not support the use of zinc supplementation for the treatment of tinnitus.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Other therapies",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of other types of treatments have been studied in patients with tinnitus, most of which have not been found to be more effective than placebo. Nevertheless, many tinnitus support groups have members who are helped by the treatments described below and individual patients who respond may be experiencing a true, nonplacebo benefit.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10015034\">",
"    <span class=\"h3\">",
"     Masking",
"    </span>",
"    &nbsp;&mdash;&nbsp;Masking devices resemble hearing aids and are designed to produce low-level sounds that reduce the perception of tinnitus [",
"    <a class=\"abstract\" href=\"UTD.htm?24/57/25495/abstract/51\">",
"     51",
"    </a>",
"    ]. Some patients report decrease in tinnitus with use of such devices, although there is no conclusive evidence from randomized trials to clarify the evidence of effectiveness. One systematic review of six randomized trials found significant risk of bias and differences in outcome measures and evaluation techniques that precluded a definitive assessment of efficacy [",
"    <a class=\"abstract\" href=\"UTD.htm?24/57/25495/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Masking can also produce the phenomenon of residual inhibition, where the reduction or elimination of tinnitus perception continues for a short time after the masker is removed. One therapy under evaluation, phase-shift treatment, aims to enhance residual inhibition that results from masking. Similar to the concept used in sound cancellation headphones, phase shift therapy uses a sound wave that is phase-shifted 180 degrees from the patient's endogenous sound wave. Residual inhibition lasting one hour to seven days was reported in 42 percent of patients during active phase-shift treatment for two weeks, and in no patients during nontreatment control weeks, in a crossover study (n = 61) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/57/25495/abstract/53\">",
"     53",
"    </a>",
"    ]. Further studies are needed to evaluate the long-term benefits of phase-shift treatment prior to clinical use.",
"   </p>",
"   <p>",
"    Potential adverse effects of masking therapy include worsening of tinnitus, associated discomfort, or worsening hyperacusis.",
"   </p>",
"   <p>",
"    For patients with tinnitus related to hearing loss, the use of an appropriately fitted hearing aid often acts to mask the tinnitus. As with other masking strategies, the tinnitus tends to return some time after the hearing aid is removed.",
"   </p>",
"   <p>",
"    Masking may also be accomplished using or enhancing ambient background noise. Use of background music, sound machines, radios on low volume, fans, and pillow speakers have been helpful to patients with tinnitus that is especially bothersome in quiet environments.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Electrical stimulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Electrical stimulation of the cochlea by directly placing electrodes on the bony cochlea or in the round window niche have resulted in tinnitus improvement in patients with hearing loss. Transcutaneous electrical stimulation is the only available electrical option that is not associated with a risk of causing hearing loss [",
"    <a class=\"abstract\" href=\"UTD.htm?24/57/25495/abstract/54\">",
"     54",
"    </a>",
"    ]. Electrical stimulation may be provided either through a single electrode or via multiply placed acupuncture needles over the mastoids or around the auricle.",
"   </p>",
"   <p>",
"    In patients without hearing loss, however, electrical stimulation external to the middle or inner ear has not been demonstrated to be more effective for tinnitus suppression than placebo treatment; responses were approximately 38 to 43 percent for both groups [",
"    <a class=\"abstract\" href=\"UTD.htm?24/57/25495/abstract/55,56\">",
"     55,56",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Case reports of increasingly invasive procedures have been published including electrodes placement directly into a site in Heschl's gyrus that was mapped to respond to the tone of the perceived tinnitus [",
"    <a class=\"abstract\" href=\"UTD.htm?24/57/25495/abstract/57\">",
"     57",
"    </a>",
"    ]. This procedure was successful in one of two patients described.",
"   </p>",
"   <p>",
"    In a case series of 21 patients with incapacitating tinnitus and unilateral deafness, cochlear implantation in the deaf ear resulted in reduction of tinnitus loudness and distress [",
"    <a class=\"abstract\" href=\"UTD.htm?24/57/25495/abstract/58\">",
"     58",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Acupuncture",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acupuncture, alone or in conjunction with electrical stimulation, has not been found to be more effective than placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?24/57/25495/abstract/59,60\">",
"     59,60",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Repetitive transcranial magnetic stimulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Repetitive transcranial magnetic stimulation (rTMS) has been investigated in patients with different medical conditions (eg, movement disorders, seizures, and depression) and has shown modest effectiveness. However, in a systematic review that included five small randomized trials of patients with tinnitus (n = 233), there were limited data showing improvement in severity or disability of tinnitus with rTMS therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?24/57/25495/abstract/61\">",
"     61",
"    </a>",
"    ]. rTMS appears to be safe in short-term treatment, but safety with long-term treatment is not known. Larger trials are needed to determine the conditions under which rTMS may be effective and safe.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?42/26/43425?source=see_link\">",
"       \"Patient information: Tinnitus (ringing in the ears) (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?17/42/18082?source=see_link\">",
"       \"Patient information: Tinnitus (ringing in the ears) (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The goal of treatment, for most patients, is to lessen awareness of tinnitus and its impact on quality of life.",
"     </li>",
"     <li>",
"      Treatment for tinnitus should be aimed at the underlying abnormality, when identified. We recommend treatment of underlying depression and insomnia, as these conditions may exacerbate symptoms of tinnitus (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). Cochlear implants for patients with severe sensorineural hearing may improve tinnitus in 75 percent of patients. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Associated factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend tinnitus retraining therapy, in the context of directive counseling, for patients who are significantly impacted by their tinnitus symptoms (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ). We suggest a trial of biofeedback or cognitive-behavioral therapy, which may also be helpful as an adjunct to tinnitus retraining therapy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Behavioral therapies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Medications for tinnitus have limited effectiveness. (See",
"      <a class=\"local\" href=\"#H504724126\">",
"       'Medications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Other medical treatments, including acupuncture and electrical stimulation (except for patients with hearing loss), are not demonstrably more effective than placebo. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Other therapies'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/57/25495/abstract/1\">",
"      Ahmad N, Seidman M. Tinnitus in the older adult: epidemiology, pathophysiology and treatment options. Drugs Aging 2004; 21:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/57/25495/abstract/2\">",
"      Hoare DJ, Kowalkowski VL, Kang S, Hall DA. Systematic review and meta-analyses of randomized controlled trials examining tinnitus management. Laryngoscope 2011; 121:1555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/57/25495/abstract/3\">",
"      Dobie RA, Sakai CS, Sullivan MD, et al. Antidepressant treatment of tinnitus patients: report of a randomized clinical trial and clinical prediction of benefit. Am J Otol 1993; 14:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/57/25495/abstract/4\">",
"      Jacobson GP, McCaslin DL. A search for evidence of a direct relationship between tinnitus and suicide. J Am Acad Audiol 2001; 12:493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/57/25495/abstract/5\">",
"      Baldo P, Doree C, Molin P, et al. Antidepressants for patients with tinnitus. Cochrane Database Syst Rev 2012; 9:CD003853.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/57/25495/abstract/6\">",
"      Robinson SK, Viirre ES, Bailey KA, et al. Randomized placebo-controlled trial of a selective serotonin reuptake inhibitor in the treatment of nondepressed tinnitus subjects. Psychosom Med 2005; 67:981.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/57/25495/abstract/7\">",
"      Folmer RL, Griest SE. Tinnitus and insomnia. Am J Otolaryngol 2000; 21:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/57/25495/abstract/8\">",
"      Aschendorff A, Pabst G, Klenzner T, Laszig R. Tinnitus in Cochlear Implant Users: The Freiburg Experience. Int Tinnitus J 1998; 4:162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/57/25495/abstract/9\">",
"      Ito J. Tinnitus suppression in cochlear implant patients. Otolaryngol Head Neck Surg 1997; 117:701.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/57/25495/abstract/10\">",
"      Miyamoto RT, Bichey BG. Cochlear implantation for tinnitus suppression. Otolaryngol Clin North Am 2003; 36:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/57/25495/abstract/11\">",
"      Quaranta N, Wagstaff S, Baguley DM. Tinnitus and cochlear implantation. Int J Audiol 2004; 43:245.",
"     </a>",
"    </li>",
"    <li>",
"     Campbell, K, Meech, R, Rybak, L, Hughes, L. The effect of D-methionine on cochlear oxidative state with and without cisplatin administration: mechanisms of otoprotection. Abstracts of the Twenty-third Midwinter Research Meeting, ARO. St. Petersburg, Fl., 2000; #5039.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/57/25495/abstract/13\">",
"      Pirvola U, Xing-Qun L, Virkkala J, et al. Rescue of hearing, auditory hair cells, and neurons by CEP-1347/KT7515, an inhibitor of c-Jun N-terminal kinase activation. J Neurosci 2000; 20:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/57/25495/abstract/14\">",
"      Attias J, Sapir S, Bresloff I, et al. Reduction in noise-induced temporary threshold shift in humans following oral magnesium intake. Clin Otolaryngol Allied Sci 2004; 29:635.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/57/25495/abstract/15\">",
"      Duan ML, Ulfendahl M, Laurell G, et al. Protection and treatment of sensorineural hearing disorders caused by exogenous factors: experimental findings and potential clinical application. Hear Res 2002; 169:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/57/25495/abstract/16\">",
"      Feghali JG, Liu W, Van De Water TR. L-n-acetyl-cysteine protection against cisplatin-induced auditory neuronal and hair cell toxicity. Laryngoscope 2001; 111:1147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/57/25495/abstract/17\">",
"      Bryce GE, Morrison MD. Botulinum toxin treatment of essential palatal myoclonus tinnitus. J Otolaryngol 1998; 27:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/57/25495/abstract/18\">",
"      Fortune DS, Haynes DS, Hall JW 3rd. Tinnitus. Current evaluation and management. Med Clin North Am 1999; 83:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/57/25495/abstract/19\">",
"      Sato T, Kawase T, Yano H, et al. Trans-tympanic silicone plug insertion for chronic patulous Eustachian tube. Acta Otolaryngol 2005; 125:1158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/57/25495/abstract/20\">",
"      Doherty JK, Slattery WH 3rd. Autologous fat grafting for the refractory patulous eustachian tube. Otolaryngol Head Neck Surg 2003; 128:88.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/57/25495/abstract/21\">",
"      Orlandi RR, Shelton C. Endoscopic closure of the eustachian tube. Am J Rhinol 2004; 18:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/57/25495/abstract/22\">",
"      Grimmer JF, Poe DS. Update on eustachian tube dysfunction and the patulous eustachian tube. Curr Opin Otolaryngol Head Neck Surg 2005; 13:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/57/25495/abstract/23\">",
"      Cima RF, Maes IH, Joore MA, et al. Specialised treatment based on cognitive behaviour therapy versus usual care for tinnitus: a randomised controlled trial. Lancet 2012; 379:1951.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/57/25495/abstract/24\">",
"      Jastreboff PJ, Gray WC, Gold SL. Neurophysiological approach to tinnitus patients. Am J Otol 1996; 17:236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/57/25495/abstract/25\">",
"      Herraiz C, Hernandez FJ, Plaza G, de los Santos G. Long-term clinical trial of tinnitus retraining therapy. Otolaryngol Head Neck Surg 2005; 133:774.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/57/25495/abstract/26\">",
"      Jastreboff PJ, Jastreboff MM. Tinnitus retraining therapy for patients with tinnitus and decreased sound tolerance. Otolaryngol Clin North Am 2003; 36:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/57/25495/abstract/27\">",
"      Berry JA, Gold SL, Frederick EA, et al. Patient-based outcomes in patients with primary tinnitus undergoing tinnitus retraining therapy. Arch Otolaryngol Head Neck Surg 2002; 128:1153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/57/25495/abstract/28\">",
"      Dobie RA. A review of randomized clinical trials in tinnitus. Laryngoscope 1999; 109:1202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/57/25495/abstract/29\">",
"      Phillips JS, McFerran D. Tinnitus Retraining Therapy (TRT) for tinnitus. Cochrane Database Syst Rev 2010; :CD007330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/57/25495/abstract/30\">",
"      Andersson G, Lyttkens L. A meta-analytic review of psychological treatments for tinnitus. Br J Audiol 1999; 33:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/57/25495/abstract/31\">",
"      Andersson G, Melin L, Hagnebo C, et al. A review of psychological treatment approaches for patients suffering from tinnitus. Ann Behav Med 1995; 17:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/57/25495/abstract/32\">",
"      Briner W, House J, O'Leary M. Synthetic prostaglandin E1 misoprostol as a treatment for tinnitus. Arch Otolaryngol Head Neck Surg 1993; 119:652.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/57/25495/abstract/33\">",
"      Yilmaz I, Akkuzu B, Cakmak O, Ozl&uuml;oglu LN. Misoprostol in the treatment of tinnitus: a double-blind study. Otolaryngol Head Neck Surg 2004; 130:604.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/57/25495/abstract/34\">",
"      Murai K, Tyler RS, Harker LA, Stouffer JL. Review of pharmacologic treatment of tinnitus. Am J Otol 1992; 13:454.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/57/25495/abstract/35\">",
"      Sakata H, Kojima Y, Koyama S, et al. Treatment of cochlear tinnitus with transtympanic infusion of 4% lidocaine into the tympanic cavity. Int Tinnitus J 2001; 7:46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/57/25495/abstract/36\">",
"      Otsuka K, Pulec JL, Suzuki M. Assessment of intravenous lidocaine for the treatment of subjective tinnitus. Ear Nose Throat J 2003; 82:781.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/57/25495/abstract/37\">",
"      Jalali MM, Kousha A, Naghavi SE, et al. The effects of alprazolam on tinnitus: a cross-over randomized clinical trial. Med Sci Monit 2009; 15:PI55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/57/25495/abstract/38\">",
"      Johnson RM, Brummett R, Schleuning A. Use of alprazolam for relief of tinnitus. A double-blind study. Arch Otolaryngol Head Neck Surg 1993; 119:842.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/57/25495/abstract/39\">",
"      Slattery WH, Fisher LM, Iqbal Z, et al. Intratympanic steroid injection for treatment of idiopathic sudden hearing loss. Otolaryngol Head Neck Surg 2005; 133:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/57/25495/abstract/40\">",
"      Gardu&ntilde;o-Anaya MA, Couthino De Toledo H, Hinojosa-Gonz&aacute;lez R, et al. Dexamethasone inner ear perfusion by intratympanic injection in unilateral M&eacute;ni&egrave;re's disease: a two-year prospective, placebo-controlled, double-blind, randomized trial. Otolaryngol Head Neck Surg 2005; 133:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/57/25495/abstract/41\">",
"      Shim HJ, Song SJ, Choi AY, et al. Comparison of various treatment modalities for acute tinnitus. Laryngoscope 2011; 121:2619.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/57/25495/abstract/42\">",
"      Hoekstra CE, Rynja SP, van Zanten GA, Rovers MM. Anticonvulsants for tinnitus. Cochrane Database Syst Rev 2011; :CD007960.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/57/25495/abstract/43\">",
"      Rosenberg SI, Silverstein H, Rowan PT, Olds MJ. Effect of melatonin on tinnitus. Laryngoscope 1998; 108:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/57/25495/abstract/44\">",
"      Rarey KE, Yao X. Localization of Cu/Zn-SOD and Mn-SOD in the rat cochlea. Acta Otolaryngol 1996; 116:833.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/57/25495/abstract/45\">",
"      McFadden SL, Ding D, Burkard RF, et al. Cu/Zn SOD deficiency potentiates hearing loss and cochlear pathology in aged 129,CD-1 mice. J Comp Neurol 1999; 413:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/57/25495/abstract/46\">",
"      Cassandro E, Sequino L, Mondola P, et al. Effect of superoxide dismutase and allopurinol on impulse noise-exposed guinea pigs--electrophysiological and biochemical study. Acta Otolaryngol 2003; 123:802.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/57/25495/abstract/47\">",
"      Arda HN, Tuncel U, Akdogan O, Ozluoglu LN. The role of zinc in the treatment of tinnitus. Otol Neurotol 2003; 24:86.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/57/25495/abstract/48\">",
"      Ochi K, Kinoshita H, Kenmochi M, et al. Zinc deficiency and tinnitus. Auris Nasus Larynx 2003; 30 Suppl:S25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/57/25495/abstract/49\">",
"      Yetiser S, Tosun F, Satar B, et al. The role of zinc in management of tinnitus. Auris Nasus Larynx 2002; 29:329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/57/25495/abstract/50\">",
"      Paaske PB, Pedersen CB, Kjems G, Sam IL. Zinc in the management of tinnitus. Placebo-controlled trial. Ann Otol Rhinol Laryngol 1991; 100:647.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/57/25495/abstract/51\">",
"      Vernon JA, Meikle MB. Masking devices and alprazolam treatment for tinnitus. Otolaryngol Clin North Am 2003; 36:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/57/25495/abstract/52\">",
"      Hobson J, Chisholm E, El Refaie A. Sound therapy (masking) in the management of tinnitus in adults. Cochrane Database Syst Rev 2010; :CD006371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/57/25495/abstract/53\">",
"      Lipman RI, Lipman SP. Phase-shift treatment for predominant tone tinnitus. Otolaryngol Head Neck Surg 2007; 136:763.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/57/25495/abstract/54\">",
"      Konopka W, Zalewski P, Olszewski J, et al. Tinnitus suppression by electrical promontory stimulation (EPS) in patients with sensorineural hearing loss. Auris Nasus Larynx 2001; 28:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/57/25495/abstract/55\">",
"      Steenerson RL, Cronin GW. Treatment of tinnitus with electrical stimulation. Otolaryngol Head Neck Surg 1999; 121:511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/57/25495/abstract/56\">",
"      Kapkin O, Satar B, Yetiser S. Transcutaneous electrical stimulation of subjective tinnitus. A placebo-controlled, randomized and comparative analysis. ORL J Otorhinolaryngol Relat Spec 2008; 70:156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/57/25495/abstract/57\">",
"      Seidman MD, Ridder DD, Elisevich K, et al. Direct electrical stimulation of Heschl's gyrus for tinnitus treatment. Laryngoscope 2008; 118:491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/57/25495/abstract/58\">",
"      Van de Heyning P, Vermeire K, Diebl M, et al. Incapacitating unilateral tinnitus in single-sided deafness treated by cochlear implantation. Ann Otol Rhinol Laryngol 2008; 117:645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/57/25495/abstract/59\">",
"      Axelsson A, Andersson S, Gu LD. Acupuncture in the management of tinnitus: a placebo-controlled study. Audiology 1994; 33:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/57/25495/abstract/60\">",
"      Park J, White AR, Ernst E. Efficacy of acupuncture as a treatment for tinnitus: a systematic review. Arch Otolaryngol Head Neck Surg 2000; 126:489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/57/25495/abstract/61\">",
"      Meng Z, Liu S, Zheng Y, Phillips JS. Repetitive transcranial magnetic stimulation for tinnitus. Cochrane Database Syst Rev 2011; :CD007946.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6856 Version 15.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-61.234.146.186-DE6246C94F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_57_25495=[""].join("\n");
var outline_f24_57_25495=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H23\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Associated factors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Depression",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Insomnia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Vascular abnormalities",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Presbycusis and other hearing loss",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Drug toxicity",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Other associated factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Behavioral therapies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Tinnitus retraining therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Biofeedback and stress reduction",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Cognitive-behavioral therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H504724126\">",
"      Medications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Other therapies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10015034\">",
"      - Masking",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Electrical stimulation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Acupuncture",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Repetitive transcranial magnetic stimulation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PC/6856\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/6856|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?4/62/5101\" title=\"table 1\">",
"      Causes of hearing loss",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?6/55/7036\" title=\"table 2\">",
"      Drugs causing tinnitus",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/28/11720?source=related_link\">",
"      Clinical use of ginkgo biloba",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/6/26727?source=related_link\">",
"      Etiology and diagnosis of tinnitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?17/42/18082?source=related_link\">",
"      Patient information: Tinnitus (ringing in the ears) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?42/26/43425?source=related_link\">",
"      Patient information: Tinnitus (ringing in the ears) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/62/13290?source=related_link\">",
"      Treatment of insomnia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f24_57_25496="Unexplained infertility";
var content_f24_57_25496=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Unexplained infertility",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/57/25496/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/57/25496/contributors\">",
"     Mark D Hornstein, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/57/25496/contributors\">",
"     William E Gibbons, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/57/25496/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/57/25496/contributors\">",
"     Robert L Barbieri, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/57/25496/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/57/25496/contributors\">",
"     Vanessa A Barss, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?24/57/25496/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 4, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is relatively simple to identify the cause of infertility in women with ovulatory disorders or tubal disease, and in men with semen abnormalities. These categories account for the source of infertility in approximately 75 percent of couples. Infertility in the remaining 25 percent of couples is due to endometriosis (8 percent) or miscellaneous factors (eg, cervical factor, immunological factor, uterine synechiae) (2 percent) or is unexplained (15 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/57/25496/abstract/1-3\">",
"     1-3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Management of couples with unexplained infertility will be reviewed here. Diagnosis and treatment of known causes of infertility are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/56/17287?source=see_link\">",
"     \"Overview of infertility\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/15/38136?source=see_link\">",
"     \"Pathogenesis and treatment of infertility in women with endometriosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/44/33481?source=see_link\">",
"     \"Evaluation of male infertility\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/33/3610?source=see_link\">",
"     \"Treatment of male infertility\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DEFINITION AND DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Unexplained infertility refers to the absence of a definable cause for a couple's failure to achieve pregnancy after 12 months of attempting conception despite a thorough evaluation, or after six months in women 35 and older [",
"    <a class=\"abstract\" href=\"UTD.htm?24/57/25496/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. Authorities vary in their concept of what constitutes a thorough evaluation, and these opinions have evolved over time. Currently, a thorough evaluation typically includes documentation of:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Ovulation",
"     </li>",
"     <li>",
"      Tubal patency",
"     </li>",
"     <li>",
"      Normal uterine cavity",
"     </li>",
"     <li>",
"      Normal semen analysis",
"     </li>",
"     <li>",
"      Adequate ovarian oocyte reserve",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A detailed description of these tests, and the role of laparoscopy in the diagnostic evaluation, can be found separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/61/40921?source=see_link\">",
"     \"Evaluation of female infertility\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     POSSIBLE ETIOLOGIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several possibilities have been proposed to explain why some couples fail to conceive in the absence of an identifiable cause. Subtle changes in follicle development, ovulation, and the luteal phase have been reported in some of these women [",
"    <a class=\"abstract\" href=\"UTD.htm?24/57/25496/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. In other couples, the male partner's semen analysis shows sperm concentration and motility at the lower end of the normal range [",
"    <a class=\"abstract\" href=\"UTD.htm?24/57/25496/abstract/8\">",
"     8",
"    </a>",
"    ]. Implantation failure, subtle cervical factors, or problems with sperm and egg transport or interaction are other possibilities [",
"    <a class=\"abstract\" href=\"UTD.htm?24/57/25496/abstract/9\">",
"     9",
"    </a>",
"    ]. Many cases of unexplained infertility are probably caused by the presence of multiple factors (eg, female partner over 35 years of age and male partner with low normal semen parameters), each of which on their own do not significantly reduce fertility, but can reduce the pregnancy rate when combined.",
"   </p>",
"   <p>",
"    Couples with unexplained infertility who are treated with IVF demonstrate reduced oocyte fertilization and embryo cleavage rates compared to couples in whom tubal factor is the cause of the infertility, although the rates of live birth per transfer are equivalent for both groups. This was illustrated in a study that showed that the oocyte fertilization and the embryo cleavage rate for unexplained and tubal factor infertility were 52 and 60 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?24/57/25496/abstract/10\">",
"     10",
"    </a>",
"    ]. Couples with unexplained infertility also had a higher rate of complete fertilization failure when treated with IVF than couples with tubal factor infertility (6 versus 3 percent). These results suggest that couples with unexplained infertility probably have subtle functional abnormalities in oocyte",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    sperm function. In this sense, IVF is also a diagnostic procedure.",
"   </p>",
"   <p>",
"    Defective endometrial receptivity is thought to prevent normal attachment, invasion, and implantation of the blastocyst, and may account for some cases of unexplained infertility and recurrent pregnancy loss [",
"    <a class=\"abstract\" href=\"UTD.htm?24/57/25496/abstract/11\">",
"     11",
"    </a>",
"    ]. No biomarkers have been validated for clinical diagnosis of these patients.",
"   </p>",
"   <p>",
"    <span class=\"nowrap\">",
"     Undiagnosed/untreated",
"    </span>",
"    celiac disease may be more prevalent in women with unexplained infertility. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/44/40650?source=see_link\">",
"     \"Pathogenesis, epidemiology, and clinical manifestations of celiac disease in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     OVERVIEW OF MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The management of couples with unexplained infertility should balance the efficacy, cost, safety, and risks of various treatment alternatives. A common approach is to start with treatments that consume few resources and are patient directed (eg, lifestyle changes, timed intercourse), and then move sequentially to treatments requiring proportionately greater resources (tubal flushing, intrauterine insemination,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/22/23909?source=see_link\">",
"     clomiphene",
"    </a>",
"    , clomiphene plus intrauterine insemination), and finally to high resource interventions (gonadotropin injections plus intrauterine insemination, IVF) (",
"    <a class=\"graphic graphic_table graphicRef61307 \" href=\"UTD.htm?34/57/35739\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/57/25496/abstract/10\">",
"     10",
"    </a>",
"    ]. The approach to treatment should be individualized for each couple. In general, if a specific fertility treatment does not result in pregnancy after three cycles, alternative treatments should be considered [",
"    <a class=\"abstract\" href=\"UTD.htm?24/57/25496/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The economic impact of medical treatments is of great concern in a resource limited environment. One study of the cost per live birth for various treatments of unexplained infertility reported the following costs:",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/22/23909?source=see_link\">",
"     clomiphene",
"    </a>",
"    plus IUI - $10,000 per pregnancy, FSH plus IUI - $17,000 per pregnancy, and IVF - $50,000 per pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?24/57/25496/abstract/13\">",
"     13",
"    </a>",
"    ]. This analysis supports the use of low resource intensive treatments prior to initiation of high resource intensive procedures in the treatment of unexplained infertility.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Expectant management",
"    </span>",
"    &nbsp;&mdash;&nbsp;One to 3 percent of couples with unexplained infertility followed prospectively without active treatment become pregnant each month [",
"    <a class=\"abstract\" href=\"UTD.htm?24/57/25496/abstract/14\">",
"     14",
"    </a>",
"    ]. Therefore, effective fertility treatment for unexplained infertility must demonstrate an increase in the pregnancy rate above this baseline fecundability.",
"   </p>",
"   <p>",
"    The age of the female partner influences the pregnancy rate associated with expectant management [",
"    <a class=\"abstract\" href=\"UTD.htm?24/57/25496/abstract/15\">",
"     15",
"    </a>",
"    ]. Women with unexplained infertility older than 37 years of age have a pregnancy rate of less than 1 percent per cycle with expectant management. In randomized trials, six months of expectant management for couples with a good prognosis for fertility (young age, no bilateral tubal disease, no sperm problems) or an intermediate prognosis (30 to 40 percent probability of pregnancy without treatment) was associated with an ongoing pregnancy rate comparable to that achieved with intrauterine insemination plus gonadotropin injections (see below) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/57/25496/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. Thus, expectant management may be an option for a couple with unexplained infertility in whom the female partner is less than 32 years of age and there is no immediate concern about oocyte depletion. However, the ovarian oocyte pool declines rapidly for women over 37 years of age, inevitably causing ovarian aging and depletion to become a major component of the fertility problem. Thus, expectant management is not recommended for these women.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     PATIENT CONTROLLED APPROACHES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Lifestyle changes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Epidemiological studies indicate cigarette smoking, abnormal body mass index, and excessive caffeine and alcohol consumption reduce fertility in the female partner, and possibly the male partner. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/13/11482?source=see_link\">",
"     \"Optimizing natural fertility in couples planning pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Couples with unexplained infertility should be informed of a possible relationship between cigarette smoking and their infertility and advised to stop smoking for this reason, as well as for benefits in overall health. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/11/34997?source=see_link\">",
"     \"Patterns of tobacco use\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The female partner should be counseled to try to achieve a body mass index between 20 and 27",
"    <span class=\"nowrap\">",
"     kg/m2,",
"    </span>",
"    reduce caffeine intake to no more than about 250 mg daily (two cups of coffee), and reduce alcohol intake to no more than four standardized drinks per week [",
"    <a class=\"abstract\" href=\"UTD.htm?24/57/25496/abstract/18\">",
"     18",
"    </a>",
"    ]. These changes may be useful for enhancing both natural and assisted conception [",
"    <a class=\"abstract\" href=\"UTD.htm?24/57/25496/abstract/19,20\">",
"     19,20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This is also an appropriate time to mention lifestyle changes for health promotion to the male partner for his general health benefits, and because the couple's coordinated efforts to modify their lifestyle may provide support and reinforcement for each other.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     LOW RESOURCE INTERVENTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Couples of all ages often become frustrated with their inability to conceive. Active treatment is recommended for these couples when less resource intensive interventions fail to result in pregnancy. The following interventions increase the number of gametes available in a given cycle",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    facilitate the ability of the gametes to interact.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Intrauterine insemination",
"    </span>",
"    &nbsp;&mdash;&nbsp;The intrauterine insemination (IUI) procedure consists of washing an ejaculated semen specimen to remove prostaglandins, concentrating the sperm in a small volume of culture media, and injecting the sperm suspension directly into the upper uterine cavity using a small catheter threaded through the cervix. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/48/25351?source=see_link\">",
"     \"Procedure for intrauterine insemination\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The efficacy of IUI for couples with unexplained infertility was demonstrated in a large clinical trial sponsored by the National Institutes of Health (NIH) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/57/25496/abstract/8\">",
"     8",
"    </a>",
"    ]. Over 900 infertile couples with unexplained infertility were randomly assigned to one of four treatment groups:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Intracervical insemination of sperm (ICI)",
"     </li>",
"     <li>",
"      Intrauterine insemination of sperm",
"     </li>",
"     <li>",
"      FSH injections plus ICI",
"     </li>",
"     <li>",
"      FSH injections plus IUI",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The purpose of the ICI was to act as a control treatment mimicking natural intercourse; the purpose of IUI was to place a large number of sperm high in the reproductive tract; and the purpose of FSH injections was to stimulate multiple follicular development and ovulation, thereby increasing the number of oocytes available for fertilization in a single cycle. Most of the women in this study had either unexplained infertility or early stage endometriosis.",
"   </p>",
"   <p>",
"    The investigators observed a 2 percent per cycle pregnancy rate in the group that received the control ICI treatment; this pregnancy rate is similar to that achieved with expectant management. IUI treatment was associated with a 5 percent per cycle pregnancy rate; thus, in the randomized trial, IUI alone was effective, but only marginally for the treatment of unexplained infertility.",
"   </p>",
"   <p>",
"    The pregnancy rates in the FSH-ICI and FSH-IUI groups were higher, and are described below (see",
"    <a class=\"local\" href=\"#H14\">",
"     'Gonadotropin injections with or without IUI'",
"    </a>",
"    below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Clomiphene citrate",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/22/23909?source=see_link\">",
"     Clomiphene",
"    </a>",
"    has been demonstrated to be effective in the treatment of infertility due to oligoanovulation or anovulation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/25/9626?source=see_link\">",
"     \"Ovulation induction with clomiphene citrate\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Data on the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/22/23909?source=see_link\">",
"     clomiphene",
"    </a>",
"    in the setting of unexplained infertility are less clear. A meta-analysis of two randomized trials of clomiphene treatment for women with unexplained infertility found no evidence that clomiphene citrate alone was more effective than no treatment or placebo (OR for clinical pregnancy per woman randomized 0.99, 95% CI 0.61-1.60) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/57/25496/abstract/21\">",
"     21",
"    </a>",
"    ]. However, these results need to be interpreted with caution as there was significant heterogeneity between trials. In one trial, clomiphene citrate was associated with significantly more pregnancies over the course of four months, with a pregnancy rate of 19 percent versus no pregnancies with placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?24/57/25496/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The main complication of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/22/23909?source=see_link\">",
"     clomiphene",
"    </a>",
"    is an increase in the incidence of multiple gestation. This risk was illustrated in a study of 2369 clomiphene induced pregnancies that reported the incidence of twins, triplets, quadruplets, and quintuplets was 7, 0.5, 0.3, and 0.13 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?24/57/25496/abstract/23\">",
"     23",
"    </a>",
"    ]. The risk of high-order multiple pregnancies with clomiphene treatment is low, but the high volume of clomiphene cycles makes this intervention an important contributor to the total number of high-order multiple gestations [",
"    <a class=\"abstract\" href=\"UTD.htm?24/57/25496/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In comparative treatment trials,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/22/23909?source=see_link\">",
"     clomiphene",
"    </a>",
"    was not as effective as gonadotropin injections [",
"    <a class=\"abstract\" href=\"UTD.htm?24/57/25496/abstract/25\">",
"     25",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Gonadotropin injections with or without IUI'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Clomiphene plus IUI",
"    </span>",
"    &nbsp;&mdash;&nbsp;The combination of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/22/23909?source=see_link\">",
"     clomiphene",
"    </a>",
"    (to increase the rate of double ovulation) plus IUI (to place a large number of motile sperm high in the female reproductive tract) may simultaneously treat mild abnormalities of ovulation, oocyte function, and sperm function. In a randomized trial, 67 couples were assigned to treatment with observation alone or with clomiphene plus IUI [",
"    <a class=\"abstract\" href=\"UTD.htm?24/57/25496/abstract/26\">",
"     26",
"    </a>",
"    ]. The pregnancy rate per cycle was 9.5 percent for clomiphene plus IUI versus 3.3 percent for observation.",
"   </p>",
"   <p>",
"    The optimal method for timing IUI is to use a commercial kit to determine daily urinary LH levels starting on day 10 of the cycle. IUI is performed when urinary LH is detected. This method is as effective, but less expensive, than timing based upon ultrasound monitoring of folliculogenesis with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/60/26564?source=see_link\">",
"     human chorionic gonadotropin",
"    </a>",
"    (hCG) injection upon development of an appropriately sized dominant follicle, followed by IUI. This approach was supported by a systematic review showing that women who underwent hCG administration before IUI had lower clinical pregnancy rates than women who underwent IUI based upon detection of urinary LH (OR 0.74, 95% CI 0.57-0.96) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/57/25496/abstract/27\">",
"     27",
"    </a>",
"    ]. No cost analysis was performed. The authors concluded that the available data did not demonstrate a consistent, clinically important benefit of hCG-induced ovulation compared with spontaneous ovulation for IUI timing.",
"   </p>",
"   <p>",
"    The question of whether two IUIs per cycle is superior to a single IUI is controversial. Some clinicians perform a single IUI the day after detection of a urinary LH surge (or 36 hours following hCG injection); others prefer two IUIs: one on the day of, and the other on the day after the LH surge, 12 to 18 hours and 36 hours after hCG injection. Several meta-analyses concluded that there is no improvement in pregnancy rate when a second IUI is performed [",
"    <a class=\"abstract\" href=\"UTD.htm?24/57/25496/abstract/28-30\">",
"     28-30",
"    </a>",
"    ], but two of the largest randomized clinical trials evaluating this issue in patients who received gonadotropin stimulation and IUI reached the opposite conclusion [",
"    <a class=\"abstract\" href=\"UTD.htm?24/57/25496/abstract/31,32\">",
"     31,32",
"    </a>",
"    ]. In the largest available trial, couples in the following subcategories had higher pregnancy rates with double IUI: ovulatory dysfunction, male factor, and use of gonadotropins [",
"    <a class=\"abstract\" href=\"UTD.htm?24/57/25496/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A retrospective multicentre cohort study of couples who underwent over 15,000 IUI cycles reported acceptable pregnancy rates after one to nine cycles [",
"    <a class=\"abstract\" href=\"UTD.htm?24/57/25496/abstract/33\">",
"     33",
"    </a>",
"    ]. In this series, 70 percent of the patients underwent both IUI and controlled ovarian stimulation (51 percent",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/22/23909?source=see_link\">",
"     clomiphene",
"    </a>",
"    -citrate, 19 percent gonadotropins) and IUI. The cumulative ongoing pregnancy rate after three, six, and nine cycles was 18, 30, and 41 percent, respectively. Thus, this study suggests that up to nine IUI cycles is an appropriate treatment course. By comparison, older literature showed that the vast majority of pregnancies occurred by the sixth treatment cycle and relatively few occurred beyond six cycles. We typically administer three to four treatment cycles before moving on to another modality.",
"   </p>",
"   <p>",
"    However, age should be taken into account; multiple treatment cycles are not beneficial in older women. One study showed that on a per patient treated basis, cumulative pregnancy rates by age were 24.2 percent under age 35, 18.5 percent ages 35 to 37, 15.1 percent ages 38 to 40, 7.4 percent ages 41 to 42, and 1.8 percent age above 42 (one pregnancy in 55 patients) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/57/25496/abstract/34\">",
"     34",
"    </a>",
"    ]. In this study, there were no pregnancies beyond the fourth cycle in women age 41 and older.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Other",
"    </span>",
"    &nbsp;&mdash;&nbsp;Aromatase inhibitors are under investigation as a therapeutic option for women who fail to conceive with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/22/23909?source=see_link\">",
"     clomiphene",
"    </a>",
"    -based approaches. These drugs are NOT FDA approved for treatment of infertility. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/6/4201?source=see_link\">",
"     \"Ovulation induction with aromatase inhibitors\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     HIGH RESOURCE INTERVENTIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Gonadotropin injections with or without IUI",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients who do not conceive with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/22/23909?source=see_link\">",
"     clomiphene",
"    </a>",
"    alone or with IUI, gonadotropin injections with or without IUI can be effective [",
"    <a class=\"abstract\" href=\"UTD.htm?24/57/25496/abstract/8,25\">",
"     8,25",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/10/13482?source=see_link&amp;anchor=H14#H14\">",
"     \"Overview of ovulation induction\", section on 'Gonadotropin therapy'",
"    </a>",
"    .) A systematic review of randomized trials showed that using both gonadotropin injections and IUI was more effective than using either treatment alone [",
"    <a class=\"abstract\" href=\"UTD.htm?24/57/25496/abstract/35\">",
"     35",
"    </a>",
"    ]. The following trials are examples illustrating the varying magnitude of this effect:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A large clinical trial sponsored by the NIH randomly assigned 932 infertile couples with unexplained infertility or early stage endometriosis to one of four treatment groups: ICI (control mimicking natural intercourse), IUI, FSH injections plus ICI, or FSH injections plus IUI [",
"      <a class=\"abstract\" href=\"UTD.htm?24/57/25496/abstract/8\">",
"       8",
"      </a>",
"      ]. The pregnancy rate in the control ICI group was 2 percent per cycle, while in the FSH plus ICI and the FSH plus IUI groups the pregnancy rate per cycle was 4 and 9 percent, respectively. Thus, FSH plus ICI and FSH plus IUI were clearly effective for the treatment of unexplained infertility.",
"     </li>",
"     <li>",
"      In a trial of gonadotropin injections with or without IUI, 62 couples with unexplained infertility were randomly assigned to receive IUI alone, gonadotropin injections alone, or gonadotropin injections plus IUI [",
"      <a class=\"abstract\" href=\"UTD.htm?24/57/25496/abstract/36\">",
"       36",
"      </a>",
"      ]. The per cycle pregnancy rate was 2.2 percent for IUI alone, 6.1 percent for gonadotropin injections alone, and 26 percent for gonadotropin injections plus IUI.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Another systematic review of randomized trials of women undergoing IUI concluded there was no convincing evidence that any gonadotropin was better than another [",
"    <a class=\"abstract\" href=\"UTD.htm?24/57/25496/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The main complication of the use of FSH injections in the treatment of infertility in women with unexplained infertility is an increase in the rates of multiple gestation and ovarian hyperstimulation. The rate of multiple gestation varies from 14 to 39 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?24/57/25496/abstract/37\">",
"     37",
"    </a>",
"    ]. Triplet and quadruplet pregnancy, in particular, are associated with major maternal and fetal complications. Some authorities believe that gonadotropin injections with or without IUI should not be widely used in the treatment of unexplained infertility because of the risk of multiple gestation [",
"    <a class=\"abstract\" href=\"UTD.htm?24/57/25496/abstract/38\">",
"     38",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/17/16660?source=see_link\">",
"     \"Pathogenesis of ovarian hyperstimulation syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/41/35479?source=see_link\">",
"     \"Classification and treatment of ovarian hyperstimulation syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The addition of GnRH agonists and antagonists is controversial. A systematic review of randomized trials of women undergoing IUI concluded that the addition of a GnRH agonist or antagonist to a",
"    <span class=\"nowrap\">",
"     gonadotropin/IUI",
"    </span>",
"    cycle did not improve pregnancy outcome, and increased the rate of multiple gestation [",
"    <a class=\"abstract\" href=\"UTD.htm?24/57/25496/abstract/25\">",
"     25",
"    </a>",
"    ]. Two subsequent randomized trials, however, reported that the addition of a GnRH antagonist, initiated at the time when the diameter of the leading follicle was &ge;16 mm, improved pregnancy rates in FSH-IUI cycles. One trial involving 360 infertile women compared treatment with FSH alone versus FSH plus a GnRH antagonist (cetrotide 0.25 mg subcutaneously daily) found higher clinical pregnancy rates in the group using the antagonist (23 versus 11 percent); however, the benefit was limited to cycles with more than one mature follicle [",
"    <a class=\"abstract\" href=\"UTD.htm?24/57/25496/abstract/39\">",
"     39",
"    </a>",
"    ]. The other trial had a similar design and used the GnRH antagonist (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/25/30099?source=see_link\">",
"     ganirelix",
"    </a>",
"    0.25 mg subcutaneously daily) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/57/25496/abstract/40\">",
"     40",
"    </a>",
"    ]. In this trial, the FSH-GnRH antagonist group had more mature follicles, a lower premature luteinization rate, and a higher clinical pregnancy rate than the FSH alone group. It should be noted that in both trials, 10,000 units of hCG was administered intramuscularly and IUI was performed 36 to 38 hours after hCG administration.",
"   </p>",
"   <p>",
"    These two trials and experience from controlled ovarian hyperstimulation in ART suggest that the addition of a GnRH antagonist reduces the risk of premature luteinization and increases the number of mature follicles at the time of hCG administration. Use of a GnRH antagonist in conjunction with gonadotropin-IUI is likely to increase as additional confirmatory data are published. However, GnRH antagonists are costly so defining the patient population most likely to benefit from their use should be a focus of further study.",
"   </p>",
"   <p>",
"    Many authorities believe that the use of gonadotropin injections plus IUI should be limited to no more than three cycles because most pregnancies with this treatment will occur in the first three cycles [",
"    <a class=\"abstract\" href=\"UTD.htm?24/57/25496/abstract/41\">",
"     41",
"    </a>",
"    ]. There is also evidence that this step may be omitted altogether [",
"    <a class=\"abstract\" href=\"UTD.htm?24/57/25496/abstract/42,43\">",
"     42,43",
"    </a>",
"    ]. An American Society for Reproductive Medicine (ASRM) practice committee opinion concluded, &ldquo;Owing to the high risk of multiple gestation with superovulation in ovulatory women, moving directly from",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/22/23909?source=see_link\">",
"     clomiphene",
"    </a>",
"    <span class=\"nowrap\">",
"     citrate/IUI",
"    </span>",
"    to IVF should be considered&rdquo; [",
"    <a class=\"abstract\" href=\"UTD.htm?24/57/25496/abstract/44\">",
"     44",
"    </a>",
"    ]. This approach is supported by a randomized trial that compared treatment outcomes of couples with unexplained infertility assigned to receive three cycles of clomiphene",
"    <span class=\"nowrap\">",
"     citrate/IUI,",
"    </span>",
"    three cycles of",
"    <span class=\"nowrap\">",
"     FSH/IUI,",
"    </span>",
"    and up to six cycles of IVF versus an accelerated approach that omitted the three cycles of",
"    <span class=\"nowrap\">",
"     FSH/IUI",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?24/57/25496/abstract/42\">",
"     42",
"    </a>",
"    ]. About 25 percent of couples achieved pregnancy with",
"    <span class=\"nowrap\">",
"     clomiphene/IUI",
"    </span>",
"    alone. Omitting the",
"    <span class=\"nowrap\">",
"     FSH/IUI",
"    </span>",
"    cycles resulted in less time to achieve pregnancy (median time 8 versus 11 months with the conventional approach), fewer treatment cycles, and significantly lower total charges per couple and per delivery. Cumulative pregnancy rates were slightly higher in the accelerated approach group initially (P = 0.03), but were similar to those in the conventional treatment group after 11 months (P = 0.08). The incidence of multiple gestation was also similar for both groups.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     In vitro fertilization",
"    </span>",
"    &nbsp;&mdash;&nbsp;IVF is the intervention that results in the highest per cycle pregnancy rate in the shortest time interval. It is also the most costly intervention and has a high rate of high order multiple pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?24/57/25496/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A randomized clinical trial of women with subfertility (unexplained in 38 percent) and tubal patency compared IVF to expectant management and found the pregnancy rate was significantly higher in couples assigned to IVF",
"    <span class=\"nowrap\">",
"     (20/68",
"    </span>",
"    versus",
"    <span class=\"nowrap\">",
"     1/71)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?24/57/25496/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A cohort study of couples with unexplained infertility initially treated the woman with gonadotropin injections plus IUI for up to three cycles and then used IVF to treat those who did not conceive [",
"    <a class=\"abstract\" href=\"UTD.htm?24/57/25496/abstract/47\">",
"     47",
"    </a>",
"    ]. The per cycle pregnancy rate was more than twice as high in couples treated with IVF compared to those treated with gonadotropin injections plus IUI (37 and 16 percent, respectively). Cohort studies of treatment of unexplained infertility with IVF with no control group have reported per cycle pregnancy rates of 20 to 40 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?24/57/25496/abstract/48\">",
"     48",
"    </a>",
"    ]. Large, comparative trials using different treatment modalities in couples with unexplained infertility are warranted [",
"    <a class=\"abstract\" href=\"UTD.htm?24/57/25496/abstract/9\">",
"     9",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/56/37770?source=see_link\">",
"     \"In vitro fertilization\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     INEFFECTIVE TREATMENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical trials of the treatment of unexplained infertility have shown that administration of either",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/40/8840?source=see_link\">",
"     bromocriptine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/0/26629?source=see_link\">",
"     danazol",
"    </a>",
"    was not effective [",
"    <a class=\"abstract\" href=\"UTD.htm?24/57/25496/abstract/49,50\">",
"     49,50",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?39/42/40610?source=see_link\">",
"       \"Patient information: Infertility in men (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?11/16/11523?source=see_link\">",
"       \"Patient information: Infertility in women (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?21/42/22180?source=see_link\">",
"       \"Patient information: Evaluation of the infertile couple (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?32/5/32851?source=see_link\">",
"       \"Patient information: Treatment of male infertility (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?34/4/34883?source=see_link\">",
"       \"Patient information: Ovulation induction with clomiphene (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?10/14/10468?source=see_link\">",
"       \"Patient information: Infertility treatment with gonadotropins (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Unexplained infertility refers to the absence of a definable cause for a couple's failure to achieve pregnancy after 12 months of attempting conception (six months in women 35 years and older) despite a thorough evaluation. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Definition and diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The infertility is probably due to subtle functional abnormalities in oocyte, sperm or endometrial function. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Possible etiologies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The management of couples with unexplained infertility usually starts with treatments that consume few resources and are low risk and patient directed (eg, lifestyle changes), and then moves sequentially to treatments requiring proportionately greater resources and risks (intrauterine insemination,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/22/23909?source=see_link\">",
"       clomiphene",
"      </a>",
"      , clomiphene plus intrauterine insemination), and finally to higher risk and high resource intensive interventions (gonadotropin injections plus intrauterine insemination, IVF) (",
"      <a class=\"graphic graphic_table graphicRef61307 \" href=\"UTD.htm?34/57/35739\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Overview of management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Lifestyle changes, such as discontinuing cigarette smoking and achieving a normal weight may increase fertility in women with unexplained infertility. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Lifestyle changes'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Approximately 1 percent of these couples will become pregnant per cycle with no intervention. Expectant management may be an appropriate therapy for couples where the female partner is less than 32 years of age. For women over 37 years of age, however, the ovarian follicular pool can become depleted during expectant management, resulting in untreatable infertility. Typically women 37 years old and above should be offered empiric treatment. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Low resource interventions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For empiric treatment of unexplained infertility, we suggest three to four cycles of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/22/23909?source=see_link\">",
"       clomiphene",
"      </a>",
"      citrate and intrauterine insemination (IUI) (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). If pregnancy does not occur, the second step is either one to three cycles of gonadotropin and IUI or in vitro fertilization, depending on patient specific factors (eg, personal costs and insurance coverage, convenience and availability of treatment). (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Low resource interventions'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H13\">",
"       'High resource interventions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      IVF is the intervention that will result in the highest per cycle pregnancy rate in the shortest time interval. It is also the most costly intervention and has a high rate of high order multiple pregnancy. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'In vitro fertilization'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/57/25496/abstract/1\">",
"      Collins JA, Crosignani PG. Unexplained infertility: a review of diagnosis, prognosis, treatment efficacy and management. Int J Gynaecol Obstet 1992; 39:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/57/25496/abstract/2\">",
"      Templeton AA, Penney GC. The incidence, characteristics, and prognosis of patients whose infertility is unexplained. Fertil Steril 1982; 37:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/57/25496/abstract/3\">",
"      Guzick DS, Grefenstette I, Baffone K, et al. Infertility evaluation in fertile women: a model for assessing the efficacy of infertility testing. Hum Reprod 1994; 9:2306.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/57/25496/abstract/4\">",
"      Moghissi KS, Wallach EE. Unexplained infertility. Fertil Steril 1983; 39:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/57/25496/abstract/5\">",
"      Practice Committee of the American Society for Reproductive Medicine. Definitions of infertility and recurrent pregnancy loss. Fertil Steril 2008; 90:560.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/57/25496/abstract/6\">",
"      Blacker CM, Ginsburg KA, Leach RE, et al. Unexplained infertility: evaluation of the luteal phase; results of the National Center for Infertility Research at Michigan. Fertil Steril 1997; 67:437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/57/25496/abstract/7\">",
"      Leach RE, Moghissi KS, Randolph JF, et al. Intensive hormone monitoring in women with unexplained infertility: evidence for subtle abnormalities suggestive of diminished ovarian reserve. Fertil Steril 1997; 68:413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/57/25496/abstract/8\">",
"      Guzick DS, Carson SA, Coutifaris C, et al. Efficacy of superovulation and intrauterine insemination in the treatment of infertility. National Cooperative Reproductive Medicine Network. N Engl J Med 1999; 340:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/57/25496/abstract/9\">",
"      Pandian Z, Bhattacharya S, Vale L, Templeton A. In vitro fertilisation for unexplained subfertility. Cochrane Database Syst Rev 2005; :CD003357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/57/25496/abstract/10\">",
"      Hull MG. Effectiveness of infertility treatments: choice and comparative analysis. Int J Gynaecol Obstet 1994; 47:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/57/25496/abstract/11\">",
"      Lessey BA. Assessment of endometrial receptivity. Fertil Steril 2011; 96:522.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/57/25496/abstract/12\">",
"      Smith JF, Eisenberg ML, Millstein SG, et al. Fertility treatments and outcomes among couples seeking fertility care: data from a prospective fertility cohort in the United States. Fertil Steril 2011; 95:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/57/25496/abstract/13\">",
"      Guzick DS, Sullivan MW, Adamson GD, et al. Efficacy of treatment for unexplained infertility. Fertil Steril 1998; 70:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/57/25496/abstract/14\">",
"      Evers JL. Female subfertility. Lancet 2002; 360:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/57/25496/abstract/15\">",
"      Hull MG, Glazener CM, Kelly NJ, et al. Population study of causes, treatment, and outcome of infertility. Br Med J (Clin Res Ed) 1985; 291:1693.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/57/25496/abstract/16\">",
"      Steures P, van der Steeg JW, Hompes PG, et al. Intrauterine insemination with controlled ovarian hyperstimulation versus expectant management for couples with unexplained subfertility and an intermediate prognosis: a randomised clinical trial. Lancet 2006; 368:216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/57/25496/abstract/17\">",
"      Custers IM, van Rumste MM, van der Steeg JW, et al. Long-term outcome in couples with unexplained subfertility and an intermediate prognosis initially randomized between expectant management and immediate treatment. Hum Reprod 2012; 27:444.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/57/25496/abstract/18\">",
"      Barbieri RL. The initial fertility consultation: recommendations concerning cigarette smoking, body mass index, and alcohol and caffeine consumption. Am J Obstet Gynecol 2001; 185:1168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/57/25496/abstract/19\">",
"      Wittemer C, Ohl J, Bailly M, et al. Does body mass index of infertile women have an impact on IVF procedure and outcome? J Assist Reprod Genet 2000; 17:547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/57/25496/abstract/20\">",
"      Fedorcs&aacute;k P, Dale PO, Storeng R, et al. Impact of overweight and underweight on assisted reproduction treatment. Hum Reprod 2004; 19:2523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/57/25496/abstract/21\">",
"      Hughes E, Collins J, Vandekerckhove P. Clomiphene citrate for unexplained subfertility in women. Cochrane Database Syst Rev 2000; :CD000057.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/57/25496/abstract/22\">",
"      Fisch P, Casper RF, Brown SE, et al. Unexplained infertility: evaluation of treatment with clomiphene citrate and human chorionic gonadotropin. Fertil Steril 1989; 51:828.",
"     </a>",
"    </li>",
"    <li>",
"     Merrill Dow Pharmaceuticals. Product information bulletin. Cincinnati Ohio 1972.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/57/25496/abstract/24\">",
"      Collins J. Global epidemiology of multiple birth. Reprod Biomed Online 2007; 15 Suppl 3:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/57/25496/abstract/25\">",
"      Cantineau AE, Cohlen BJ, Heineman MJ. Ovarian stimulation protocols (anti-oestrogens, gonadotrophins with and without GnRH agonists/antagonists) for intrauterine insemination (IUI) in women with subfertility. Cochrane Database Syst Rev 2007; :CD005356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/57/25496/abstract/26\">",
"      Deaton JL, Gibson M, Blackmer KM, et al. A randomized, controlled trial of clomiphene citrate and intrauterine insemination in couples with unexplained infertility or surgically corrected endometriosis. Fertil Steril 1990; 54:1083.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/57/25496/abstract/27\">",
"      Kosmas IP, Tatsioni A, Fatemi HM, et al. Human chorionic gonadotropin administration vs. luteinizing monitoring for intrauterine insemination timing, after administration of clomiphene citrate: a meta-analysis. Fertil Steril 2007; 87:607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/57/25496/abstract/28\">",
"      Cantineau AE, Heineman MJ, Cohlen BJ. Single versus double intrauterine insemination (IUI) in stimulated cycles for subfertile couples. Cochrane Database Syst Rev 2003; :CD003854.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/57/25496/abstract/29\">",
"      Osuna C, Matorras R, Pijoan JI, Rodr&iacute;guez-Escudero FJ. One versus two inseminations per cycle in intrauterine insemination with sperm from patients' husbands: a systematic review of the literature. Fertil Steril 2004; 82:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/57/25496/abstract/30\">",
"      Polyzos NP, Tzioras S, Mauri D, Tatsioni A. Double versus single intrauterine insemination for unexplained infertility: a meta-analysis of randomized trials. Fertil Steril 2010; 94:1261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/57/25496/abstract/31\">",
"      Ragni G, Maggioni P, Guermandi E, et al. Efficacy of double intrauterine insemination in controlled ovarian hyperstimulation cycles. Fertil Steril 1999; 72:619.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/57/25496/abstract/32\">",
"      Randall GW, Gantt PA. Double vs. single intrauterine insemination per cycle: use in gonadotropin cycles and in diagnostic categories of ovulatory dysfunction and male factor infertility. J Reprod Med 2008; 53:196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/57/25496/abstract/33\">",
"      Custers IM, Steures P, Hompes P, et al. Intrauterine insemination: how many cycles should we perform? Hum Reprod 2008; 23:885.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/57/25496/abstract/34\">",
"      Dovey S, Sneeringer RM, Penzias AS. Clomiphene citrate and intrauterine insemination: analysis of more than 4100 cycles. Fertil Steril 2008; 90:2281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/57/25496/abstract/35\">",
"      Veltman-Verhulst SM, Cohlen BJ, Hughes E, Heineman MJ. Intra-uterine insemination for unexplained subfertility. Cochrane Database Syst Rev 2012; 9:CD001838.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/57/25496/abstract/36\">",
"      Serhal PF, Katz M, Little V, Woronowski H. Unexplained infertility--the value of Pergonal superovulation combined with intrauterine insemination. Fertil Steril 1988; 49:602.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/57/25496/abstract/37\">",
"      Kaplan PF, Patel M, Austin DJ, Freund R. Assessing the risk of multiple gestation in gonadotropin intrauterine insemination cycles. Am J Obstet Gynecol 2002; 186:1244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/57/25496/abstract/38\">",
"      Stewart JA. Stimulated intra-uterine insemination is not a natural choice for the treatment of unexplained subfertility. Should the guidelines be changed? Hum Reprod 2003; 18:903.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/57/25496/abstract/39\">",
"      G&oacute;mez-Palomares JL, Acevedo-Mart&iacute;n B, Ch&aacute;vez M, et al. Multifollicular recruitment in combination with gonadotropin-releasing hormone antagonist increased pregnancy rates in intrauterine insemination cycles. Fertil Steril 2008; 89:620.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/57/25496/abstract/40\">",
"      Bakas P, Konidaris S, Liapis A, et al. Role of gonadotropin-releasing hormone antagonist in the management of subfertile couples with intrauterine insemination and controlled ovarian stimulation. Fertil Steril 2011; 95:2024.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/57/25496/abstract/41\">",
"      Aboulghar M, Mansour R, Serour G, et al. Controlled ovarian hyperstimulation and intrauterine insemination for treatment of unexplained infertility should be limited to a maximum of three trials. Fertil Steril 2001; 75:88.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/57/25496/abstract/42\">",
"      Reindollar RH, Regan MM, Neumann PJ, et al. A randomized clinical trial to evaluate optimal treatment for unexplained infertility: the fast track and standard treatment (FASTT) trial. Fertil Steril 2010; 94:888.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/57/25496/abstract/43\">",
"      Custers IM, K&ouml;nig TE, Broekmans FJ, et al. Couples with unexplained subfertility and unfavorable prognosis: a randomized pilot trial comparing the effectiveness of in&nbsp;vitro fertilization with elective single embryo transfer versus intrauterine insemination with controlled ovarian stimulation. Fertil Steril 2011; 96:1107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/57/25496/abstract/44\">",
"      Practice Committee of American Society for Reproductive Medicine. Multiple gestation associated with infertility therapy: an American Society for Reproductive Medicine Practice Committee opinion. Fertil Steril 2012; 97:825.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/57/25496/abstract/45\">",
"      Kansal-Kalra S, Milad MP, Grobman WA. In vitro fertilization (IVF) versus gonadotropins followed by IVF as treatment for primary infertility: a cost-based decision analysis. Fertil Steril 2005; 84:600.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/57/25496/abstract/46\">",
"      Hughes EG, Beecroft ML, Wilkie V, et al. A multicentre randomized controlled trial of expectant management versus IVF in women with Fallopian tube patency. Hum Reprod 2004; 19:1105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/57/25496/abstract/47\">",
"      Aboulghar MA, Mansour RT, Serour GI, et al. Management of long-standing unexplained infertility: A prospective study. Am J Obstet Gynecol 1999; 181:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/57/25496/abstract/48\">",
"      G&uuml;rgan T, Urman B, Yarali H, Ki��ni��&ccedil;i HA. The results of in vitro fertilization-embryo transfer in couples with unexplained infertility failing to conceive with superovulation and intrauterine insemination. Fertil Steril 1995; 64:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/57/25496/abstract/49\">",
"      Hughes E, Collins J, Vandekerckhove P. Bromocriptine for unexplained subfertility in women. Cochrane Database Syst Rev 2000; :CD000044.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/57/25496/abstract/50\">",
"      Hughes E, Tiffin G, Vandekerckhove P. Danazol for unexplained infertilty. Cochrane Database Syst Rev 2000; :CD000069.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7410 Version 14.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-221.10.40.232-BF0A88A09A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_57_25496=[""].join("\n");
var outline_f24_57_25496=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H18\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DEFINITION AND DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      POSSIBLE ETIOLOGIES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      OVERVIEW OF MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Expectant management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      PATIENT CONTROLLED APPROACHES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Lifestyle changes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      LOW RESOURCE INTERVENTIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Intrauterine insemination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Clomiphene citrate",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Clomiphene plus IUI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Other",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      HIGH RESOURCE INTERVENTIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Gonadotropin injections with or without IUI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      In vitro fertilization",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      INEFFECTIVE TREATMENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/7410\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/7410|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?34/57/35739\" title=\"table 1\">",
"      Pregnancy rate and cost per cycle for treatment",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/41/35479?source=related_link\">",
"      Classification and treatment of ovarian hyperstimulation syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/61/40921?source=related_link\">",
"      Evaluation of female infertility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/44/33481?source=related_link\">",
"      Evaluation of male infertility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/56/37770?source=related_link\">",
"      In vitro fertilization",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/13/11482?source=related_link\">",
"      Optimizing natural fertility in couples planning pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/56/17287?source=related_link\">",
"      Overview of infertility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/10/13482?source=related_link\">",
"      Overview of ovulation induction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/6/4201?source=related_link\">",
"      Ovulation induction with aromatase inhibitors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/25/9626?source=related_link\">",
"      Ovulation induction with clomiphene citrate",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/15/38136?source=related_link\">",
"      Pathogenesis and treatment of infertility in women with endometriosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/17/16660?source=related_link\">",
"      Pathogenesis of ovarian hyperstimulation syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/44/40650?source=related_link\">",
"      Pathogenesis, epidemiology, and clinical manifestations of celiac disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?21/42/22180?source=related_link\">",
"      Patient information: Evaluation of the infertile couple (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?39/42/40610?source=related_link\">",
"      Patient information: Infertility in men (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?11/16/11523?source=related_link\">",
"      Patient information: Infertility in women (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?10/14/10468?source=related_link\">",
"      Patient information: Infertility treatment with gonadotropins (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?34/4/34883?source=related_link\">",
"      Patient information: Ovulation induction with clomiphene (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?32/5/32851?source=related_link\">",
"      Patient information: Treatment of male infertility (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/11/34997?source=related_link\">",
"      Patterns of tobacco use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/48/25351?source=related_link\">",
"      Procedure for intrauterine insemination",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/33/3610?source=related_link\">",
"      Treatment of male infertility",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f24_57_25497="Complications of prosthetic heart valves";
var content_f24_57_25497=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Complications of prosthetic heart valves",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/57/25497/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/57/25497/contributors\">",
"     William H Gaasch, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/57/25497/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/57/25497/contributors\">",
"     Catherine M Otto, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/57/25497/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/57/25497/contributors\">",
"     Susan B Yeon, MD, JD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?24/57/25497/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 1, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prosthetic heart valves can be classified as mechanical or biological (",
"    <a class=\"graphic graphic_table graphicRef50825 \" href=\"UTD.htm?10/58/11181\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?24/57/25497/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Mechanical valves are those that are manufactured entirely from manmade materials; these valves typically have a tilting disk or bileaflet design and are composed of carbon alloys.",
"     </li>",
"     <li>",
"      Biological valves are composed primarily of material that originated as living tissue, including porcine aortic valves, valves manufactured from bovine pericardium, valves transplanted from other human beings (homografts), and autografts from the patient.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Prosthetic heart valves are associated with a variety of complications:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Structural deterioration, particularly with bioprosthetic valves",
"     </li>",
"     <li>",
"      Valve obstruction due to thrombosis or pannus formation",
"     </li>",
"     <li>",
"      Systemic embolization",
"     </li>",
"     <li>",
"      Bleeding",
"     </li>",
"     <li>",
"      Endocarditis and other infections",
"     </li>",
"     <li>",
"      Left ventricular systolic dysfunction, which may be pre-existing",
"     </li>",
"     <li>",
"      Hemolytic anemia",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These complications plus replacement of a prosthetic heart valve will be reviewed here. Issues related to the monitoring and antithrombotic therapy in patients with prosthetic valves are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/56/15238?source=see_link\">",
"     \"Management of patients with prosthetic heart valves\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/11/18618?source=see_link\">",
"     \"Antithrombotic therapy in patients with prosthetic heart valves\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     FREQUENCY OF COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Replacement of a diseased heart valve with a prosthetic valve exchanges the native disease for complications that are peculiar to the prosthesis. The frequency of serious complications depends upon the valve type and position, and multiple clinical risk factors. The overall incidence of complications in appropriately managed patients is approximately",
"    <strong>",
"     3 percent per year",
"    </strong>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?24/57/25497/abstract/1-6\">",
"     1-6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The following observations illustrate the rate of complications with different types and locations of prosthetic valves.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a meta-analysis of 5837 patients who received an aortic valve bioprosthesis, the annual rates of valve thrombosis, thromboembolism, hemorrhage, and nonstructural dysfunction were 0.03, 0.87, 0.38, and 0.38 percent, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?24/57/25497/abstract/7\">",
"       7",
"      </a>",
"      ]. The rate of endocarditis within the first six months of implantation was 3.4 percent, but decreased thereafter to an annual rate of 0.68 percent. The actual risk of ever experiencing a valve-related event or needing valve replacement decreased with age, from 83 and 63 percent, respectively, at age 35, to 24 and 11 percent, respectively, at age 75 years.",
"     </li>",
"     <li>",
"      Another study evaluated 440 patients receiving a St Jude mechanical valve in the mitral position who were followed for 19 years [",
"      <a class=\"abstract\" href=\"UTD.htm?24/57/25497/abstract/8\">",
"       8",
"      </a>",
"      ]. The rate in percent patient-years of thromboembolism, valve thrombosis, and hemorrhage were 0.7, 0.2, and 1, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?24/57/25497/abstract/8\">",
"       8",
"      </a>",
"      ]. At 19 years, the freedom from endocarditis and reoperation were 99 and 90 percent, respectively.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Mechanical versus bioprosthetic valves",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two major randomized trials published in the 1990s directly compared the outcomes with mechanical and bioprosthetic valves [",
"    <a class=\"abstract\" href=\"UTD.htm?24/57/25497/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. Mechanical valves have an extremely low rate of structural failure but the disadvantage of requiring long-term",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    therapy, while bioprosthetic valves usually do not require warfarin therapy in the absence of other risk factors but have the disadvantage of a relatively high rate of structural failure. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Long-term outcomes'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    These differences were illustrated in the Veterans Affairs Cooperative Study, for example, 575 patients were randomly assigned to therapy with a Bjork-Shiley mechanical or bioprosthetic valve [",
"    <a class=\"abstract\" href=\"UTD.htm?24/57/25497/abstract/3\">",
"     3",
"    </a>",
"    ]. The following findings were noted at an average follow-up of 11 years:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Overall patient survival was similar &mdash; 38 percent for mechanical valves versus 43 percent for bioprostheses",
"     </li>",
"     <li>",
"      The likelihood of structural failure with bioprosthetic valves was 15 percent for aortic valves and 36 percent for mitral valves; there were no failures with mechanical valves",
"     </li>",
"     <li>",
"      The risk of bleeding was greater with mechanical valves (42 versus 26 percent)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These differences influence the choice of valve in individual patients in both the aortic and mitral position. As an example, Table 2 and Table 3 summarize recommendations from the 2006 American College of",
"    <span class=\"nowrap\">",
"     Cardiology/American",
"    </span>",
"    Heart Association",
"    <span class=\"nowrap\">",
"     (ACC/AHA)",
"    </span>",
"    guidelines on the management of valvular heart disease on the selection of a prosthetic aortic valve (",
"    <a class=\"graphic graphic_table graphicRef63902 \" href=\"UTD.htm?9/61/10204\">",
"     table 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef75650 \" href=\"UTD.htm?28/61/29659\">",
"     table 3",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?24/57/25497/abstract/9\">",
"     9",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/37/11865?source=see_link&amp;anchor=H2#H2\">",
"     \"Surgical valve replacement in aortic stenosis in adults\", section on 'Choice of valve'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/29/25050?source=see_link&amp;anchor=H23#H23\">",
"     \"Course and management of chronic aortic regurgitation in adults\", section on 'Choice of valve'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/53/36697?source=see_link&amp;anchor=H17#H17\">",
"     \"Surgical procedures for severe chronic mitral regurgitation\", section on 'Mechanical versus bioprosthetic valve'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     SERIAL MONITORING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because of the appreciable rate of complications in prosthetic heart valves, serial monitoring is recommended in asymptomatic patients and at any time in patients with a change in clinical status. The 2006",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    guidelines recommended an approach to follow-up monitoring after prosthetic heart valve implantation that is summarized in Table 4 and is discussed in detail elsewhere (",
"    <a class=\"graphic graphic_table graphicRef63090 \" href=\"UTD.htm?5/54/5996\">",
"     table 4",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?24/57/25497/abstract/9\">",
"     9",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/56/15238?source=see_link&amp;anchor=H3#H3\">",
"     \"Management of patients with prosthetic heart valves\", section on 'Serial monitoring of valve function'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     STRUCTURAL FAILURE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11276958\">",
"    <span class=\"h2\">",
"     Spectrum of paravalvular regurgitation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Paravalvular leaks early after surgery, as detected with intraoperative transesophageal echocardiography (TEE) or postoperative transthoracic echocardiography (TTE), are common. The reported incidence ranges from 18 to 48 percent of patients with a mitral or aortic prosthesis; the majority of leaks are trivial or mild and do not progress over a two to five year follow-up [",
"    <a class=\"abstract\" href=\"UTD.htm?24/57/25497/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. In contrast, the later development of new, often severe regurgitation results from prosthetic valve endocarditis or structural failure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Long-term outcomes",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of late structural failure varies with the type of valve and with valve position. The risk with current mechanical valves is extremely low, and most series have not observed any such events [",
"    <a class=\"abstract\" href=\"UTD.htm?24/57/25497/abstract/3\">",
"     3",
"    </a>",
"    ]. Most mechanical valves can be expected to last at least 20 to 30 years with the exception of the Bjork-Shiley convexoconcave (BSCC) valve described in the next section.",
"   </p>",
"   <p>",
"    In contrast, 10 to 20 percent of human aortic homograft prostheses, and 30 to 35 percent of porcine heterograft prostheses have failed within 10 to 15 years of implantation [",
"    <a class=\"abstract\" href=\"UTD.htm?24/57/25497/abstract/1,3-6,12\">",
"     1,3-6,12",
"    </a>",
"    ]. Pericardial prostheses may be more durable than porcine valves [",
"    <a class=\"abstract\" href=\"UTD.htm?24/57/25497/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. The failure rate with porcine valves is higher with valves in the mitral position (eg, 44 versus 26 percent in the aortic position at 15 years in the Veterans Administration trial) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/57/25497/abstract/12\">",
"     12",
"    </a>",
"    ]. However, the rate of structural failure with current bioprostheses appears to be lower than those with the first-generation bioprostheses used in the above studies [",
"    <a class=\"abstract\" href=\"UTD.htm?24/57/25497/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A variety of factors can contribute to structural failure with bioprosthetic valves, including mechanical stress, immunologic rejection, endocarditis, and cusp tear, leading to severe valvular regurgitation.",
"   </p>",
"   <p>",
"    The structural failure rate with bioprosthetic valves falls dramatically with age [",
"    <a class=\"abstract\" href=\"UTD.htm?24/57/25497/abstract/12,15,16\">",
"     12,15,16",
"    </a>",
"    ]. In the Veterans Affairs trial cited above, the rate of valve failure at 15 years varied from 26 percent under age 65 to 9 percent in patients &ge;65 years of age [",
"    <a class=\"abstract\" href=\"UTD.htm?24/57/25497/abstract/12\">",
"     12",
"    </a>",
"    ]. Similar findings were noted in another study in which the actuarial estimate of the rate of structural deterioration of bioprosthetic aortic valves at 15 years varied from 63 percent between the ages of 40 and 49 (and perhaps higher under age 40) to 10 percent over age 70 [",
"    <a class=\"abstract\" href=\"UTD.htm?24/57/25497/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The lower rate of bioprosthetic valve failure in elderly adults is due at least in part to decreased activity in older patients. Because of this observation and the apparently lower failure rates with current bioprostheses, the 2006",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    guidelines on the choice of valve considered it reasonable to use a bioprosthesis in patients &ge;65 years of age who do not have risk factors for thromboembolism and who understand the likelihood that a second valve replacement will be required in the future (",
"    <a class=\"graphic graphic_table graphicRef63902 \" href=\"UTD.htm?9/61/10204\">",
"     table 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef75650 \" href=\"UTD.htm?28/61/29659\">",
"     table 3",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?24/57/25497/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     BSCC valve",
"    </span>",
"    &nbsp;&mdash;&nbsp;The major example of mechanical valve failure was the Bjork-Shiley convexoconcave valve, which was implanted in approximately 86,000 between 1978 and 1986. Modest design changes from the previous model resulted in an unanticipated increase in stress on the welded outflow strut, which led to outflow strut fracture (OSF) and disc migration. It has been estimated that the mortality rate exceeds 90 percent with aortic valve OSFs, while emergency surgery can lead to survival rates of 35 to 45 percent with mitral valve OSFs [",
"    <a class=\"abstract\" href=\"UTD.htm?24/57/25497/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The following findings were noted in a review of BSCC valve outcomes through the end of 2003; it was estimated that 22,000 patients were still alive (median age slightly greater than 70 years) and therefore still at risk at that time [",
"    <a class=\"abstract\" href=\"UTD.htm?24/57/25497/abstract/17\">",
"     17",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The overall incidence of OSFs with two different models by the end of 2003 was 0.6 percent with the more common 60&ordm; opening angle valves and 3.9 percent with the 70&ordm; valves. On an annualized basis and taking into account reductions in the number of patients due to mortality, the estimated risk for OSF was 0.05 and 0.32 percent, respectively. After adjustment of suspected underreporting, these values increased to 0.14 and 0.72 percent, respectively.",
"     </li>",
"     <li>",
"      A variety of risk factors for OSF were identified, with the most important being the 70&ordm; valves, larger valve size (&ge;29 mm), and mitral valve position. Certain manufacturing characteristics were also important. On the other hand, the risk fell by about 5 percent with each increasing year of age, ranging from 0.29 percent per year under age 45 to 0.02 percent per year over age 75. The lower OSF risk with aging is thought to reflect lower stresses on the valve.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The lifetime risk of OSF for most patients is much less than the immediate risk associated with explant surgery. As a result, prophylactic replacement of the valve is only recommended in highly selected patients. (See",
"    <a class=\"local\" href=\"#H21\">",
"     'BSCC valve replacement'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     VALVE OBSTRUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;When, in a newly symptomatic patient, there is an unexpected rise in transprosthetic gradient from a baseline determination or from established normal values for valves of that type and size, the possibility of critical obstruction should be considered. Causes of obstruction include thrombus, pannus, and vegetation. In a surgical study of 112 obstructed mechanical valves, thrombus alone was responsible for 77 percent, pannus formation for 11 percent, pannus formation in combination with thrombus for 12 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?24/57/25497/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The clinical manifestations of prosthetic valve obstruction include dyspnea, heart failure, and, with thrombus formation, systemic embolization [",
"    <a class=\"abstract\" href=\"UTD.htm?24/57/25497/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Valve thrombosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prosthetic valve thrombosis (PVT), which can lead to valvular obstruction, occurs with equal frequency in patients with bioprosthetic valves and in those with mechanical valves who are treated with anticoagulants. The reported annual incidence of PVT ranges from 0.03 to 5.7 percent; higher rates are observed in patients with mitral prostheses (in some reports)",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    subtherapeutic anticoagulation [",
"    <a class=\"abstract\" href=\"UTD.htm?24/57/25497/abstract/1,7,8,18,20\">",
"     1,7,8,18,20",
"    </a>",
"    ]. In one report of PVT in mechanical valves, for example, 70 percent of patients with coagulation tests measured at the time of PVT were receiving inadequate anticoagulant therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?24/57/25497/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The gold standard for the diagnosis of PVT is transesophageal echocardiography (TEE)",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    cine-fluoroscopy to assess both valve motion and clot burden [",
"    <a class=\"abstract\" href=\"UTD.htm?24/57/25497/abstract/9,21\">",
"     9,21",
"    </a>",
"    ]. However, transthoracic Doppler echocardiography can establish the diagnosis in many patients [",
"    <a class=\"abstract\" href=\"UTD.htm?24/57/25497/abstract/22,23\">",
"     22,23",
"    </a>",
"    ] and is also indicated to assess hemodynamic severity [",
"    <a class=\"abstract\" href=\"UTD.htm?24/57/25497/abstract/9\">",
"     9",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/18/6438?source=see_link\">",
"     \"Echocardiographic evaluation of prosthetic heart valves\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are two options for the treatment of PVT, surgery and thrombolytic therapy, but neither is ideal. With surgery, there is a high operative mortality that is largely related to clinical functional class (17.5 percent in patients in NYHA class IV compared to 4.7 percent with less severe disease in a review of 106 patients) (",
"    <a class=\"graphic graphic_table graphicRef52683 \" href=\"UTD.htm?3/2/3117\">",
"     table 5",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?24/57/25497/abstract/18\">",
"     18",
"    </a>",
"    ]. Mortality rates as high as 35 percent have been described in these critically ill patients [",
"    <a class=\"abstract\" href=\"UTD.htm?24/57/25497/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As a result, thrombolytic therapy has evolved as an alternative to surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?24/57/25497/abstract/19,24-29\">",
"     19,24-29",
"    </a>",
"    ]. The largest study consisted of 127 episodes of obstructive PVT (almost all left-sided) in 110 patients with mechanical valves who were treated with various thrombolytic agents: streptokinase and urokinase initially and recombinant tissue-type plasminogen activator (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/41/11929?source=see_link\">",
"     alteplase",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/57/25497/abstract/19\">",
"     19",
"    </a>",
"    ]. The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Complete hemodynamic resolution in 71 percent, partial resolution in 17 percent, and no resolution in 12 percent. Surgery was performed in 23 percent, primarily because of lack of complete resolution.",
"     </li>",
"     <li>",
"      There was a trend toward greater efficacy in aortic valve prostheses (80 versus 65 percent in mitral valve prostheses). This difference was not noted in other series [",
"      <a class=\"abstract\" href=\"UTD.htm?24/57/25497/abstract/24,25\">",
"       24,25",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Serial echocardiography was used to assess the efficacy of therapy. A second dose of the thrombolytic agent was required in 30 percent and a third in 9 percent. A single course of thrombolytic therapy may be more likely to be effective in patients with nonobstructive thrombi (75 versus 40 percent with obstructive thrombi) in another report [",
"      <a class=\"abstract\" href=\"UTD.htm?24/57/25497/abstract/25\">",
"       25",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Complications occurred in 25 percent of patients. These included major bleeding in 4.7 percent (including two intracranial hemorrhages), systemic embolization in 15 percent, and death in 11.8 percent due to complications or primary failure of therapy.",
"     </li>",
"     <li>",
"      Recurrent PVT developed in 24 patients (19 percent) at a mean interval of 2.1 years (range three months to seven years). Sixteen received another course of thrombolytic therapy (with complete resolution in 75 percent) and five underwent surgery.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Similar findings were noted in another series of 110 patients with left-sided obstructive PVT, almost all of whom were treated with streptokinase [",
"    <a class=\"abstract\" href=\"UTD.htm?24/57/25497/abstract/24\">",
"     24",
"    </a>",
"    ]. A complete hemodynamic response was noted in 82 percent; the response rate did not vary with the type, position of prosthesis, duration of symptoms, or time since surgery. The rate of embolization during therapy was 19 percent (occurring more often in patients with atrial fibrillation), and recurrent PVT developed in 23 percent during a 31 month follow-up, most of whom were retreated with thrombolytic therapy.",
"   </p>",
"   <p>",
"    It may be possible to stratify patients undergoing thrombolysis according to the risk of complications. This was demonstrated in a report of a registry of 107 patients who had undergone TEE prior to thrombolysis for valve thrombosis (79 mitral, 13 aortic, 15 tricuspid) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/57/25497/abstract/29\">",
"     29",
"    </a>",
"    ]. Within the first week after treatment, 19 patients (18 percent) experienced a complication (15 embolic). Significant predictors of complications on multivariate analysis were thrombus area by TEE &ge;0.8 cm2 and prior history of stroke. Patients with neither risk factor had a complication rate of 8 percent, while those with both risk factors had a complication rate of 79 percent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Recommendations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Controlled data for the therapy of PVT are not available and both surgery (appreciable perioperative mortality) and thrombolytic therapy (major bleeding and systemic embolization) have important limitations.",
"   </p>",
"   <p>",
"    The 2006",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    guidelines on the management of valvular heart disease included recommendations for the treatment of PVT (",
"    <a class=\"graphic graphic_table graphicRef71538 \" href=\"UTD.htm?6/45/6876\">",
"     table 6",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?24/57/25497/abstract/9\">",
"     9",
"    </a>",
"    ]. The approach is based upon a variety of factors such as the site of valve thrombosis, symptom status as determined by NYHA functional class (",
"    <a class=\"graphic graphic_table graphicRef52683 \" href=\"UTD.htm?3/2/3117\">",
"     table 5",
"    </a>",
"    ), the size of the clot burden, the patient risk for and availability of surgery. This approach, in which fibrinolytic therapy is preferred for right-sided PVT and surgery (if available) is usually preferred for left-sided PVT has also been proposed by others [",
"    <a class=\"abstract\" href=\"UTD.htm?24/57/25497/abstract/19,22,27\">",
"     19,22,27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Thrombolytic regimens include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/41/11929?source=see_link\">",
"     alteplase",
"    </a>",
"    (100 mg given as a 10 mg bolus followed by 90 mg as an infusion over 90 minutes) or streptokinase (500,000 IU over 20 minutes followed by 1.5 million IU over 10 hours). Intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    is typically given concurrently to achieve an activated partial thromboplastin time 1.5 to 2.0 times control.",
"   </p>",
"   <p>",
"    We agree with the 2006",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    guideline recommendations for treatment of PVT (",
"    <a class=\"graphic graphic_table graphicRef71538 \" href=\"UTD.htm?6/45/6876\">",
"     table 6",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/57/25497/abstract/9\">",
"     9",
"    </a>",
"    ] (which differ somewhat from the 2008 ACCP recommendations [",
"    <a class=\"abstract\" href=\"UTD.htm?24/57/25497/abstract/30\">",
"     30",
"    </a>",
"    ]):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For left-sided PVT with NYHA functional class III to IV symptoms OR large clot burden, emergency operation is suggested.",
"     </li>",
"     <li>",
"      For left-sided PVT with NYHA functional class III to IV symptoms with small or large clot burden, fibrinolytic therapy may be considered if surgery is high risk or not available. This recommendation also applies to patients with NYHA class II symptoms with large clot burden.",
"     </li>",
"     <li>",
"      For left-sided PVT with NYHA functional class II to IV symptoms and a large clot burden, fibrinolytic therapy may be considered if emergency surgery is high risk or not available.",
"     </li>",
"     <li>",
"      For left-sided PVT with NYHA functional class I to II and small clot burden, fibrinolytic therapy may be considered as a first-line therapy. Alternatively, intravenous unfractionated",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      may be considered.",
"     </li>",
"     <li>",
"      For right-sided PVT with NYHA functional class III to IV OR large clot burden, fibrinolytic therapy is suggested.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A size threshold for small versus large clot burden is not specified in the 2006",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    guidelines since studies have used differing thresholds ranging from 5 to 8 mm. In the 2008 ACCP guidelines a small thrombus area is defined as &lt;80 mm2 and a large thrombus area is defined as &ge;80 mm2.",
"   </p>",
"   <p>",
"    For patients who have had successful resolution of PVT, initiation of IV UFH and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    (or other vitamin K antagonist) therapy is suggested [",
"    <a class=\"abstract\" href=\"UTD.htm?24/57/25497/abstract/9,30\">",
"     9,30",
"    </a>",
"    ]. Continuation of IV UFH is suggested until a therapeutic INR is achieved and has been maintained for 24 to 48 hours.",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      For a mechanical valve in the aortic position, a goal INR of 3.5 (range 3.0 to 4.0) plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      (50 to 100",
"      <span class=\"nowrap\">",
"       mg/d)",
"      </span>",
"      is suggested.",
"     </li>",
"     <li>",
"      For a mechanical valve in the mitral position, a goal INR of 4.0 (range 3.5 to 4.5) plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      (50 to 100",
"      <span class=\"nowrap\">",
"       mg/d)",
"      </span>",
"      is suggested.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Pannus formation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pannus formation due to fibrous tissue ingrowth is a less common cause of valve obstruction [",
"    <a class=\"abstract\" href=\"UTD.htm?24/57/25497/abstract/18\">",
"     18",
"    </a>",
"    ]. Since thrombolytic therapy is an alternative to surgery only for thrombosis, distinction between these two causes is important; echocardiography and clinical features are helpful in distinguishing between these (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/18/6438?source=see_link&amp;anchor=H4#H4\">",
"     \"Echocardiographic evaluation of prosthetic heart valves\", section on 'Distinction between thrombus and pannus'",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    In one report of 23 patients who presented with 24 obstructed valves, the established cause at the time of surgery was thrombus in 14 and pannus in 10. Pannus formation was more common in the aortic position. Compared to patients with pannus, those with thrombus had the following findings [",
"    <a class=\"abstract\" href=\"UTD.htm?24/57/25497/abstract/31\">",
"     31",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      A shorter time from valve insertion to valve dysfunction (62 versus 178 days)",
"     </li>",
"     <li>",
"      A shorter duration of symptoms before reoperation (9 versus 305 days)",
"     </li>",
"     <li>",
"      A lower rate of adequate anticoagulation (21 versus 89 percent)",
"     </li>",
"     <li>",
"      A greater total mass length (2.8 versus 1.2 cm), primarily due to extension into the left atrium",
"     </li>",
"     <li>",
"      An ultrasound video density less than the density of the mechanical valve (92 versus 29 percent)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     SYSTEMIC EMBOLIZATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Systemic embolization can result from valve thrombosis (even when nonobstructed), vegetations, or left atrial thrombus, particularly in patients with atrial fibrillation [",
"    <a class=\"abstract\" href=\"UTD.htm?24/57/25497/abstract/32\">",
"     32",
"    </a>",
"    ]. Transesophageal echocardiography may be the preferred method for evaluating these patients [",
"    <a class=\"abstract\" href=\"UTD.htm?24/57/25497/abstract/33\">",
"     33",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/18/6438?source=see_link\">",
"     \"Echocardiographic evaluation of prosthetic heart valves\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The frequency of systemic embolization, predominantly cerebrovascular events, is approximately 0.7 to 1.0 percent per patient-year in patients with mechanical valves who are treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?24/57/25497/abstract/34,35\">",
"     34,35",
"    </a>",
"    ]. In comparison, the risk is 2.2 percent per patient-year with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    and 4.0 percent with no anticoagulation; patients with mitral valve prostheses are at",
"    <strong>",
"     twice",
"    </strong>",
"    the risk of those with aortic valve prostheses [",
"    <a class=\"abstract\" href=\"UTD.htm?24/57/25497/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The embolic risk appears to be similar in patients with mechanical valves who are treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    and those with bioprosthetic valves, which usually do not require chronic warfarin therapy. A large controlled trial found no difference in the incidence of embolization between a Bjork-Shiley mechanical valve and porcine biosynthetic valves (21 versus 26 percent at 12 years) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/57/25497/abstract/4\">",
"     4",
"    </a>",
"    ]. A similar lack of difference between a Bjork-Shiley mechanical valve and porcine biosynthetic valves was noted in the Veterans Affairs Cooperative Study [",
"    <a class=\"abstract\" href=\"UTD.htm?24/57/25497/abstract/3\">",
"     3",
"    </a>",
"    ]. In two other reports evaluating only one type of valve, the rates were similar with an aortic valve bioprosthesis and a St Jude mechanical valve plus warfarin therapy in the mitral position (0.7 and 0.87 percent per year) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/57/25497/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/11/18618?source=see_link\">",
"     \"Antithrombotic therapy in patients with prosthetic heart valves\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In contrast, a retrospective study of valve-related complications in young women with prosthetic heart valves found a much higher incidence of thromboembolic events with mechanical valves (45 versus 13 percent at five years) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/57/25497/abstract/36\">",
"     36",
"    </a>",
"    ]. However, the majority of mechanical valves were Starr-Edwards valves, which have a much higher risk of thromboembolism than noted in the above studies with Bjork-Shiley or St Jude valves [",
"    <a class=\"abstract\" href=\"UTD.htm?24/57/25497/abstract/3,4,8\">",
"     3,4,8",
"    </a>",
"    ]. In addition, most of the events occurred in women who were not adequately anticoagulated. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/11/18618?source=see_link\">",
"     \"Antithrombotic therapy in patients with prosthetic heart valves\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     BLEEDING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bleeding is a not infrequent problem in patients with prosthetic heart valves [",
"    <a class=\"abstract\" href=\"UTD.htm?24/57/25497/abstract/1,3,4,7,8\">",
"     1,3,4,7,8",
"    </a>",
"    ]. The risk is greater with mechanical values which, because they are thrombogenic, require chronic anticoagulation. In contrast, most patients who receive a bioprosthetic valve are given only short-term anticoagulation unless there is an additional risk factor such as atrial fibrillation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/11/18618?source=see_link\">",
"     \"Antithrombotic therapy in patients with prosthetic heart valves\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In the Veterans Affairs Cooperative Study, for example, 575 patients were randomly assigned to therapy with a mechanical or bioprosthetic valve [",
"    <a class=\"abstract\" href=\"UTD.htm?24/57/25497/abstract/3\">",
"     3",
"    </a>",
"    ]. The 11-year probability of bleeding was significantly greater with mechanical valves (42 versus 26 percent). A similar difference at 12 years (19 versus 7 percent) was noted in another controlled trial [",
"    <a class=\"abstract\" href=\"UTD.htm?24/57/25497/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     ENDOCARDITIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infective endocarditis and other infections such as valve abscess can occur with prosthetic valves. Transesophageal echocardiography is superior to standard transthoracic echocardiography for the detection of valvular vegetation, ring abscesses, and other complications, particularly with mitral prostheses (",
"    <a class=\"graphic graphic_movie graphicRef58762 \" href=\"UTD.htm?40/16/41230\">",
"     movie 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_movie graphicRef74517 \" href=\"UTD.htm?25/30/26082\">",
"     movie 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Issues related to the presentation, diagnosis, antithrombotic management and antimicrobial and possible surgical therapy of PVE are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/40/2697?source=see_link\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of prosthetic valve endocarditis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/40/33415?source=see_link\">",
"     \"Anticoagulant and antiplatelet therapy in patients with infective endocarditis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/57/34712?source=see_link\">",
"     \"Antimicrobial therapy of prosthetic valve endocarditis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/32/3591?source=see_link\">",
"     \"Surgery for prosthetic valve endocarditis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     LEFT VENTRICULAR SYSTOLIC DYSFUNCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with prosthetic heart valves may develop left ventricular systolic dysfunction with or without heart failure. One or more of the following factors may contribute [",
"    <a class=\"abstract\" href=\"UTD.htm?24/57/25497/abstract/9\">",
"     9",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Preoperative left ventricular dysfunction that persists or partially improves",
"     </li>",
"     <li>",
"      Perioperative myocardial infarction",
"     </li>",
"     <li>",
"      Progression of other valve disease",
"     </li>",
"     <li>",
"      Complications of the prosthetic valve",
"     </li>",
"     <li>",
"      An unrelated disorder such as coronary heart disease or hypertension",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Appropriate testing in such patients includes transthoracic Doppler echocardiography, TEE if necessary, or, if the cause remains uncertain, cardiac catheterization with arteriography.",
"   </p>",
"   <p>",
"    The 2006",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    guidelines recommended that patients with left ventricular systolic dysfunction after valve replacement should be treated with standard medical therapy for systolic heart failure [",
"    <a class=\"abstract\" href=\"UTD.htm?24/57/25497/abstract/9\">",
"     9",
"    </a>",
"    ]. Such therapy should be continued even if left ventricular function improves. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/63/38906?source=see_link\">",
"     \"Overview of the therapy of heart failure due to systolic dysfunction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     HEMOLYTIC ANEMIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hemolytic anemia, due to mechanical damage, is seen more commonly with prosthetic mechanical heart valves than with bioprosthetic valves. Among patients with prosthetic mitral regurgitation, hemolysis is associated with rapid acceleration and deceleration of the regurgitant jet",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    high peak shear rates [",
"    <a class=\"abstract\" href=\"UTD.htm?24/57/25497/abstract/37\">",
"     37",
"    </a>",
"    ]. Hemolysis is usually mild and subclinical, but is severe in up to 15 percent of patients with certain prostheses, such as ball-cage and bileaflet valves, or those with paravalvular regurgitation [",
"    <a class=\"abstract\" href=\"UTD.htm?24/57/25497/abstract/38-40\">",
"     38-40",
"    </a>",
"    ]. It is uncommon with tissue valves, although hemolytic anemia may be the initial presentation of porcine valve failure [",
"    <a class=\"abstract\" href=\"UTD.htm?24/57/25497/abstract/41\">",
"     41",
"    </a>",
"    ]. Presenting features may be subtle and include anemia, heart failure, jaundice, dark urine, increasing serum lactate dehydrogenase, and a new or changed regurgitant murmur [",
"    <a class=\"abstract\" href=\"UTD.htm?24/57/25497/abstract/42\">",
"     42",
"    </a>",
"    ]. The peripheral smear shows variable numbers of schistocytes and smaller red cell fragments (",
"    <a class=\"graphic graphic_picture graphicRef74544 \" href=\"UTD.htm?23/11/23734\">",
"     picture 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/62/9194?source=see_link&amp;anchor=H13#H13\">",
"     \"Extrinsic nonimmune hemolytic anemia due to mechanical damage: Fragmentation hemolysis and hypersplenism\", section on 'Malfunctioning cardiac valves'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Oral iron replacement is effective in the majority of patients, although transfusion may be required; in occasional patients, the administration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/48/2825?source=see_link\">",
"     recombinant human erythropoietin",
"    </a>",
"    may eliminate the need for transfusion [",
"    <a class=\"abstract\" href=\"UTD.htm?24/57/25497/abstract/43\">",
"     43",
"    </a>",
"    ]. Reoperation may be required, especially if hemolysis is due to regurgitation from a paravalvular leak or valve failure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     REPLACEMENT OF A PROSTHETIC VALVE",
"    </span>",
"    &nbsp;&mdash;&nbsp;As survival after a first valve replacement improves, more patients ultimately require a second operation for replacement of a dysfunctional prosthetic valve. As an example, outcomes at mean 24 year follow-up were reported for 1512 patients undergoing aortic or mitral valve operation at age &lt;60 years [",
"    <a class=\"abstract\" href=\"UTD.htm?24/57/25497/abstract/44\">",
"     44",
"    </a>",
"    ]. The 20 year mean actuarial freedom from valve reoperation was 11.4 and 15.8 percent for aortic and mitral bioprosthesis as compared to 73 and 65 percent in those with mechanical prostheses. However the use of a tissue versus mechanical prosthesis at initial implant was not associated with a significant difference in survival.",
"   </p>",
"   <p>",
"    In addition to moderate to severe prosthetic valve dysfunction or dehiscence, reoperation may also be required for a number of other complications including endocarditis, recurrent thromboembolism, severe hemolysis, severe and recurrent bleeding due to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    therapy, valve obstruction, and, in selected patients with a small aortic annulus, prosthetic valve-patient mismatch [",
"    <a class=\"abstract\" href=\"UTD.htm?24/57/25497/abstract/9\">",
"     9",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/53/36697?source=see_link&amp;anchor=H19#H19\">",
"     \"Surgical procedures for severe chronic mitral regurgitation\", section on 'Prosthetic valve-patient mismatch'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Mortality and morbidity",
"    </span>",
"    &nbsp;&mdash;&nbsp;The overall perioperative mortality following nonemergent replacement of prosthetic heart valves is approximately 10 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?24/57/25497/abstract/17,45\">",
"     17,45",
"    </a>",
"    ]. However, the rate varies markedly among patients. In a review of 2246 consecutive procedures in 1984 patients between 1963 and 1992, the in-hospital mortality rates in patients with New York Heart Association class I, II, III, and IV (",
"    <a class=\"graphic graphic_table graphicRef52683 \" href=\"UTD.htm?3/2/3117\">",
"     table 5",
"    </a>",
"    ) were 2.3, 5.7, 9.1, and 21.0 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?24/57/25497/abstract/45\">",
"     45",
"    </a>",
"    ]. In-hospital mortality was lowest (1.3 percent) in the healthiest patients undergoing a first elective reoperation. Similar findings have been noted in other series [",
"    <a class=\"abstract\" href=\"UTD.htm?24/57/25497/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Age is another important determinant. It has been estimated that the perioperative mortality increases about three-fold from age 35 to age 75 [",
"    <a class=\"abstract\" href=\"UTD.htm?24/57/25497/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The likelihood of serious morbidity (eg, myocardial infarction, stroke, renal failure) is thought to be at least as great as perioperative mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?24/57/25497/abstract/17\">",
"     17",
"    </a>",
"    ]. In the review cited above, 1.1 percent of patients (but only 0.3 percent of the healthiest patients) had a neurologic deficit at hospital discharge [",
"    <a class=\"abstract\" href=\"UTD.htm?24/57/25497/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     BSCC valve replacement",
"    </span>",
"    &nbsp;&mdash;&nbsp;As discussed above, Bjork-Shiley convexoconcave valves carry a risk of outflow strut fracture (OSF), which raises the question of prophylactic valve replacement. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'BSCC valve'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    This issue was addressed in a high-resolution cineradiography study of 315 patients believed to be at increased risk for OSF, mostly those with large (&gt;29 mm) mitral valves [",
"    <a class=\"abstract\" href=\"UTD.htm?24/57/25497/abstract/46\">",
"     46",
"    </a>",
"    ]. The imaging studies looked for evidence of fracture of one of the two legs of the outflow strut, assuming that such a finding is a precursor to OSF. Eleven patients had probable or definite single leg separations; ten were confirmed by removal of the valve. However, imaging did not detect all patients at risk since two patients had complete OSFs three and seven months after a normal study.",
"   </p>",
"   <p>",
"    Almost all of the patients with a single leg separation chose to have the valve replaced. More than one-half had difficulty walking up more than one flight of stairs [",
"    <a class=\"abstract\" href=\"UTD.htm?24/57/25497/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Unpublished outcomes data are available for 33 patients with single leg separations and 24 other patients who had elective explantation for other reasons [",
"    <a class=\"abstract\" href=\"UTD.htm?24/57/25497/abstract/17\">",
"     17",
"    </a>",
"    ]. The respective 90-day mortality rates were 12 percent (4 of 33) and 4 percent (1 of 24). When combined with data from other studies of patients who underwent replacement of a BSCC, the mortality rate was 8 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?24/57/25497/abstract/17,47\">",
"     17,47",
"    </a>",
"    ]. As with replacement of non-BSCC valves, the mortality rate was significantly lower in younger patients and higher with emergency surgery, coronary heart disease, and poor left ventricular function. The lower risk in younger patients is an important observation since these patients are also at the greatest risk for OSF (0.29 percent per year under age 45 and 0.15 percent per year between the ages of 45 and 64) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/57/25497/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Risk models have suggested that prophylactic BSCC valve replacement is likely to increase life expectancy only in high risk (eg, larger valves) younger patients (under age 65). Such guidelines are widely used in the Netherlands [",
"    <a class=\"abstract\" href=\"UTD.htm?24/57/25497/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?11/23/11635?source=see_link\">",
"       \"Patient information: Prosthetic valves (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11276806\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Complications of prosthetic heart valves include structural deterioration (particularly with bioprosthetic valves), valve obstruction due to thrombosis or pannus formation, systemic embolization, bleeding (particularly with anticoagulation for mechanical valves), endocarditis, left ventricular systolic dysfunction (may be preexisting), and hemolytic anemia. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H3\">",
"       'Mechanical versus bioprosthetic valves'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The overall incidence of prosthetic heart valves related complications in appropriately managed patients is approximately 3 percent per year. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Frequency of complications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Guidelines for serial monitoring of patients with prosthetic valves are discussed separately (",
"      <a class=\"graphic graphic_table graphicRef63090 \" href=\"UTD.htm?5/54/5996\">",
"       table 4",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/56/15238?source=see_link&amp;anchor=H3#H3\">",
"       \"Management of patients with prosthetic heart valves\", section on 'Serial monitoring of valve function'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Paravalvular regurgitation identified immediately after valve replacement is usually trivial or mild and not progressive. In contrast, paravalvular regurgitation developing late after valve replacement is often significant and is a sign of prosthetic valve endocarditis or structural failure. (See",
"      <a class=\"local\" href=\"#H11276958\">",
"       'Spectrum of paravalvular regurgitation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Most mechanical valves can be expected to last at least 20 to 30 years. In contrast, approximately 10 to 20 percent of human aortic homograft prostheses, and 30 to 35 percent of porcine heterograft prostheses have failed within 10 to 15 years of implantation. Pericardial prostheses may be more durable than porcine valves. However, the rate of structural failure may be lower with current bioprosthesis. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Long-term outcomes'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      When a patient develops symptoms of heart failure and an unexpected rise in transprosthetic gradient from a baseline determination or from established normal values for valves of that type and size, the possibility of critical obstruction should be considered. Causes of obstruction include thrombus, pannus, and vegetation. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Valve obstruction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Prosthetic valve thrombosis occurs with equal frequency in patients with bioprosthetic valves and in those with mechanical valves who are treated with anticoagulants. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Valve thrombosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Recommendations for treatment of prosthetic valve thrombosis vary depending upon patient symptoms, valve location (left- or right-sided valve), and size of clot burden (",
"      <a class=\"graphic graphic_table graphicRef71538 \" href=\"UTD.htm?6/45/6876\">",
"       table 6",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Recommendations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Valve obstruction due to pannus formation is treated surgically. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Pannus formation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients with prosthetic heart valves, systemic embolization arises from valve thrombosis, vegetations, or left atrial thrombus. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Systemic embolization'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Factors that may contribute to left ventricular systolic dysfunction in patients with prosthetic valves include preoperative left ventricular dysfunction, perioperative myocardial infarction, progression of other valve disease, complications of the prosthetic valve, and unrelated disorders such as coronary heart disease or hypertension. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Left ventricular systolic dysfunction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Hemolysis associated with prosthetic heart valves is more common with mechanical than bioprosthetic valves. It is usually mild and subclinical but is severe in up to 15 percent of patients with certain prosthesis, such as ball-cage and bileaflet valves, and those with paravalvular regurgitation. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Hemolytic anemia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Reoperation is more frequent following bioprosthetic valve replacement than after mechanical valve replacement, although long-term survival rates are similar. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Replacement of a prosthetic valve'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12962622\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The UpToDate editorial staff would&nbsp;like to thank Dr. Gerard P. Aurigemma for his contributions as an author to previous versions of this topic review.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/57/25497/abstract/1\">",
"      Vongpatanasin W, Hillis LD, Lange RA. Prosthetic heart valves. N Engl J Med 1996; 335:407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/57/25497/abstract/2\">",
"      Akins CW. Mechanical cardiac valvular prostheses. Ann Thorac Surg 1991; 52:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/57/25497/abstract/3\">",
"      Hammermeister KE, Sethi GK, Henderson WG, et al. A comparison of outcomes in men 11 years after heart-valve replacement with a mechanical valve or bioprosthesis. Veterans Affairs Cooperative Study on Valvular Heart Disease. N Engl J Med 1993; 328:1289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/57/25497/abstract/4\">",
"      Bloomfield P, Wheatley DJ, Prescott RJ, Miller HC. Twelve-year comparison of a Bjork-Shiley mechanical heart valve with porcine bioprostheses. N Engl J Med 1991; 324:573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/57/25497/abstract/5\">",
"      Yacoub M, Rasmi NR, Sundt TM, et al. Fourteen-year experience with homovital homografts for aortic valve replacement. J Thorac Cardiovasc Surg 1995; 110:186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/57/25497/abstract/6\">",
"      O'Brien MF, Stafford EG, Gardner MA, et al. Allograft aortic valve replacement: long-term follow-up. Ann Thorac Surg 1995; 60:S65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/57/25497/abstract/7\">",
"      Puvimanasinghe JP, Steyerberg EW, Takkenberg JJ, et al. Prognosis after aortic valve replacement with a bioprosthesis: predictions based on meta-analysis and microsimulation. Circulation 2001; 103:1535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/57/25497/abstract/8\">",
"      Remadi JP, Baron O, Roussel C, et al. Isolated mitral valve replacement with St. Jude medical prosthesis: long-term results: a follow-up of 19 years. Circulation 2001; 103:1542.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/57/25497/abstract/9\">",
"      Bonow RO, Carabello BA, Chatterjee K, et al. 2008 Focused update incorporated into the ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease): endorsed by the Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Circulation 2008; 118:e523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/57/25497/abstract/10\">",
"      Rallidis LS, Moyssakis IE, Ikonomidis I, Nihoyannopoulos P. Natural history of early aortic paraprosthetic regurgitation: a five-year follow-up. Am Heart J 1999; 138:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/57/25497/abstract/11\">",
"      O'Rourke DJ, Palac RT, Malenka DJ, et al. Outcome of mild periprosthetic regurgitation detected by intraoperative transesophageal echocardiography. J Am Coll Cardiol 2001; 38:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/57/25497/abstract/12\">",
"      Hammermeister K, Sethi GK, Henderson WG, et al. Outcomes 15 years after valve replacement with a mechanical versus a bioprosthetic valve: final report of the Veterans Affairs randomized trial. J Am Coll Cardiol 2000; 36:1152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/57/25497/abstract/13\">",
"      Glower DD, Landolfo KP, Cheruvu S, et al. Determinants of 15-year outcome with 1,119 standard Carpentier-Edwards porcine valves. Ann Thorac Surg 1998; 66:S44.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/57/25497/abstract/14\">",
"      Poirer NC, Pelletier LC, Pellerin M, Carrier M. 15-year experience with the Carpentier-Edwards pericardial bioprosthesis. Ann Thorac Surg 1998; 66:S57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/57/25497/abstract/15\">",
"      Yun KL, Miller DC, Moore KA, et al. Durability of the Hancock MO bioprosthesis compared with standard aortic valve bioprostheses. Ann Thorac Surg 1995; 60:S221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/57/25497/abstract/16\">",
"      Rahimtoola SH. Choice of prosthetic heart valve for adult patients. J Am Coll Cardiol 2003; 41:893.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/57/25497/abstract/17\">",
"      Blot WJ, Ibrahim MA, Ivey TD, et al. Twenty-five-year experience with the Bj&ouml;rk-Shiley convexoconcave heart valve: a continuing clinical concern. Circulation 2005; 111:2850.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/57/25497/abstract/18\">",
"      Deviri E, Sareli P, Wisenbaugh T, Cronje SL. Obstruction of mechanical heart valve prostheses: clinical aspects and surgical management. J Am Coll Cardiol 1991; 17:646.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/57/25497/abstract/19\">",
"      Roudaut R, Lafitte S, Roudaut MF, et al. Fibrinolysis of mechanical prosthetic valve thrombosis: a single-center study of 127 cases. J Am Coll Cardiol 2003; 41:653.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/57/25497/abstract/20\">",
"      D&uuml;rrleman N, Pellerin M, Bouchard D, et al. Prosthetic valve thrombosis: twenty-year experience at the Montreal Heart Institute. J Thorac Cardiovasc Surg 2004; 127:1388.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/57/25497/abstract/21\">",
"      Girard SE, Miller FA Jr, Orszulak TA, et al. Reoperation for prosthetic aortic valve obstruction in the era of echocardiography: trends in diagnostic testing and comparison with surgical findings. J Am Coll Cardiol 2001; 37:579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/57/25497/abstract/22\">",
"      Alpert JS. The thrombosed prosthetic valve: current recommendations based on evidence from the literature. J Am Coll Cardiol 2003; 41:659.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/57/25497/abstract/23\">",
"      Montorsi P, De Bernardi F, Muratori M, et al. Role of cine-fluoroscopy, transthoracic, and transesophageal echocardiography in patients with suspected prosthetic heart valve thrombosis. Am J Cardiol 2000; 85:58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/57/25497/abstract/24\">",
"      Gupta D, Kothari SS, Bahl VK, et al. Thrombolytic therapy for prosthetic valve thrombosis: short- and long-term results. Am Heart J 2000; 140:906.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/57/25497/abstract/25\">",
"      Ozkan M, Kaymaz C, Kirma C, et al. Intravenous thrombolytic treatment of mechanical prosthetic valve thrombosis: a study using serial transesophageal echocardiography. J Am Coll Cardiol 2000; 35:1881.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/57/25497/abstract/26\">",
"      Lengyel M, Fuster V, Keltai M, et al. Guidelines for management of left-sided prosthetic valve thrombosis: a role for thrombolytic therapy. Consensus Conference on Prosthetic Valve Thrombosis. J Am Coll Cardiol 1997; 30:1521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/57/25497/abstract/27\">",
"      Shapira Y, Herz I, Vaturi M, et al. Thrombolysis is an effective and safe therapy in stuck bileaflet mitral valves in the absence of high-risk thrombi. J Am Coll Cardiol 2000; 35:1874.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/57/25497/abstract/28\">",
"      Vitale N, Renzulli A, Cerasuolo F, et al. Prosthetic valve obstruction: thrombolysis versus operation. Ann Thorac Surg 1994; 57:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/57/25497/abstract/29\">",
"      Tong AT, Roudaut R, Ozkan M, et al. Transesophageal echocardiography improves risk assessment of thrombolysis of prosthetic valve thrombosis: results of the international PRO-TEE registry. J Am Coll Cardiol 2004; 43:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/57/25497/abstract/30\">",
"      Salem DN, O'Gara PT, Madias C, et al. Valvular and structural heart disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133:593S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/57/25497/abstract/31\">",
"      Barbetseas J, Nagueh SF, Pitsavos C, et al. Differentiating thrombus from pannus formation in obstructed mechanical prosthetic valves: an evaluation of clinical, transthoracic and transesophageal echocardiographic parameters. J Am Coll Cardiol 1998; 32:1410.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/57/25497/abstract/32\">",
"      Barbetseas J, Pitsavos C, Aggeli C, et al. Comparison of frequency of left atrial thrombus in patients with mechanical prosthetic cardiac valves and stroke versus transient ischemic attacks. Am J Cardiol 1997; 80:526.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/57/25497/abstract/33\">",
"      Shiran A, Weissman NJ, Merdler A, et al. Transesophageal echocardiographic findings in patients with nonobstructed prosthetic valves and suspected cardiac source of embolism. Am J Cardiol 2001; 88:1441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/57/25497/abstract/34\">",
"      Cannegieter SC, Rosendaal FR, Wintzen AR, et al. Optimal oral anticoagulant therapy in patients with mechanical heart valves. N Engl J Med 1995; 333:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/57/25497/abstract/35\">",
"      Cannegieter SC, Rosendaal FR, Bri&euml;t E. Thromboembolic and bleeding complications in patients with mechanical heart valve prostheses. Circulation 1994; 89:635.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/57/25497/abstract/36\">",
"      North RA, Sadler L, Stewart AW, et al. Long-term survival and valve-related complications in young women with cardiac valve replacements. Circulation 1999; 99:2669.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/57/25497/abstract/37\">",
"      Garcia MJ, Vandervoort P, Stewart WJ, et al. Mechanisms of hemolysis with mitral prosthetic regurgitation. Study using transesophageal echocardiography and fluid dynamic simulation. J Am Coll Cardiol 1996; 27:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/57/25497/abstract/38\">",
"      Kloster FE. Diagnosis and management of complications of prosthetic heart valves. Am J Cardiol 1975; 35:872.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/57/25497/abstract/39\">",
"      Ismeno G, Renzulli A, Carozza A, et al. Intravascular hemolysis after mitral and aortic valve replacement with different types of mechanical prostheses. Int J Cardiol 1999; 69:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/57/25497/abstract/40\">",
"      Skoularigis J, Essop MR, Skudicky D, et al. Frequency and severity of intravascular hemolysis after left-sided cardiac valve replacement with Medtronic Hall and St. Jude Medical prostheses, and influence of prosthetic type, position, size and number. Am J Cardiol 1993; 71:587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/57/25497/abstract/41\">",
"      Enzenauer RJ, Berenberg JL, Cassell PF Jr. Microangiopathic hemolytic anemia as the initial manifestation of porcine valve failure. South Med J 1990; 83:912.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/57/25497/abstract/42\">",
"      Maraj R, Jacobs LE, Ioli A, Kotler MN. Evaluation of hemolysis in patients with prosthetic heart valves. Clin Cardiol 1998; 21:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/57/25497/abstract/43\">",
"      Hirawat S, Lichtman SM, Allen SL. Recombinant human erythropoietin use in hemolytic anemia due to prosthetic heart valves: a promising treatment. Am J Hematol 2001; 66:224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/57/25497/abstract/44\">",
"      Ruel M, Chan V, B&eacute;dard P, et al. Very long-term survival implications of heart valve replacement with tissue versus mechanical prostheses in adults &lt;60 years of age. Circulation 2007; 116:I294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/57/25497/abstract/45\">",
"      Piehler JM, Blackstone EH, Bailey KR, et al. Reoperation on prosthetic heart values. Patient-specific estimates of in-hospital events. J Thorac Cardiovasc Surg 1995; 109:30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/57/25497/abstract/46\">",
"      O'Neill WW, Chandler JG, Gordon RE, et al. Radiographic detection of strut separations in Bj&ouml;rk-Shiley convexo-concave mitral valves. N Engl J Med 1995; 333:414.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/57/25497/abstract/47\">",
"      van Gorp MJ, Steyerberg EW, Kallewaard M, van der Graaf Y. Clinical prediction rule for 30-day mortality in Bj&ouml;rk-Shiley convexo-concave valve replacement. J Clin Epidemiol 2003; 56:1006.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/57/25497/abstract/48\">",
"      van Gorp MJ, Steyerberg EW, Van der Graaf Y. Decision guidelines for prophylactic replacement of Bj&ouml;rk-Shiley convexo-concave heart valves: impact on clinical practice. Circulation 2004; 109:2092.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8121 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-178.219.2.221-6D749065E6-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_57_25497=[""].join("\n");
var outline_f24_57_25497=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H11276806\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      FREQUENCY OF COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Mechanical versus bioprosthetic valves",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      SERIAL MONITORING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      STRUCTURAL FAILURE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11276958\">",
"      Spectrum of paravalvular regurgitation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Long-term outcomes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      BSCC valve",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      VALVE OBSTRUCTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Valve thrombosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Treatment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Recommendations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Pannus formation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      SYSTEMIC EMBOLIZATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      BLEEDING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      ENDOCARDITIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      LEFT VENTRICULAR SYSTOLIC DYSFUNCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      HEMOLYTIC ANEMIA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      REPLACEMENT OF A PROSTHETIC VALVE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Mortality and morbidity",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - BSCC valve replacement",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11276806\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12962622\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/8121\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/8121|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?23/11/23734\" title=\"picture 1\">",
"      Waring blender syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/8121|MOV\">",
"      <a href=\"#\" title=\"MOVIES\">",
"       MOVIES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?40/16/41230\" title=\"movie 1\">",
"      TEE prosthetic mitral valve vegetation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?25/30/26082\" title=\"movie 2\">",
"      TEE mechanical mitral valve vegetations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/8121|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?10/58/11181\" title=\"table 1\">",
"      FDA approved prosthetic valves",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?9/61/10204\" title=\"table 2\">",
"      ACC AHA selection aortic valve",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?28/61/29659\" title=\"table 3\">",
"      ACC AHA selection mitral valve",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?5/54/5996\" title=\"table 4\">",
"      Followup prosthetic heart valve",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?3/2/3117\" title=\"table 5\">",
"      Methods to assess cardiovascular disability",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?6/45/6876\" title=\"table 6\">",
"      Rx prosthetic valve thrombosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/40/33415?source=related_link\">",
"      Anticoagulant and antiplatelet therapy in patients with infective endocarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/57/34712?source=related_link\">",
"      Antimicrobial therapy of prosthetic valve endocarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/11/18618?source=related_link\">",
"      Antithrombotic therapy in patients with prosthetic heart valves",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/29/25050?source=related_link\">",
"      Course and management of chronic aortic regurgitation in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/18/6438?source=related_link\">",
"      Echocardiographic evaluation of prosthetic heart valves",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/40/2697?source=related_link\">",
"      Epidemiology, clinical manifestations, and diagnosis of prosthetic valve endocarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/62/9194?source=related_link\">",
"      Extrinsic nonimmune hemolytic anemia due to mechanical damage: Fragmentation hemolysis and hypersplenism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/56/15238?source=related_link\">",
"      Management of patients with prosthetic heart valves",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/63/38906?source=related_link\">",
"      Overview of the therapy of heart failure due to systolic dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?11/23/11635?source=related_link\">",
"      Patient information: Prosthetic valves (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/32/3591?source=related_link\">",
"      Surgery for prosthetic valve endocarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/53/36697?source=related_link\">",
"      Surgical procedures for severe chronic mitral regurgitation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/37/11865?source=related_link\">",
"      Surgical valve replacement in aortic stenosis in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f24_57_25498="Immunizations after hematopoietic cell transplantation";
var content_f24_57_25498=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Immunizations after hematopoietic cell transplantation",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/57/25498/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/57/25498/contributors\">",
"     Patricia L Hibberd, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/57/25498/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/57/25498/contributors\">",
"     Michael Boeckh, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/57/25498/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/57/25498/contributors\">",
"     Anna R Thorner, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?24/57/25498/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 28, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prevention of infection is of paramount importance to the ever-increasing population of patients who have impaired immunity, such as those who have undergone hematopoietic cell transplantation (HCT). Infection in these patients often results in excessive morbidity and mortality, and antimicrobial therapy is typically less effective than in the unimpaired host [",
"    <a class=\"abstract\" href=\"UTD.htm?24/57/25498/abstract/1\">",
"     1",
"    </a>",
"    ]. Although immunization appears to be an obvious way to prevent infection, many patients with impaired immunity are unable to mount a protective immune response to active vaccination. Furthermore, immunization with live virus vaccines may result in unchecked proliferation of attenuated strains.",
"   </p>",
"   <p>",
"    The rationale for immunizing patients who have undergone HCT will be reviewed here. Issues related to immunizations in patients who have had or are waiting for a solid organ transplant, who have undergone chemotherapy for treatment of hematologic malignancies or solid tumors, or who have other immunocompromising conditions, including HIV infection, and in healthy adults and healthcare workers are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/48/23306?source=see_link\">",
"     \"Immunizations in solid organ transplant candidates and recipients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/37/30296?source=see_link\">",
"     \"Immunizations in patients with cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/25/37273?source=see_link\">",
"     \"Immunizations in HIV-infected patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/44/41670?source=see_link\">",
"     \"Approach to immunizations in healthy adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/0/13322?source=see_link\">",
"     \"Immunizations for healthcare providers\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     OVERVIEW",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk of acquiring infection and the inability to prevent infection by immunization are directly related to the patient's \"net state of immunosuppression\" or severity of disease. The greater the degree of immunosuppression, the less likely the patient is to respond to immunization. Although certain vaccines provide some benefit to the immunocompromised patient, an adequate response cannot be assumed. Successful protection of the immunocompromised adult may require the use of vaccines",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    passive immunization (ie, immune globulin) as well as adjunctive measures, such as antiviral drug prophylaxis during influenza A outbreaks. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/13/44249?source=see_link\">",
"     \"Prevention of seasonal influenza in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The degree of immunosuppression after hematopoietic cell transplantation (HCT) varies with the type of transplant.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      After allogeneic HCT, the immune system of the recipient is replaced by the immune system of the donor. The factors contributing to the patient's \"net state of immunosuppression\" are the preparative regimen for HCT, the presence of graft-versus-host disease (GVHD), and the immunosuppressive therapy administered after transplantation.",
"     </li>",
"     <li>",
"      Since there is no immunologic disparity between graft and host after autologous HCT, the factors contributing to the \"net state of immunosuppression\" are the high dose chemotherapy and radiotherapy administered before transplantation as well as the underlying disease.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Both autologous and allogeneic HCT recipients are at risk of developing infectious complications during the period of immune reconstitution. Both types of HCT recipients initially have profound humoral and cell-mediated immunodeficiency, but gradually recover to the point of being capable of functional B and T cell responses [",
"    <a class=\"abstract\" href=\"UTD.htm?24/57/25498/abstract/2\">",
"     2",
"    </a>",
"    ]. Although controversial, CD4 count recovery provides a reasonable guide to immune system recovery [",
"    <a class=\"abstract\" href=\"UTD.htm?24/57/25498/abstract/3-5\">",
"     3-5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The challenge is to maintain protective immunity through this period of profound immunosuppression when the recipient is unable to respond to immunization. Strategies focus on transferring, maintaining, and eventually eliciting protective immunity.",
"   </p>",
"   <p>",
"    Surveys performed in Europe and the United States have shown that immunization practices after HCT vary widely [",
"    <a class=\"abstract\" href=\"UTD.htm?24/57/25498/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. In an attempt to standardize prophylactic strategies in HCT recipients, international guidelines were published in 2009 that include recommendations for immunizations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     GUIDELINES",
"    </span>",
"    &nbsp;&mdash;&nbsp;In 2009, guidelines for preventing infectious complications after HCT were published, which represent the collaboration of several organizations from Europe and North America, including the European Blood and Marrow Transplant Group, the American Society of Blood and Marrow Transplantation, the Canadian Blood and Marrow Transplant Group, the Infectious Diseases Society of America, and the US Centers for Disease Control and Prevention (",
"    <a class=\"graphic graphic_table graphicRef59497 \" href=\"UTD.htm?19/58/20397\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?24/57/25498/abstract/2\">",
"     2",
"    </a>",
"    ]. These guidelines replace the 2000 guidelines from the US Centers for Disease Control and Prevention [",
"    <a class=\"abstract\" href=\"UTD.htm?24/57/25498/abstract/8\">",
"     8",
"    </a>",
"    ]. The 2009 guidelines recommend earlier vaccination of HCT recipients compared with the 2000 guidelines. Our recommendations are generally in keeping with these guidelines.",
"   </p>",
"   <p>",
"    Although the 2009 guidelines make recommendations regarding the optimal time to initiate each of the vaccine series following HCT, no recommendations were made regarding dosing intervals when more than one dose is required given the lack of data regarding this issue [",
"    <a class=\"abstract\" href=\"UTD.htm?24/57/25498/abstract/2\">",
"     2",
"    </a>",
"    ]. However, European guidelines from 2005 made recommendations regarding dosing intervals; we have followed these recommendations where relevant [",
"    <a class=\"abstract\" href=\"UTD.htm?24/57/25498/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These recommendations are based largely upon small studies of transplant recipients or information extrapolated from healthy individuals when no information is available in HCT recipients. It is well recognized that vaccine responses vary by type of HCT (eg, allogeneic, autologous, umbilical cord blood, reduced intensity) but there are insufficient data to make separate recommendations for each type.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     INACTIVATED VACCINES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Tetanus, diphtheria, and pertussis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tetanus and diphtheria are rare in the developed world. However, tetanus remains common in the developing world and sporadic cases continue to occur in developed countries. Large epidemics of diphtheria have occurred in states of the former Soviet Union, and the disease remains endemic in parts of the developing world. The incidence of pertussis has been increasing in the United States and worldwide due largely to waning immunity among adolescents and adults (",
"    <a class=\"graphic graphic_figure graphicRef73317 \" href=\"UTD.htm?34/14/35053\">",
"     figure 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/11/7353?source=see_link\">",
"     \"Tetanus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/38/29287?source=see_link\">",
"     \"Epidemiology, pathophysiology and clinical manifestations of diphtheria\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/27/20918?source=see_link\">",
"     \"Microbiology, epidemiology, and pathogenesis of Bordetella pertussis infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A significant proportion of HCT recipients lack immunity to tetanus, diphtheria, and pertussis after transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?24/57/25498/abstract/10-14\">",
"     10-14",
"    </a>",
"    ]. Titers of both tetanus and diphtheria antibodies vary by age at transplantation, underlying diagnosis, dose intensity, duration of treatment before transplantation, and the transplantation conditioning regimen. Approximately 50 percent of allogeneic HCT recipients and 19 percent of autologous HCT recipients who had protective levels of tetanus antibody before transplantation become seronegative within one year of transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?24/57/25498/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. Only 36 percent of HCT recipients retain immunity to diphtheria [",
"    <a class=\"abstract\" href=\"UTD.htm?24/57/25498/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Diphtheria-pertussis",
"    </span>",
"    &nbsp;&mdash;&nbsp;HCT recipients due to receive the diphtheria and tetanus toxoid-containing booster vaccine should ideally receive the formulation that contains the full dose of diphtheria toxin (DT) rather than the one containing a reduced dose of diphtheria toxin (Td) since the former is more immunogenic in HCT recipients; the latter is used for booster immunizations of the general adult population in order to reduce local reactions that have been associated with DT [",
"    <a class=\"abstract\" href=\"UTD.htm?24/57/25498/abstract/2\">",
"     2",
"    </a>",
"    ]. Although DT is not approved for individuals &gt;7 years of age in the United States, it appears to be associated with a lower rate of adverse effects among HCT recipients compared with healthy adults. However, further research is needed before DT can be recommended in HCT recipients &ge;7 years of age. If Td is administered, then checking diphtheria titers following vaccination should be considered. (See",
"    <a class=\"local\" href=\"#H27\">",
"     'Serologic testing'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Since single doses of Td are associated with poor responses [",
"    <a class=\"abstract\" href=\"UTD.htm?24/57/25498/abstract/13,16\">",
"     13,16",
"    </a>",
"    ], in the US HCT recipients &ge;7 years of age should receive three doses of Td, one of which may be given in combination with acellular pertussis vaccine (Tdap), as discussed below (see",
"    <a class=\"local\" href=\"#H7\">",
"     'Pertussis'",
"    </a>",
"    below). Prior recommendations were for immunization with Td 12, 14, and 24 months after transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?24/57/25498/abstract/10\">",
"     10",
"    </a>",
"    ], but good responses have been achieved with regimens starting 6 months after transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?24/57/25498/abstract/14\">",
"     14",
"    </a>",
"    ]. The 2009 guidelines recommend beginning the series 6 to 12 months posttransplant, although no recommendations were made regarding the dosing interval [",
"    <a class=\"abstract\" href=\"UTD.htm?24/57/25498/abstract/2\">",
"     2",
"    </a>",
"    ]. The European 2005 recommendations suggest that doses should be spaced 1 to 3 months apart [",
"    <a class=\"abstract\" href=\"UTD.htm?24/57/25498/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    After the posttransplant series, tetanus and diphtheria booster vaccines can be administered according to routine recommendations for adults and children.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Pertussis",
"    </span>",
"    &nbsp;&mdash;&nbsp;There has been increasing concern about lack of pertussis immunity in adolescents and adults leading to revised recommendations from the United States Advisory Panel on Immunization Practices that all individuals aged 11 years or older receive a single reduced dose of pertussis vaccine with their next Td booster (as Tdap) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/57/25498/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. HCT recipients are particularly vulnerable to pertussis infection because of pulmonary damage due to chemotherapy",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    total body irradiation. In one study, only 13.5 percent of HCT recipients had protective titers against pertussis after transplantation and only 2 of the 28 patients developed a twofold or greater response to vaccination with Tdap [",
"    <a class=\"abstract\" href=\"UTD.htm?24/57/25498/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the United States, the formulation that contains the full dose of the diphtheria and acellular pertussis components (DTaP) is only FDA-approved for children &lt;7 years of age, but it is the only formulation that is approved for multiple use. Although not supported by CDC recommendations because they have not been updated since 2000 [",
"    <a class=\"abstract\" href=\"UTD.htm?24/57/25498/abstract/8\">",
"     8",
"    </a>",
"    ], it seems reasonable to use one dose of Tdap followed by two doses of Td in HCT recipients &ge;7 years of age pending new information. In order to optimize the immune response to Tdap, we suggest administering Tdap at least 9 to 12 months following HCT, although this has not been adequately studied; the 2009 guidelines do not make a specific recommendation for or against the use of Tdap in HCT recipients or about the optimal timing of Tdap administration [",
"    <a class=\"abstract\" href=\"UTD.htm?24/57/25498/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Immunization of the donor prior to stem cell harvesting is likely to enhance immunity against tetanus and diphtheria toxoids in the HCT recipient; it is unknown whether donor vaccination against pertussis improves immunity against pertussis in the HCT recipient [",
"    <a class=\"abstract\" href=\"UTD.htm?24/57/25498/abstract/19\">",
"     19",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H28\">",
"     'Donor vaccination'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Vaccination against pertussis is discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/14/25833?source=see_link&amp;anchor=H23#H23\">",
"     \"Treatment and prevention of Bordetella pertussis infection in infants and children\", section on 'Vaccination'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/22/39271?source=see_link&amp;anchor=H12882667#H12882667\">",
"     \"Treatment and prevention of Bordetella pertussis infection in adolescents and adults\", section on 'Vaccination'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Poliovirus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately 33 percent of allogeneic HCT recipients lose protective antibody to all three",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/58/35749?source=see_link\">",
"     poliovirus vaccine",
"    </a>",
"    types 2 to 3 years after transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?24/57/25498/abstract/20\">",
"     20",
"    </a>",
"    ], whereas 20 percent of autologous transplant recipients become seronegative to at least one poliovirus vaccine type within the first transplant year [",
"    <a class=\"abstract\" href=\"UTD.htm?24/57/25498/abstract/21\">",
"     21",
"    </a>",
"    ]. In different studies, the inactivated poliovirus vaccine was moderately to highly immunogenic among HCT recipients [",
"    <a class=\"abstract\" href=\"UTD.htm?24/57/25498/abstract/20,22\">",
"     20,22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The inactivated poliovirus vaccination is recommended for all HCT recipients; the three-dose series should be initiated 6 to 12 months following transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?24/57/25498/abstract/2\">",
"     2",
"    </a>",
"    ]. As above, doses can be administered 1 to 3 months apart, per the 2005 European recommendations [",
"    <a class=\"abstract\" href=\"UTD.htm?24/57/25498/abstract/9\">",
"     9",
"    </a>",
"    ]. The live oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/58/35749?source=see_link\">",
"     poliovirus vaccine",
"    </a>",
"    should NOT be given to HCT recipients, their household contacts, or their health care providers. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/52/17223?source=see_link\">",
"     \"Poliovirus vaccination\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Encapsulated bacteria",
"    </span>",
"    &nbsp;&mdash;&nbsp;After the first 6 months following transplantation, HCT recipients are at increased risk for invasive disease from encapsulated bacteria such as Streptococcus pneumoniae and Haemophilus influenzae type b (Hib) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/57/25498/abstract/23-31\">",
"     23-31",
"    </a>",
"    ]. The risk is higher for allogeneic than autologous transplant recipients [",
"    <a class=\"abstract\" href=\"UTD.htm?24/57/25498/abstract/29\">",
"     29",
"    </a>",
"    ], and it is highest among allogeneic transplant recipients with graft-versus-host disease [",
"    <a class=\"abstract\" href=\"UTD.htm?24/57/25498/abstract/25-27\">",
"     25-27",
"    </a>",
"    ]. Invasive pneumococcal infection occurs in 3.8 per 1000 autologous HCT recipients, 8.23 per 1000 allogeneic HCT recipients and in 20.8 per 1000 with chronic GVHD [",
"    <a class=\"abstract\" href=\"UTD.htm?24/57/25498/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The incidence of Haemophilus influenzae type b infections is less well established in HCT recipients, although fatal infections due to this pathogen are rare. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/30/25066?source=see_link\">",
"     \"Overview of infections following hematopoietic cell transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The increased susceptibility to these organisms is caused by low serum anti-capsular antibody concentrations following transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?24/57/25498/abstract/27,30\">",
"     27,30",
"    </a>",
"    ]. In one study, for example, less than 30 percent of HCT recipients had protective antibodies against Hib one year after transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?24/57/25498/abstract/31\">",
"     31",
"    </a>",
"    ]. Immunization with all unconjugated polysaccharide vaccines (pneumococcus, Hib, and meningococcus) does not increase anti-capsular polysaccharide antibody concentrations because HCT recipients respond poorly to T cell-independent polysaccharide antigens [",
"    <a class=\"abstract\" href=\"UTD.htm?24/57/25498/abstract/30,33\">",
"     30,33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Fortunately, the polysaccharide-conjugate vaccines against H. influenzae and S. pneumoniae are promising alternatives to the unconjugated vaccines in HCT recipients [",
"    <a class=\"abstract\" href=\"UTD.htm?24/57/25498/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Pneumococcus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Inducing immunity against pneumococcus is challenging in HCT recipients because the 23-valent polysaccharide vaccine (PPSV23) is poorly immunogenic in this population, whereas conjugate pneumococcal vaccines are more immunogenic but cover fewer serotypes. The 2009 international guidelines for vaccination of HCT recipients recommend that HCT recipients receive three doses of the pneumococcal conjugate vaccine (eg, the 13-valent pneumococcal conjugate vaccine, PCV13) starting 3 to 6 months following transplantation (",
"    <a class=\"graphic graphic_table graphicRef59497 \" href=\"UTD.htm?19/58/20397\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/57/25498/abstract/2\">",
"     2",
"    </a>",
"    ]. A single dose of PPSV23 following the three-dose series of pneumococcal conjugate vaccine is also suggested in an attempt to broaden the immune response. For patients with chronic graft-versus-host disease, a fourth dose of pneumococcal conjugate vaccine should be given instead of PPSV23 since such patients respond particularly poorly to polysaccharide antigens.",
"   </p>",
"   <p>",
"    Although the guidelines do not make a recommendation regarding donor immunization, we favor donor immunization with the pneumococcal conjugate vaccine when feasible. (See",
"    <a class=\"local\" href=\"#H28\">",
"     'Donor vaccination'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Serologic testing following pneumococcal vaccination is suggested at one month or more following the third or fourth dose of vaccine [",
"    <a class=\"abstract\" href=\"UTD.htm?24/57/25498/abstract/2\">",
"     2",
"    </a>",
"    ]. However, it is unclear which of the available methods for serologic testing is optimal. There are no guidelines for revaccination of nonresponders since there is no accepted definition of an adequate serologic response. The European 2005 guidelines also suggest testing of pneumococcal immunity every 2 to 3 years in patients with chronic graft-versus-host disease, with revaccination in those lacking immunity [",
"    <a class=\"abstract\" href=\"UTD.htm?24/57/25498/abstract/9\">",
"     9",
"    </a>",
"    ]. Data from the Invasive Bacterial Diseases Network surveillance program in Canada indicate that the most frequent serotypes causing invasive pneumococcal disease in HCT recipients were 23F, 6B and 9V, all of which are included in PCV7, so it is reasonable to test for antibodies against the serotypes in PCV7 [",
"    <a class=\"abstract\" href=\"UTD.htm?24/57/25498/abstract/35\">",
"     35",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/48/24328?source=see_link\">",
"     \"Assessing the immunologic response to vaccination\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A trial evaluating the safety and immunogenicity of three doses of PCV13 followed by a dose of PPV23 in HCT recipients is ongoing [",
"    <a class=\"abstract\" href=\"UTD.htm?24/57/25498/abstract/36\">",
"     36",
"    </a>",
"    ]. Until the results are published, it seems reasonable to substitute PCV13 for the 7-valent pneumococcal conjugate vaccine (PCV7) that PCV13 has replaced in the United States. The data in support of use of PCV7 are discussed below.",
"   </p>",
"   <p>",
"    The superior immunogenicity of the conjugate compared with the polysaccharide pneumococcal vaccine was demonstrated in a trial of 64 pairs of donors and recipients scheduled to undergo HCT [",
"    <a class=\"abstract\" href=\"UTD.htm?24/57/25498/abstract/37\">",
"     37",
"    </a>",
"    ]. The pairs were randomly assigned to receive either PCV7 or PPSV23. The donors were vaccinated before transplantation and the recipients were vaccinated 6 months following transplantation. At 6 and 12 months, a response to at least one serotype was seen in significantly more patients receiving conjugate compared with polysaccharide vaccine (39 versus 0 percent at 6 months, 91 versus 56 percent at 12 months). However, the overall immunogenicity of both vaccines was found to be poor; patients receiving PPSV23 responded to a mean of only 1.8 serotypes, whereas those receiving PCV7 responded to a mean of only 3.1 serotypes.",
"   </p>",
"   <p>",
"    PCV7 elicits protective antibody responses when administered during the first year following HCT [",
"    <a class=\"abstract\" href=\"UTD.htm?24/57/25498/abstract/38,39\">",
"     38,39",
"    </a>",
"    ]. One trial has shown that initiating the PCV7 series 3 months following transplantation induces antibody responses that are not inferior to responses following a regimen initiated 9 months following transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?24/57/25498/abstract/39\">",
"     39",
"    </a>",
"    ]. Furthermore, vaccinating donors prior to stem cell harvesting enhances early immune responses in HCT recipients who are vaccinated with PCV7 at 3, 6, and 12 months following transplantation compared with recipients whose donors were not vaccinated [",
"    <a class=\"abstract\" href=\"UTD.htm?24/57/25498/abstract/40\">",
"     40",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H28\">",
"     'Donor vaccination'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Haemophilus influenzae",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Haemophilus influenzae type B (Hib) conjugate vaccine prevents invasive disease in infants and is recommended for routine childhood immunizations [",
"    <a class=\"abstract\" href=\"UTD.htm?24/57/25498/abstract/41\">",
"     41",
"    </a>",
"    ]. The Hib conjugate vaccine is well-tolerated and immunogenic in HCT recipients [",
"    <a class=\"abstract\" href=\"UTD.htm?24/57/25498/abstract/34,42,43\">",
"     34,42,43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The 2009 guidelines for vaccination of HCT recipients recommend that HCT recipients receive three doses of Hib conjugate vaccine starting 6 to 12 months following transplantation, dosed at 1 to 3 month intervals as per the European 2005 recommendations (",
"    <a class=\"graphic graphic_table graphicRef59497 \" href=\"UTD.htm?19/58/20397\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?24/57/25498/abstract/2,9\">",
"     2,9",
"    </a>",
"    ]. Although the guidelines do not make a recommendation regarding donor immunization, we favor this practice when feasible. (See",
"    <a class=\"local\" href=\"#H28\">",
"     'Donor vaccination'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Meningococcus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although little is known about the immunogenicity of meningococcal vaccination in HCT recipients, it is plausible that the conjugate vaccine is more immunogenic than the polysaccharide vaccine in this population since polysaccharide vaccines are known to generally be less immunogenic in HCT recipients than conjugate vaccines.",
"   </p>",
"   <p>",
"    The target groups for meningococcal vaccination of HCT recipients are similar to those in the general population; HCT recipients who are at increased risk of meningococcal disease (eg, asplenia, college students living in dormitories, and travelers to endemic regions) should be vaccinated. When indicated, the meningococcal conjugate vaccine should be administered as a single dose 6 to 12 months following transplantation (",
"    <a class=\"graphic graphic_table graphicRef59497 \" href=\"UTD.htm?19/58/20397\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?24/57/25498/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Influenza",
"    </span>",
"    &nbsp;&mdash;&nbsp;Influenza A and B infections can be life-threatening in HCT recipients [",
"    <a class=\"abstract\" href=\"UTD.htm?24/57/25498/abstract/44-47\">",
"     44-47",
"    </a>",
"    ]. In one series, 5 to 6 percent of HCT recipients admitted with a respiratory illness had influenza and, in more than half, upper respiratory tract infection progressed to pneumonia (invasive influenza or secondary bacterial or fungal disease), resulting in a 50 percent mortality rate [",
"    <a class=\"abstract\" href=\"UTD.htm?24/57/25498/abstract/47\">",
"     47",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/1/18456?source=see_link\">",
"     \"Clinical manifestations of seasonal influenza in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Timing of vaccine administration predicts the response. In one study, the response rate to influenza vaccine after HCT was zero if given in the first 6 months after transplant, 25 percent between months 6 and 24, and more than 60 percent after month 24 [",
"    <a class=\"abstract\" href=\"UTD.htm?24/57/25498/abstract/48\">",
"     48",
"    </a>",
"    ]. More recent data showed that influenza immunization at least 6 months after HCT was 80 percent effective in preventing influenza [",
"    <a class=\"abstract\" href=\"UTD.htm?24/57/25498/abstract/49\">",
"     49",
"    </a>",
"    ], and influenza-specific T-cell responses that might modify the course of infection could be elicited in patients vaccinated 3 to 6 months after HCT [",
"    <a class=\"abstract\" href=\"UTD.htm?24/57/25498/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Lifelong annual administration of the inactivated formulation of the influenza vaccine is recommended for all HCT candidates and recipients over 6 months of age; vaccination should ideally be performed beginning 4 to 6 months following transplantation (",
"    <a class=\"graphic graphic_table graphicRef59497 \" href=\"UTD.htm?19/58/20397\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?24/57/25498/abstract/2\">",
"     2",
"    </a>",
"    ]. In those who are vaccinated less than 6 months following transplantation, a second dose should be considered. Individuals &lt;9 years of age who have not previously been vaccinated against influenza should receive two doses of the influenza vaccine, approximately one month apart. The live attenuated (intranasal) formulation should NOT be given to HCT recipients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/8/37002?source=see_link\">",
"     \"Seasonal influenza vaccination in adults\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H18\">",
"     'Live vaccines'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/18/27946?source=see_link&amp;anchor=H7#H7\">",
"     \"Seasonal influenza vaccination in children\", section on 'Indications'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Adjunctive strategies for protection of HCT recipients involves immunizing close contacts and hospital staff, as well as chemoprophylaxis of HCT recipients in some cases. (See",
"    <a class=\"local\" href=\"#H29\">",
"     'Household contacts'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/8/37002?source=see_link\">",
"     \"Seasonal influenza vaccination in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/34/2599?source=see_link\">",
"     \"Infection control measures to prevent seasonal influenza in healthcare settings\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/13/44249?source=see_link\">",
"     \"Prevention of seasonal influenza in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/18/27946?source=see_link&amp;anchor=H7#H7\">",
"     \"Seasonal influenza vaccination in children\", section on 'Indications'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/7/26746?source=see_link&amp;anchor=H14#H14\">",
"     \"Antiviral drugs for the prevention and treatment of seasonal influenza in children\", section on 'Chemoprophylaxis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Hepatitis B",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hepatitis B is a well-recognized cause of morbidity and mortality in transplant recipients. However, universal immunization of HCT recipients is not recommended in the United States because of the elimination of HCT donors infected with hepatitis B. The risk of acquiring hepatitis B after transplantation remains low unless the recipient has well known risk factors such as receiving hemodialysis.",
"   </p>",
"   <p>",
"    Hepatitis B immunization is recommended for all HCT recipients who have risk factors for exposure to the virus. Autologous HCT recipients immunized close to transplantation and allogeneic recipients immunized after transplantation with recombinant HBsAg had variable and suboptimal responses [",
"    <a class=\"abstract\" href=\"UTD.htm?24/57/25498/abstract/51,52\">",
"     51,52",
"    </a>",
"    ]. In a study of 292 allogeneic transplant recipients, not receiving immunosuppression and considered immune competent, 64 percent seroconverted following immunization with recombinant",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/36/27207?source=see_link\">",
"     hepatitis B vaccine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?24/57/25498/abstract/53\">",
"     53",
"    </a>",
"    ]. In a multivariate analysis, factors significantly associated with a poor immunologic response included age &gt;18 years and previous chronic graft-versus-host disease.",
"   </p>",
"   <p>",
"    There are case reports of attempts to clear chronically infected HCT recipients by immunizing the donor with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/36/27207?source=see_link\">",
"     hepatitis B vaccine",
"    </a>",
"    and immunizing the recipient with hepatitis B vaccine in the early posttransplant period [",
"    <a class=\"abstract\" href=\"UTD.htm?24/57/25498/abstract/51,54\">",
"     51,54",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For HCT recipients who are positive for hepatitis B core antibody (HBcAb), hepatitis B vaccination is recommended because vaccination may reduce the risk of hepatitis B reactivation (",
"    <a class=\"graphic graphic_table graphicRef59497 \" href=\"UTD.htm?19/58/20397\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?24/57/25498/abstract/2\">",
"     2",
"    </a>",
"    ]. For individuals who are HBsAg- and HBcAb-negative, hepatitis B vaccination should be given according to recommendations for the general population. The three-dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/36/27207?source=see_link\">",
"     hepatitis B vaccine",
"    </a>",
"    series should be initiated 6 to 12 months following transplantation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/60/31690?source=see_link\">",
"     \"Hepatitis B virus vaccination\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Serologic testing to assess the response to hepatitis B vaccination is recommended &ge;1 month following the third dose [",
"    <a class=\"abstract\" href=\"UTD.htm?24/57/25498/abstract/2\">",
"     2",
"    </a>",
"    ]. A second three-dose series is recommended in nonresponders. In those with an obvious reason for a poor response, such as chronic graft-versus-host disease, it is preferable to wait until the underlying issue has improved.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Hepatitis A",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no data on the use of the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/30/44518?source=see_link\">",
"     hepatitis A vaccine",
"    </a>",
"    in HCT recipients. Hepatitis A vaccination should be given according to the recommendations for the general population&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?24/57/25498/abstract/2\">",
"     2",
"    </a>",
"    ]. Patients with chronic liver disease (eg, graft-versus-host disease, concurrent infection with other hepatitis viruses) may benefit from hepatitis A vaccine [",
"    <a class=\"abstract\" href=\"UTD.htm?24/57/25498/abstract/55\">",
"     55",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/38/1641?source=see_link\">",
"     \"Hepatitis A virus vaccination and postexposure prophylaxis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Indications for the use of hepatitis A immunoglobulin are discussed below. (See",
"    <a class=\"local\" href=\"#H24\">",
"     'Hepatitis A immunoglobulin'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Human papillomavirus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vaccination against human papillomavirus can be considered in HCT recipients who have an indication based upon recommendations for the general population, although there are no data regarding the efficacy among HCT recipients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/17/19738?source=see_link\">",
"     \"Recommendations for the use of human papillomavirus vaccines\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Varicella (inactivated)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two studies provide suggestive evidence that use of heat-inactivated",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/28/4551?source=see_link\">",
"     varicella vaccine",
"    </a>",
"    may be effective in reducing the incidence of herpes zoster in HCT recipients [",
"    <a class=\"abstract\" href=\"UTD.htm?24/57/25498/abstract/56,57\">",
"     56,57",
"    </a>",
"    ]. Although promising, heat-inactivated varicella vaccine has not been licensed and more studies are needed to establish its efficacy and safety.",
"   </p>",
"   <p>",
"    A trial in 111 recipients of autologous HCT for Hodgkin or non-Hodgkin lymphoma showed a significantly decreased rate of herpes zoster in those who received one dose of vaccine within 30 days before transplantation and at 30, 60, and 90 days after HCT compared with those who were not vaccinated (13 versus 30 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/57/25498/abstract/57\">",
"     57",
"    </a>",
"    ]. Stimulation of CD4 cell proliferation correlated with protection over a 12 month follow-up period.",
"   </p>",
"   <p>",
"    A small study evaluated heat-inactivated",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/28/4551?source=see_link\">",
"     varicella vaccine",
"    </a>",
"    in HCT recipients to assess early reconstitution of VZV immunity [",
"    <a class=\"abstract\" href=\"UTD.htm?24/57/25498/abstract/56\">",
"     56",
"    </a>",
"    ]. Among 14 HCT patients who received one dose of inactivated vaccine, VZV disease was not altered. However, disease severity was reduced among 24 patients who received three doses of the heat-inactivated vaccine; vaccinated individuals had fewer lesions and fewer individuals experienced fever or postherpetic neuralgia compared with an unvaccinated cohort.",
"   </p>",
"   <p>",
"    Further studies are needed to determine if heat-inactivated",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/28/4551?source=see_link\">",
"     varicella vaccine",
"    </a>",
"    is a practical approach for reducing VZV morbidity in HCT recipients and whether this heat-inactivated vaccine preparation will provide long-term efficacy.",
"   </p>",
"   <p>",
"    The use of the live",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/28/4551?source=see_link\">",
"     varicella vaccine",
"    </a>",
"    in HCT recipients is discussed below. (See",
"    <a class=\"local\" href=\"#H20\">",
"     'Varicella (live)'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     LIVE VACCINES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Live vaccines are generally avoided in HCT recipients, particularly during the early post-transplant period, although certain vaccines (measles, mumps, rubella; varicella) are indicated under some circumstances.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Measles, mumps, and rubella",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although measles, mumps, and rubella are vaccine-preventable diseases, outbreaks of measles and mumps continue to occur due to incomplete vaccination of the population. Measles can cause severe disease in immunocompromised patients as evidenced by an epidemic in HCT recipients that occurred in Sao Paulo, Brazil [",
"    <a class=\"abstract\" href=\"UTD.htm?24/57/25498/abstract/58\">",
"     58",
"    </a>",
"    ]. In addition, protection against rubella is important for female patients who may become pregnant. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/61/8154?source=see_link\">",
"     \"Epidemiology, clinical manifestations, diagnosis and management of mumps\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/14/26855?source=see_link\">",
"     \"Rubella\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Antibody titers to measles, mumps, and rubella decrease over time in HCT recipients [",
"    <a class=\"abstract\" href=\"UTD.htm?24/57/25498/abstract/59-61\">",
"     59-61",
"    </a>",
"    ]. In one report, for example, 24, 49, and 58 percent of allogeneic HCT recipients had lost antibody to measles, mumps, and rubella, respectively, 1 to 2 years after transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?24/57/25498/abstract/59\">",
"     59",
"    </a>",
"    ]. MMR appears to be safe and effective in both autologous and allogeneic HCT recipients [",
"    <a class=\"abstract\" href=\"UTD.htm?24/57/25498/abstract/34,59\">",
"     34,59",
"    </a>",
"    ]. In a study of 38 pediatric autologous or allogeneic HCT recipients, all patients developed protective antibodies to measles following vaccination [",
"    <a class=\"abstract\" href=\"UTD.htm?24/57/25498/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    MMR should be administered to all pediatric HCT recipients and to adult HCT recipients who are seronegative for measles; it should be given in one or two doses beginning 24 months following transplantation in patients who do not have active graft-versus-disease and are not receiving immunosuppression [",
"    <a class=\"abstract\" href=\"UTD.htm?24/57/25498/abstract/2\">",
"     2",
"    </a>",
"    ]. Women who had natural infection are much less likely to become seronegative to MMR than those who were previously immunized with MMR. In women who may become pregnant, vaccination against rubella, either as a single vaccine or in combination with measles and mumps vaccines, is recommended. However, those with active GVHD, or who remain on immunosuppression should not receive MMR [",
"    <a class=\"abstract\" href=\"UTD.htm?24/57/25498/abstract/9\">",
"     9",
"    </a>",
"    ]. In women who may become pregnant, it is reasonable to check antibodies to rubella after HCT and prior to vaccination with MMR.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Varicella (live)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Primary varicella infections cause severe and even fatal illness in both autologous and allogeneic HCT recipients, typically occurring in the first post-transplant year [",
"    <a class=\"abstract\" href=\"UTD.htm?24/57/25498/abstract/62\">",
"     62",
"    </a>",
"    ]. The safety and efficacy of live attenuated",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/28/4551?source=see_link\">",
"     varicella vaccine",
"    </a>",
"    , either before or after transplantation, are not well established.",
"   </p>",
"   <p>",
"    The live attenuated",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/28/4551?source=see_link\">",
"     varicella vaccine",
"    </a>",
"    was evaluated in 15 pediatric HCT recipients immunized 12 to 23 months after autologous or allogeneic transplant [",
"    <a class=\"abstract\" href=\"UTD.htm?24/57/25498/abstract/63\">",
"     63",
"    </a>",
"    ]. The vaccine was well tolerated and humoral immune responses were elicited in eight of nine patients, with persistence of responses in six patients after 2 years.",
"   </p>",
"   <p>",
"    There are two live vaccines to protect against infections caused by varicella-zoster virus. One is the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/28/4551?source=see_link\">",
"     varicella vaccine",
"    </a>",
"    that prevents chickenpox, and the other is the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/4/5190?source=see_link\">",
"     zoster vaccine",
"    </a>",
"    that prevents herpes zoster (shingles) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/57/25498/abstract/2\">",
"     2",
"    </a>",
"    ]. The varicella vaccine has lower viral titers than the zoster vaccine. The varicella vaccine can be used in HCT recipients with indications for varicella vaccination. In contrast, the zoster vaccine is not recommended.",
"   </p>",
"   <p>",
"    The",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/28/4551?source=see_link\">",
"     varicella vaccine",
"    </a>",
"    can be administered to HCT recipients who are seronegative, but should only be given &ge;24 months following transplantation in patients who do not have active graft-versus-disease and are not receiving immunosuppression [",
"    <a class=\"abstract\" href=\"UTD.htm?24/57/25498/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although not licensed, a heat-inactivated",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/28/4551?source=see_link\">",
"     varicella vaccine",
"    </a>",
"    has been developed, which could be a useful alternative to the live vaccine for HCT recipients; however, more studies are needed to establish its efficacy and safety. (See",
"    <a class=\"local\" href=\"#H17\">",
"     'Varicella (inactivated)'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     CONTRAINDICATED VACCINES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some vaccines are contraindicated in HCT due to safety concerns, particularly live vaccines,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    those that lack efficacy data. The following vaccines are contraindicated in HCT recipients: Bacillus Calmette-Guerin (BCG), oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/58/35749?source=see_link\">",
"     poliovirus vaccine",
"    </a>",
"    , intranasal influenza vaccine, cholera vaccine, oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/7/25718?source=see_link\">",
"     typhoid vaccine",
"    </a>",
"    , intramuscular typhoid vaccine, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/4/5190?source=see_link\">",
"     zoster vaccine",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?24/57/25498/abstract/2\">",
"     2",
"    </a>",
"    ]. The",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/50/42789?source=see_link\">",
"     rotavirus vaccine",
"    </a>",
"    must be given before 12 weeks of age due to safety issues in older individuals.",
"   </p>",
"   <p>",
"    The live vaccines that are indicated following HCT (eg, measles, mumps, and rubella; varicella) must be given only to those who meet specific criteria for timing",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    immune function. (See",
"    <a class=\"local\" href=\"#H19\">",
"     'Measles, mumps, and rubella'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H20\">",
"     'Varicella (live)'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     PASSIVE IMMUNIZATION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Varicella",
"    </span>",
"    &nbsp;&mdash;&nbsp;Varicella seronegative HCT recipients who were transplanted within the previous 24 months, as well as those requiring immunosuppression or having chronic graft-versus-host disease, should be given varicella-zoster immune globulin (VariZIG) within 10 days of close or household contact with a person with either chickenpox or shingles [",
"    <a class=\"abstract\" href=\"UTD.htm?24/57/25498/abstract/2,64\">",
"     2,64",
"    </a>",
"    ]. In addition, seronegative patients undergoing conditioning for HCT who are exposed to an individual who has a varicella-like rash following varicella vaccination should receive VariZIG. Close contact for adults is defined as continuous household contact, hospital contact in the same two- to four-bed room, or prolonged face-to-face contact with an infectious staff member.",
"   </p>",
"   <p>",
"    If VariZIG is not available, postexposure",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/44/39622?source=see_link\">",
"     valacyclovir",
"    </a>",
"    should be given [",
"    <a class=\"abstract\" href=\"UTD.htm?24/57/25498/abstract/2\">",
"     2",
"    </a>",
"    ]. HCT recipients who were seropositive prior to transplantation and who are highly immunosuppressed due to high-dose glucocorticoid therapy or a T-cell depleted allograft and who are exposed to an individual with chickenpox, shingles, or a post-vaccine varicella-like rash can also receive intravenous immunoglobulin (IVIG) or postexposure valacyclovir if VariZIG is not available.",
"   </p>",
"   <p>",
"    Details regarding formulation and dosing of VariZIG and antivirals are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/3/41016?source=see_link\">",
"     \"Post-exposure prophylaxis against varicella-zoster virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Hepatitis A immunoglobulin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hepatitis A-susceptible HCT recipients who anticipate possible exposure to hepatitis A (eg, during travel to endemic regions) or who have a known exposure should receive hepatitis A immunoglobulin (",
"    <a class=\"graphic graphic_figure graphicRef69392 \" href=\"UTD.htm?8/14/8424\">",
"     figure 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?24/57/25498/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/38/1641?source=see_link\">",
"     \"Hepatitis A virus vaccination and postexposure prophylaxis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Intravenous immunoglobulin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the rationale for considering passive antibody immunotherapy may be clear, the cost-effectiveness of using immune globulin preparations for the prevention of infections other than varicella and hepatitis A continues to be intensely debated and investigated. The possible use of intravenous immune globulin (IVIG) and CMV-specific immune globulin are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/57/32666?source=see_link&amp;anchor=H37#H37\">",
"     \"Prophylaxis of infections in hematopoietic cell transplant recipients\", section on 'Immunoglobulins'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Respiratory syncytial virus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Respiratory syncytial virus (RSV) is a serious cause of pneumonitis in HCT recipients that tends to occur in outbreaks; mortality rates are between 15 and 70 percent in cohorts with and without treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?24/57/25498/abstract/65-69\">",
"     65-69",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Preemptive therapy with aerosolized",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    has been recommended by some for HCT recipients who develop RSV upper respiratory tract infection during the first 3 months after transplant, particularly if they have lymphopenia, or at any time after transplantation if they have obstructive lung disease [",
"    <a class=\"abstract\" href=\"UTD.htm?24/57/25498/abstract/69,70\">",
"     69,70",
"    </a>",
"    ]. However, the only randomized trial to evaluate the efficacy of ribavirin to prevent RSV pneumonitis in this patient population was only able to conclude that aerosolized ribavirin appeared to be safe, due to an inability to recruit sufficient subjects to address efficacy. Small studies have used systemic ribavirin to prevent RSV pneumonitis, however, there are insufficient data to recommend this strategy [",
"    <a class=\"abstract\" href=\"UTD.htm?24/57/25498/abstract/66\">",
"     66",
"    </a>",
"    ]. Also, there is no evidence that preemptive",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/27/40371?source=see_link\">",
"     palivizumab",
"    </a>",
"    effectively prevents progression from upper to lower tract disease [",
"    <a class=\"abstract\" href=\"UTD.htm?24/57/25498/abstract/71\">",
"     71",
"    </a>",
"    ]. For pediatric patients aged 4 and younger, some HCT centers recommend month prophylaxis with palivizumab during RSV season, to prevent primary RSV pneumonitis, although this recommendation is also not supported by clinical trials. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/27/38327?source=see_link\">",
"     \"Respiratory syncytial virus infection: Treatment\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/17/15640?source=see_link&amp;anchor=H104282503#H104282503\">",
"     \"Respiratory syncytial virus infection: Prevention\", section on 'Immunocompromised'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     SEROLOGIC TESTING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serologic testing is recommended prior to measles and varicella vaccination in HCT recipients, and vaccination against these viruses should only be performed in individuals who are seronegative [",
"    <a class=\"abstract\" href=\"UTD.htm?24/57/25498/abstract/2\">",
"     2",
"    </a>",
"    ]. Although the 2009 guidelines do not address rubella specifically, we suggest that the same approach be used for rubella. Serologic testing following vaccination is recommended after pneumococcal and hepatitis B vaccination to document an adequate response.",
"   </p>",
"   <p>",
"    Periodic testing is also recommended in HCT recipients to assess for the maintenance of antibody responses [",
"    <a class=\"abstract\" href=\"UTD.htm?24/57/25498/abstract/2\">",
"     2",
"    </a>",
"    ]. Testing should be repeated approximately every 4 to 5 years to assess immunity to hepatitis B, measles, tetanus, diphtheria, and poliovirus. Testing for immunity to pneumococcus should also be considered every 2 years for the first 4 years after transplantation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h1\">",
"     DONOR VACCINATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal timing of immunization following HCT requires a balance between the ability to induce adequate immune responses, which increases over time, and the importance of providing protection during the highest risk period. As an example, the median time for developing invasive pneumococcal and Hib disease was about 9 months after transplantation in one study [",
"    <a class=\"abstract\" href=\"UTD.htm?24/57/25498/abstract/72\">",
"     72",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One possible approach to earlier protection has been shown in studies with Pseudomonas aeruginosa polysaccharide conjugate vaccine, diphtheria and tetanus toxoid vaccines, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/36/27207?source=see_link\">",
"     hepatitis B vaccine",
"    </a>",
"    : adoptive transfer of specific antibodies was achieved from immunized HCT donors to both non T-cell and T-cell depleted allogeneic HCT recipients [",
"    <a class=\"abstract\" href=\"UTD.htm?24/57/25498/abstract/73-77\">",
"     73-77",
"    </a>",
"    ]. In one report, for example, donors immunized with tetanus toxoid shortly before stem cell collection transferred a larger and more diverse tetanus toxoid-specific T cell repertoire to the recipient, indicating that donor immunization allows adoptive transfer of both B cells actively synthesizing antibody as well as antigen specific T cells [",
"    <a class=\"abstract\" href=\"UTD.htm?24/57/25498/abstract/76\">",
"     76",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Donor immunizations with tetanus toxoid, diphtheria toxoid, Haemophilus influenzae B conjugate vaccine, and pneumococcal conjugate vaccine have been shown to improve immunity in HCT recipients [",
"    <a class=\"abstract\" href=\"UTD.htm?24/57/25498/abstract/19,40,77,78\">",
"     19,40,77,78",
"    </a>",
"    ]. As an example, donor immunization with Hib conjugate vaccine resulted in significantly higher antibody concentrations in recipients of non T-cell depleted allogeneic transplants as early as 3 months posttransplant compared with recipients of unimmunized donors [",
"    <a class=\"abstract\" href=\"UTD.htm?24/57/25498/abstract/77\">",
"     77",
"    </a>",
"    ]. However, although this strategy may be effective, it is unlikely to be cost-effective for the prevention of invasive Hib disease in HCT recipients.",
"   </p>",
"   <p>",
"    The ability of donor immunization with pneumococcal conjugate vaccines to enhance early protective antibody response was seen in HCT recipients whose donors were randomly assigned to receive either a dose of PCV7 vaccine or no vaccine before transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?24/57/25498/abstract/40\">",
"     40",
"    </a>",
"    ]. Following transplantation all HCT recipients received PCV7 at 3, 6, and 12 months. After the first dose of vaccine, 76 percent of HCT recipients in the immunized donor group had protective antibody concentrations to all seven serotypes compared with 36 percent in the unimmunized donor group. This strategy may prove to be cost-effective since pneumococcal infections are more common than Hib infections during the first transplant year.",
"   </p>",
"   <p>",
"    The 2009 guidelines regarding immunization of HCT recipients do not make a recommendation regarding donor vaccination due to practical and ethical challenges [",
"    <a class=\"abstract\" href=\"UTD.htm?24/57/25498/abstract/2\">",
"     2",
"    </a>",
"    ]. We favor donor immunization prior to stem cell harvesting when it is feasible, such as when the donor is related to the recipient and agrees to being vaccinated in order to enhance the immune responses of the recipient. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Tetanus, diphtheria, and pertussis'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H10\">",
"     'Pneumococcus'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H11\">",
"     'Haemophilus influenzae'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h1\">",
"     HOUSEHOLD CONTACTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Household contacts should receive recommended routine vaccinations and should also receive annual influenza vaccination. When both inactivated and live attenuated vaccines are available to prevent an infection (eg, influenza, poliovirus), household members should receive the inactivated formulation to reduce the risk of transmission of the attenuated vaccine virus to the HCT recipient [",
"    <a class=\"abstract\" href=\"UTD.htm?24/57/25498/abstract/2\">",
"     2",
"    </a>",
"    ]. Household contacts with an indication for live vaccines should ideally receive them before the HCT candidate undergoes transplantation provided there are no contraindications. (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/44/41670?source=see_link\">",
"     \"Approach to immunizations in healthy adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/56/39818?source=see_link\">",
"     \"Standard immunizations for children and adolescents\"",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Under some circumstances, a household member may have received a live attenuated vaccine. The following precautions should be followed for preventing possible transmission of the attenuated vaccine virus to the HCT recipient when this situation arises [",
"    <a class=\"abstract\" href=\"UTD.htm?24/57/25498/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/58/35749?source=see_link\">",
"       Poliovirus vaccine",
"      </a>",
"      &mdash; All household contacts with an indication for poliovirus vaccination should receive the inactivated poliovirus vaccine rather than the oral formulation, which is a live attenuated vaccine. If a household member inadvertently receives the oral formulation, close contact between the household member and the HCT recipient should be avoided for 4 to 6 weeks. If avoidance of close contact is not possible, then the HCT recipient should practice stringent hand hygiene after contact with the feces of the vaccinee (eg, after changing a diaper) and avoid contact with saliva from the vaccinee, including not sharing food or eating utensils. Infants and children who have recently received the oral poliovirus vaccine should not visit the HCT unit for 4 to 6 weeks after receipt of the vaccine. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/52/17223?source=see_link\">",
"       \"Poliovirus vaccination\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/50/42789?source=see_link\">",
"       Rotavirus vaccine",
"      </a>",
"      &mdash; Two formulations of rotavirus vaccine, RV1 and RV5, are available. Both are live attenuated vaccines and used in infants. Although no cases of transmission of the attenuated vaccine virus have been reported, HCT recipients should avoid handling diapers of vaccinees. When this is not possible, HCT recipients should adhere to strict hand hygiene practices after contact with the vaccinees feces. Some HCT units prohibit infants who have received the rotavirus vaccine within the previous 2 to 4 weeks from visiting the HCT unit. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/62/40937?source=see_link&amp;anchor=H12#H12\">",
"       \"Rotavirus vaccines\", section on 'Viral shedding'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Influenza vaccine &mdash; All household members should be vaccinated with an inactivated formulation of the influenza vaccines rather than a live attenuated formulation. Annual influenza vaccination is recommended for all family members and close or household contacts beginning the season before HCT and continuing for 24 months after HCT, or longer when the HCT recipient's immunocompromise persists beyond 24 months following transplantation. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/8/37002?source=see_link\">",
"       \"Seasonal influenza vaccination in adults\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/18/27946?source=see_link&amp;anchor=H7#H7\">",
"       \"Seasonal influenza vaccination in children\", section on 'Indications'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/4/5190?source=see_link\">",
"       Zoster vaccine",
"      </a>",
"      &mdash; The",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/4/5190?source=see_link\">",
"       herpes zoster vaccine",
"      </a>",
"      is recommended for adults &ge;60 years of age in the United States. The 2009 guidelines do not make a recommendation regarding zoster vaccination of household contacts, although we suggest that this vaccine not be given to household contacts for 2 years following HCT. The decision of whether to vaccinate household contacts should be made on a case by case basis.",
"      <br/>",
"      <br/>",
"      Although no cases of transmission of the attenuated vaccine virus has been reported, HCT centers should prohibit visitors who develop a varicella- or zoster-like rash following vaccination from visiting. If a household member develops such a rash after vaccination against herpes zoster, he or she should avoid close contact with the HCT recipient and should keep the rash covered. Management of HCT recipients who have been exposed to an individual with a zoster-like rash is discussed above. (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Varicella'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/22/36200?source=see_link\">",
"       \"Prevention of varicella-zoster virus infection: Herpes zoster\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/28/4551?source=see_link\">",
"       Varicella vaccine",
"      </a>",
"      &mdash; Transmission of the attenuated varicella vaccine virus has been reported very rarely [",
"      <a class=\"abstract\" href=\"UTD.htm?24/57/25498/abstract/79\">",
"       79",
"      </a>",
"      ]. The 2009 guidelines recommend that household members who have not had varicella infection receive the varicella vaccine to protect the HCT recipient from potential exposure to wild-type virus. We suggest that household contacts be vaccinated before HCT has occurred when feasible. Individuals who develop a varicella-like rash within one month of vaccination should be prohibited from visiting the HCT unit and should avoid close contact with the HCT recipient in the home setting. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/26/37289?source=see_link\">",
"       \"Prevention of varicella-zoster virus infection: Chickenpox\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Measles, mumps, rubella vaccine &mdash; Household members should receive the measles, mumps, rubella (MMR) vaccine as indicated by age. Individuals who develop a fever",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      rash following vaccination should be prohibited from visiting the HCT until signs and symptoms have resolved and should avoid close contact with the HCT recipient in the home setting. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/56/39818?source=see_link\">",
"       \"Standard immunizations for children and adolescents\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/30/14822?source=see_link\">",
"       \"Measles-mumps-rubella vaccination in high risk adults\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h1\">",
"     TRAVELERS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Certain vaccines (rabies, tick-borne encephalitis, Japanese encephalitis, yellow fever) can be considered for travelers to endemic areas [",
"    <a class=\"abstract\" href=\"UTD.htm?24/57/25498/abstract/2\">",
"     2",
"    </a>",
"    ]. However, there are few data regarding the safety and efficacy of these vaccines in HCT recipients and the decision of whether to administer them should be based upon the individual patient's risk of infection and the potential adverse effects. Of these vaccines, only the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/13/14550?source=see_link\">",
"     yellow fever vaccine",
"    </a>",
"    is a live vaccine; it should only be used in HCT recipients who underwent transplantation &gt;24 months earlier, do not have active graft-versus-host disease and are not receiving immunosuppression.",
"   </p>",
"   <p>",
"    Immunizations in travelers are discussed in detail separately; the use of the different vaccines in HCT recipients must be considered in relation to the issues described in this topic. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/21/2394?source=see_link\">",
"     \"Immunizations for travel\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Prevention of infection is of paramount importance to the ever-increasing population of patients who have impaired immunity, such as those who have undergone hematopoietic cell transplantation (HCT). Although immunization appears to be an obvious way to prevent infection, many patients with impaired immunity are unable to mount a protective immune response to active vaccination. Furthermore, immunization with live virus vaccines may result in unchecked proliferation of attenuated strains. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Inactivated vaccines are safe, but are less immunogenic, in HCT recipients compared with immunocompetent individuals. Following transplantation, HCT recipients typically lose immunity to pathogens against which they were previously immunized. Thus, HCT recipients should be immunized against a number of pathogens such as pneumococcus, Haemophilus influenzae, tetanus, and others (",
"      <a class=\"graphic graphic_table graphicRef59497 \" href=\"UTD.htm?19/58/20397\">",
"       table 1",
"      </a>",
"      ). Most inactivated vaccine series should be initiated 6 to 12 months following transplantation. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Overview'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H4\">",
"       'Inactivated vaccines'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend using inactivated vaccines rather than live vaccines in HCT recipients when an inactivated formulation exists, such as with the poliovirus and influenza vaccines (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Live vaccines'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Serologic testing should be performed prior to measles, rubella, and varicella vaccination in HCT recipients. Serologic testing following vaccination is recommended after certain other vaccines to document an adequate response",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      assess for the maintenance of antibody responses over time. (See",
"      <a class=\"local\" href=\"#H27\">",
"       'Serologic testing'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest that the measles, mumps, and rubella vaccine be administered to all pediatric HCT recipients and to adult HCT recipients who are seronegative for measles (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). It should be given beginning 24 months following transplantation in patients who do not have active graft-versus-disease and are not receiving immunosuppression. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Measles, mumps, and rubella'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In women who are seronegative for rubella and who may become pregnant, we suggest vaccination against rubella (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Measles, mumps, and rubella'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/28/4551?source=see_link\">",
"       varicella vaccine",
"      </a>",
"      for HCT recipients who are seronegative, but it should only be given &ge;24 months following transplantation in patients who do not have active graft-versus-host disease and who are not receiving immunosuppression (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Varicella (live)'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Passive immunization is indicated in non-immune HCT recipients under certain circumstances, such as following exposure to an individual with varicella or hepatitis A infection. (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Passive immunization'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest donor vaccination of related donors with tetanus toxoid, diphtheria toxoid, conjugate pneumococcal vaccine (PCV7), and H. influenzae conjugate vaccine prior to stem cell harvesting when feasible (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H28\">",
"       'Donor vaccination'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Household contacts should receive recommended routine vaccinations and should also receive annual influenza vaccination. When both inactivated and live attenuated vaccines are available to prevent an infection (eg, influenza, poliovirus), household members should receive the inactivated formulation to reduce the risk of transmission of the attenuated vaccine virus to the HCT recipient. (See",
"      <a class=\"local\" href=\"#H29\">",
"       'Household contacts'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Certain vaccines (rabies, tick-borne encephalitis, Japanese encephalitis, yellow fever) can be considered for travelers to endemic areas. However, there are few data regarding the safety and efficacy of these vaccines in HCT recipients and the decision of whether to administer them should be based upon the individual patient's risk of infection and the potential adverse effects. (See",
"      <a class=\"local\" href=\"#H30\">",
"       'Travelers'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/57/25498/abstract/1\">",
"      Hibberd PL, Rubin RH. Approach to immunization in the immunosuppressed host. Infect Dis Clin North Am 1990; 4:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/57/25498/abstract/2\">",
"      Tomblyn M, Chiller T, Einsele H, et al. Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. Biol Blood Marrow Transplant 2009; 15:1143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/57/25498/abstract/3\">",
"      Berger M, Figari O, Bruno B, et al. Lymphocyte subsets recovery following allogeneic bone marrow transplantation (BMT): CD4+ cell count and transplant-related mortality. Bone Marrow Transplant 2008; 41:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/57/25498/abstract/4\">",
"      Talmadge JE. Lymphocyte subset recovery following allogeneic bone marrow transplantation: CD4(+)-cell count and transplant-related mortality. Bone Marrow Transplant 2008; 41:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/57/25498/abstract/5\">",
"      Kim DH, Sohn SK, Won DI, et al. Rapid helper T-cell recovery above 200 x 10 6/l at 3 months correlates to successful transplant outcomes after allogeneic stem cell transplantation. Bone Marrow Transplant 2006; 37:1119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/57/25498/abstract/6\">",
"      Ljungman P, Cordonnier C, de Bock R, et al. Immunisations after bone marrow transplantation: results of a European survey and recommendations from the infectious diseases working party of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 1995; 15:455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/57/25498/abstract/7\">",
"      Henning KJ, White MH, Sepkowitz KA, Armstrong D. A national survey of immunization practices following allogeneic bone marrow transplantation. JAMA 1997; 277:1148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/57/25498/abstract/8\">",
"      Centers for Disease Control and Prevention, Infectious Disease Society of America, American Society of Blood and Marrow Transplantation. Guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients. MMWR Recomm Rep 2000; 49:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/57/25498/abstract/9\">",
"      Ljungman P, Engelhard D, de la C&aacute;mara R, et al. Vaccination of stem cell transplant recipients: recommendations of the Infectious Diseases Working Party of the EBMT. Bone Marrow Transplant 2005; 35:737.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/57/25498/abstract/10\">",
"      Ljungman P, Wiklund-Hammarsten M, Duraj V, et al. Response to tetanus toxoid immunization after allogeneic bone marrow transplantation. J Infect Dis 1990; 162:496.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/57/25498/abstract/11\">",
"      Hammarstr&ouml;m V, Pauksen K, Bj&ouml;rkstrand B, et al. Tetanus immunity in autologous bone marrow and blood stem cell transplant recipients. Bone Marrow Transplant 1998; 22:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/57/25498/abstract/12\">",
"      Lum LG, Munn NA, Schanfield MS, Storb R. The detection of specific antibody formation to recall antigens after human bone marrow transplantation. Blood 1986; 67:582.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/57/25498/abstract/13\">",
"      Small TN, Zelenetz AD, Noy A, et al. Pertussis immunity and response to tetanus-reduced diphtheria-reduced pertussis vaccine (Tdap) after autologous peripheral blood stem cell transplantation. Biol Blood Marrow Transplant 2009; 15:1538.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/57/25498/abstract/14\">",
"      Parkkali T, Olander RM, Ruutu T, et al. A randomized comparison between early and late vaccination with tetanus toxoid vaccine after allogeneic BMT. Bone Marrow Transplant 1997; 19:933.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/57/25498/abstract/15\">",
"      Nord&oslash;y T, Husebekk A, Aaberge IS, et al. Humoral immunity to viral and bacterial antigens in lymphoma patients 4-10 years after high-dose therapy with ABMT. Serological responses to revaccinations according to EBMT guidelines. Bone Marrow Transplant 2001; 28:681.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/57/25498/abstract/16\">",
"      Gandhi MK, Egner W, Sizer L, et al. Antibody responses to vaccinations given within the first two years after transplant are similar between autologous peripheral blood stem cell and bone marrow transplant recipients. Bone Marrow Transplant 2001; 28:775.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/57/25498/abstract/17\">",
"      Centers for Disease Control and Prevention (CDC). Updated recommendations for use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis (Tdap) vaccine from the Advisory Committee on Immunization Practices, 2010. MMWR Morb Mortal Wkly Rep 2011; 60:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/57/25498/abstract/18\">",
"      Centers for Disease Control and Prevention (CDC). Updated recommendations for use of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccine in adults aged 65 years and older - Advisory Committee on Immunization Practices (ACIP), 2012. MMWR Morb Mortal Wkly Rep 2012; 61:468.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/57/25498/abstract/19\">",
"      Storek J, Dawson MA, Lim LC, et al. Efficacy of donor vaccination before hematopoietic cell transplantation and recipient vaccination both before and early after transplantation. Bone Marrow Transplant 2004; 33:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/57/25498/abstract/20\">",
"      Ljungman P, Duraj V, Magnius L. Response to immunization against polio after allogeneic marrow transplantation. Bone Marrow Transplant 1991; 7:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/57/25498/abstract/21\">",
"      Pauksen K, Hammarstr&ouml;m V, Ljungman P, et al. Immunity to poliovirus and immunization with inactivated poliovirus vaccine after autologous bone marrow transplantation. Clin Infect Dis 1994; 18:547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/57/25498/abstract/22\">",
"      Engelhard D, Handsher R, Naparstek E, et al. Immune response to polio vaccination in bone marrow transplant recipients. Bone Marrow Transplant 1991; 8:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/57/25498/abstract/23\">",
"      Atkinson K, Storb R, Prentice RL, et al. Analysis of late infections in 89 long-term survivors of bone marrow transplantation. Blood 1979; 53:720.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/57/25498/abstract/24\">",
"      Winston DJ, Schiffman G, Wang DC, et al. Pneumococcal infections after human bone-marrow transplantation. Ann Intern Med 1979; 91:835.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/57/25498/abstract/25\">",
"      Cordonnier C, Bernaudin JF, Bierling P, et al. Pulmonary complications occurring after allogeneic bone marrow transplantation. A study of 130 consecutive transplanted patients. Cancer 1986; 58:1047.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/57/25498/abstract/26\">",
"      Aucouturier P, Barra A, Intrator L, et al. Long lasting IgG subclass and antibacterial polysaccharide antibody deficiency after allogeneic bone marrow transplantation. Blood 1987; 70:779.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/57/25498/abstract/27\">",
"      Sheridan JF, Tutschka PJ, Sedmak DD, Copelan EA. Immunoglobulin G subclass deficiency and pneumococcal infection after allogeneic bone marrow transplantation. Blood 1990; 75:1583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/57/25498/abstract/28\">",
"      Hoyle C, Goldman JM. Life-threatening infections occurring more than 3 months after BMT. 18 UK Bone Marrow Transplant Teams. Bone Marrow Transplant 1994; 14:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/57/25498/abstract/29\">",
"      Rege K, Mehta J, Treleaven J, et al. Fatal pneumococcal infections following allogeneic bone marrow transplant. Bone Marrow Transplant 1994; 14:903.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/57/25498/abstract/30\">",
"      Winston DJ, Ho WG, Schiffman G, et al. Pneumococcal vaccination of recipients of bone marrow transplants. Arch Intern Med 1983; 143:1735.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/57/25498/abstract/31\">",
"      Vance E, George S, Guinan EC, et al. Comparison of multiple immunization schedules for Haemophilus influenzae type b-conjugate and tetanus toxoid vaccines following bone marrow transplantation. Bone Marrow Transplant 1998; 22:735.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/57/25498/abstract/32\">",
"      Engelhard D, Cordonnier C, Shaw PJ, et al. Early and late invasive pneumococcal infection following stem cell transplantation: a European Bone Marrow Transplantation survey. Br J Haematol 2002; 117:444.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/57/25498/abstract/33\">",
"      Giebink GS, Warkentin PI, Ramsay NK, Kersey JH. Titers of antibody to pneumococci in allogeneic bone marrow transplant recipients before and after vaccination with pneumococcal vaccine. J Infect Dis 1986; 154:590.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/57/25498/abstract/34\">",
"      Patel SR, Ort&iacute;n M, Cohen BJ, et al. Revaccination with measles, tetanus, poliovirus, Haemophilus influenzae type B, meningococcus C, and pneumococcus vaccines in children after hematopoietic stem cell transplantation. Clin Infect Dis 2007; 44:625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/57/25498/abstract/35\">",
"      Kumar D, Humar A, Plevneshi A, et al. Invasive pneumococcal disease in adult hematopoietic stem cell transplant recipients: a decade of prospective population-based surveillance. Bone Marrow Transplant 2008; 41:743.",
"     </a>",
"    </li>",
"    <li>",
"     Study to evaluate 13vPnC vaccine followed by 23vPS vaccine in allogeneic hematopoietic stem cell transplant recipients. file://clinicaltrials.gov/ct2/show/study/NCT00980655?term=pneumococcal+and+vaccine+and+transplant&amp;rank= (Accessed on June 09, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/57/25498/abstract/37\">",
"      Kumar D, Chen MH, Welsh B, et al. A randomized, double-blind trial of pneumococcal vaccination in adult allogeneic stem cell transplant donors and recipients. Clin Infect Dis 2007; 45:1576.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/57/25498/abstract/38\">",
"      Meisel R, Kuypers L, Dirksen U, et al. Pneumococcal conjugate vaccine provides early protective antibody responses in children after related and unrelated allogeneic hematopoietic stem cell transplantation. Blood 2007; 109:2322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/57/25498/abstract/39\">",
"      Cordonnier C, Labopin M, Chesnel V, et al. Randomized study of early versus late immunization with pneumococcal conjugate vaccine after allogeneic stem cell transplantation. Clin Infect Dis 2009; 48:1392.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/57/25498/abstract/40\">",
"      Molrine DC, Antin JH, Guinan EC, et al. Donor immunization with pneumococcal conjugate vaccine and early protective antibody responses following allogeneic hematopoietic cell transplantation. Blood 2003; 101:831.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/57/25498/abstract/41\">",
"      Black SB, Shinefield HR, Fireman B, et al. Efficacy in infancy of oligosaccharide conjugate Haemophilus influenzae type b (HbOC) vaccine in a United States population of 61,080 children. The Northern California Kaiser Permanente Vaccine Study Center Pediatrics Group. Pediatr Infect Dis J 1991; 10:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/57/25498/abstract/42\">",
"      Guinan EC, Molrine DC, Antin JH, et al. Polysaccharide conjugate vaccine responses in bone marrow transplant patients. Transplantation 1994; 57:677.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/57/25498/abstract/43\">",
"      Barra A, Cordonnier C, Preziosi MP, et al. Immunogenicity of Haemophilus influenzae type b conjugate vaccine in allogeneic bone marrow recipients. J Infect Dis 1992; 166:1021.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/57/25498/abstract/44\">",
"      Aschan J, Ringd&eacute;n O, Ljungman P, et al. Influenza B in transplant patients. Scand J Infect Dis 1989; 21:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/57/25498/abstract/45\">",
"      Ljungman P, Andersson J, Aschan J, et al. Influenza A in immunocompromised patients. Clin Infect Dis 1993; 17:244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/57/25498/abstract/46\">",
"      Whimbey E, Elting LS, Couch RB, et al. Influenza A virus infections among hospitalized adult bone marrow transplant recipients. Bone Marrow Transplant 1994; 13:437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/57/25498/abstract/47\">",
"      Whimbey E, Champlin RE, Couch RB, et al. Community respiratory virus infections among hospitalized adult bone marrow transplant recipients. Clin Infect Dis 1996; 22:778.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/57/25498/abstract/48\">",
"      Engelhard D, Nagler A, Hardan I, et al. Antibody response to a two-dose regimen of influenza vaccine in allogeneic T cell-depleted and autologous BMT recipients. Bone Marrow Transplant 1993; 11:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/57/25498/abstract/49\">",
"      Machado CM, Cardoso MR, da Rocha IF, et al. The benefit of influenza vaccination after bone marrow transplantation. Bone Marrow Transplant 2005; 36:897.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/57/25498/abstract/50\">",
"      Avetisyan G, Aschan J, Hassan M, Ljungman P. Evaluation of immune responses to seasonal influenza vaccination in healthy volunteers and in patients after stem cell transplantation. Transplantation 2008; 86:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/57/25498/abstract/51\">",
"      Ilan Y, Nagler A, Adler R, et al. Adoptive transfer of immunity to hepatitis B virus after T cell-depleted allogeneic bone marrow transplantation. Hepatology 1993; 18:246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/57/25498/abstract/52\">",
"      Nagler A, Ilan Y, Adler R, et al. Successful immunization of autologous bone marrow transplantation recipients against hepatitis B virus by active vaccination. Bone Marrow Transplant 1995; 15:475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/57/25498/abstract/53\">",
"      Jaffe D, Papadopoulos EB, Young JW, et al. Immunogenicity of recombinant hepatitis B vaccine (rHBV) in recipients of unrelated or related allogeneic hematopoietic cell (HC) transplants. Blood 2006; 108:2470.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/57/25498/abstract/54\">",
"      Brugger SA, Oesterreicher C, Hofmann H, et al. Hepatitis B virus clearance by transplantation of bone marrow from hepatitis B immunised donor. Lancet 1997; 349:996.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/57/25498/abstract/55\">",
"      Prevention of hepatitis A through active or passive immunization: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 1999; 48:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/57/25498/abstract/56\">",
"      Redman RL, Nader S, Zerboni L, et al. Early reconstitution of immunity and decreased severity of herpes zoster in bone marrow transplant recipients immunized with inactivated varicella vaccine. J Infect Dis 1997; 176:578.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/57/25498/abstract/57\">",
"      Hata A, Asanuma H, Rinki M, et al. Use of an inactivated varicella vaccine in recipients of hematopoietic-cell transplants. N Engl J Med 2002; 347:26.",
"     </a>",
"    </li>",
"    <li>",
"     Machado, C, Goncalves, F, Pannuti, C, et al. Measles in BMT recipients during an outbreak in Sao Paulo, Brazil. ICAAC abstract LB-24 Toronto, Canada, 1997.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/57/25498/abstract/59\">",
"      Ljungman P, Fridell E, L&ouml;nnqvist B, et al. Efficacy and safety of vaccination of marrow transplant recipients with a live attenuated measles, mumps, and rubella vaccine. J Infect Dis 1989; 159:610.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/57/25498/abstract/60\">",
"      Pauksen K, Duraj V, Ljungman P, et al. Immunity to and immunization against measles, rubella and mumps in patients after autologous bone marrow transplantation. Bone Marrow Transplant 1992; 9:427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/57/25498/abstract/61\">",
"      King SM, Saunders EF, Petric M, Gold R. Response to measles, mumps and rubella vaccine in paediatric bone marrow transplant recipients. Bone Marrow Transplant 1996; 17:633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/57/25498/abstract/62\">",
"      Han CS, Miller W, Haake R, Weisdorf D. Varicella zoster infection after bone marrow transplantation: incidence, risk factors and complications. Bone Marrow Transplant 1994; 13:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/57/25498/abstract/63\">",
"      Sauerbrei A, Prager J, Hengst U, et al. Varicella vaccination in children after bone marrow transplantation. Bone Marrow Transplant 1997; 20:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/57/25498/abstract/64\">",
"      Centers for Disease Control and Prevention (CDC). FDA approval of an extended period for administering VariZIG for postexposure prophylaxis of varicella. MMWR Morb Mortal Wkly Rep 2012; 61:212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/57/25498/abstract/65\">",
"      Harrington RD, Hooton TM, Hackman RC, et al. An outbreak of respiratory syncytial virus in a bone marrow transplant center. J Infect Dis 1992; 165:987.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/57/25498/abstract/66\">",
"      Khanna N, Widmer AF, Decker M, et al. Respiratory syncytial virus infection in patients with hematological diseases: single-center study and review of the literature. Clin Infect Dis 2008; 46:402.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/57/25498/abstract/67\">",
"      Small TN, Casson A, Malak SF, et al. Respiratory syncytial virus infection following hematopoietic stem cell transplantation. Bone Marrow Transplant 2002; 29:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/57/25498/abstract/68\">",
"      Boeckh M, Berrey MM, Bowden RA, et al. Phase 1 evaluation of the respiratory syncytial virus-specific monoclonal antibody palivizumab in recipients of hematopoietic stem cell transplants. J Infect Dis 2001; 184:350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/57/25498/abstract/69\">",
"      Chemaly RF, Ghosh S, Bodey GP, et al. Respiratory viral infections in adults with hematologic malignancies and human stem cell transplantation recipients: a retrospective study at a major cancer center. Medicine (Baltimore) 2006; 85:278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/57/25498/abstract/70\">",
"      Boeckh M, Englund J, Li Y, et al. Randomized controlled multicenter trial of aerosolized ribavirin for respiratory syncytial virus upper respiratory tract infection in hematopoietic cell transplant recipients. Clin Infect Dis 2007; 44:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/57/25498/abstract/71\">",
"      de Fontbrune FS, Robin M, Porcher R, et al. Palivizumab treatment of respiratory syncytial virus infection after allogeneic hematopoietic stem cell transplantation. Clin Infect Dis 2007; 45:1019.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/57/25498/abstract/72\">",
"      Kulkarni, S, Powles, R, Singhal, S, et al. Late pneumococcal infections in bone marrow transplant recipients: is penicillin prophylaxis inadequate? (abstract). Blood 1998; 92:320a.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/57/25498/abstract/73\">",
"      Wimperis JZ, Brenner MK, Prentice HG, et al. Transfer of a functioning humoral immune system in transplantation of T-lymphocyte-depleted bone marrow. Lancet 1986; 1:339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/57/25498/abstract/74\">",
"      Wimperis JZ, Brenner MK, Prentice HG, et al. B cell development and regulation after T cell-depleted marrow transplantation. J Immunol 1987; 138:2445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/57/25498/abstract/75\">",
"      Gottlieb DJ, Cryz SJ Jr, Furer E, et al. Immunity against Pseudomonas aeruginosa adoptively transferred to bone marrow transplant recipients. Blood 1990; 76:2470.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/57/25498/abstract/76\">",
"      Vavassori M, Maccario R, Moretta A, et al. Restricted TCR repertoire and long-term persistence of donor-derived antigen-experienced CD4+ T cells in allogeneic bone marrow transplantation recipients. J Immunol 1996; 157:5739.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/57/25498/abstract/77\">",
"      Molrine DC, Guinan EC, Antin JH, et al. Donor immunization with Haemophilus influenzae type b (HIB)-conjugate vaccine in allogeneic bone marrow transplantation. Blood 1996; 87:3012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/57/25498/abstract/78\">",
"      Parkkali T, K&auml;yhty H, Hovi T, et al. A randomized study on donor immunization with tetanus-diphtheria, Haemophilus influenzae type b and inactivated poliovirus vaccines to improve the recipient responses to the same vaccines after allogeneic bone marrow transplantation. Bone Marrow Transplant 2007; 39:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/57/25498/abstract/79\">",
"      Marin M, G&uuml;ris D, Chaves SS, et al. Prevention of varicella: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2007; 56:1.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3882 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-213.134.24.46-F1BE05E961-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_57_25498=[""].join("\n");
var outline_f24_57_25498=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H31\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      OVERVIEW",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      GUIDELINES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      INACTIVATED VACCINES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Tetanus, diphtheria, and pertussis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Diphtheria-pertussis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Pertussis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Poliovirus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Encapsulated bacteria",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Pneumococcus",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Haemophilus influenzae",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Meningococcus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Influenza",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Hepatitis B",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Hepatitis A",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Human papillomavirus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Varicella (inactivated)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      LIVE VACCINES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Measles, mumps, and rubella",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Varicella (live)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      CONTRAINDICATED VACCINES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      PASSIVE IMMUNIZATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Varicella",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Hepatitis A immunoglobulin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Intravenous immunoglobulin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Respiratory syncytial virus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      SEROLOGIC TESTING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      DONOR VACCINATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      HOUSEHOLD CONTACTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      TRAVELERS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/3882\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/3882|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?34/14/35053\" title=\"figure 1\">",
"      Incidence pertussis US 1990 to 2011",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?8/14/8424\" title=\"figure 2\">",
"      Geography hepatitis A",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/3882|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?19/58/20397\" title=\"table 1\">",
"      Vaccines for HCT recipients",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/7/26746?source=related_link\">",
"      Antiviral drugs for the prevention and treatment of seasonal influenza in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/44/41670?source=related_link\">",
"      Approach to immunizations in healthy adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/48/24328?source=related_link\">",
"      Assessing the immunologic response to vaccination",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/1/18456?source=related_link\">",
"      Clinical manifestations of seasonal influenza in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/61/8154?source=related_link\">",
"      Epidemiology, clinical manifestations, diagnosis and management of mumps",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/38/29287?source=related_link\">",
"      Epidemiology, pathophysiology and clinical manifestations of diphtheria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/38/1641?source=related_link\">",
"      Hepatitis A virus vaccination and postexposure prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/60/31690?source=related_link\">",
"      Hepatitis B virus vaccination",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/0/13322?source=related_link\">",
"      Immunizations for healthcare providers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/21/2394?source=related_link\">",
"      Immunizations for travel",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/25/37273?source=related_link\">",
"      Immunizations in HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/37/30296?source=related_link\">",
"      Immunizations in patients with cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/48/23306?source=related_link\">",
"      Immunizations in solid organ transplant candidates and recipients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/34/2599?source=related_link\">",
"      Infection control measures to prevent seasonal influenza in healthcare settings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/30/14822?source=related_link\">",
"      Measles-mumps-rubella vaccination in high risk adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/27/20918?source=related_link\">",
"      Microbiology, epidemiology, and pathogenesis of Bordetella pertussis infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/30/25066?source=related_link\">",
"      Overview of infections following hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/52/17223?source=related_link\">",
"      Poliovirus vaccination",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/3/41016?source=related_link\">",
"      Post-exposure prophylaxis against varicella-zoster virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/13/44249?source=related_link\">",
"      Prevention of seasonal influenza in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/26/37289?source=related_link\">",
"      Prevention of varicella-zoster virus infection: Chickenpox",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/22/36200?source=related_link\">",
"      Prevention of varicella-zoster virus infection: Herpes zoster",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/57/32666?source=related_link\">",
"      Prophylaxis of infections in hematopoietic cell transplant recipients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/17/19738?source=related_link\">",
"      Recommendations for the use of human papillomavirus vaccines",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/17/15640?source=related_link\">",
"      Respiratory syncytial virus infection: Prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/27/38327?source=related_link\">",
"      Respiratory syncytial virus infection: Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/62/40937?source=related_link\">",
"      Rotavirus vaccines",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/14/26855?source=related_link\">",
"      Rubella",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/8/37002?source=related_link\">",
"      Seasonal influenza vaccination in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/18/27946?source=related_link\">",
"      Seasonal influenza vaccination in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/56/39818?source=related_link\">",
"      Standard immunizations for children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/11/7353?source=related_link\">",
"      Tetanus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/22/39271?source=related_link\">",
"      Treatment and prevention of Bordetella pertussis infection in adolescents and adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/14/25833?source=related_link\">",
"      Treatment and prevention of Bordetella pertussis infection in infants and children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f24_57_25499="Urine test drugs of abuse";
var content_f24_57_25499=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F58181&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F58181&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Urine testing for drugs of abuse",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup width=\"10%\">",
"     </colgroup>",
"     <colgroup span=\"2\" width=\"45%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Drug",
"       </td>",
"       <td class=\"subtitle1\">",
"        Duration of detectability in urine",
"       </td>",
"       <td class=\"subtitle1\">",
"        Drugs causing false positive preliminary urine screens",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Amphetamines",
"       </td>",
"       <td>",
"        2 to 3 days",
"       </td>",
"       <td>",
"        Ephedrine, pseudoephedrine, phenylephrine, selegiline, chlorpromazine, trazodone, bupropion, desipramine, amantadine, ranitidine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cocaine",
"       </td>",
"       <td>",
"        2 to 3 days",
"       </td>",
"       <td>",
"        Topical anesthetics containing cocaine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Marijuana",
"       </td>",
"       <td>",
"        1 to 7 days (light use); 1 month with chronic moderate to heavy use",
"       </td>",
"       <td>",
"        Ibuprofen, naproxyn, dronabinol, efavirenz, hemp seed oil",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Opiates",
"       </td>",
"       <td>",
"        1 to 3 days",
"       </td>",
"       <td>",
"        Rifampin, fluoroquinolones, poppy seeds, quinine in tonic water",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Phencyclidine",
"       </td>",
"       <td>",
"        7 to 14 days",
"       </td>",
"       <td>",
"        Ketamine, dextromethorphan",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: The Medical Letter 2002; 44:71.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_57_25499=[""].join("\n");
var outline_f24_57_25499=null;
var title_f24_57_25500="Etiologies of MVP";
var content_f24_57_25500=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F83655&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F83655&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Etiologies of mitral valve prolapse and mechanisms of regurgitation",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Disease",
"       </td>",
"       <td class=\"subtitle1\">",
"        Mechanism of regurgitation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Primary MVP",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Fibroelastic deficiency",
"       </td>",
"       <td>",
"        <p>",
"         Isolated prolapse of the mitral leaflet (commonly P2 scallop)",
"        </p>",
"        <p>",
"         Frequent chordal rupture",
"        </p>",
"        <p>",
"         Mild annular enlargement",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Forme fruste Barlow disease",
"       </td>",
"       <td>",
"        Intermediate",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Barlow disease",
"       </td>",
"       <td>",
"        <p>",
"         Diffusely thickened, redundant mitral leaflets",
"        </p>",
"        <p>",
"         Chordal elongation/rupture",
"        </p>",
"        <p>",
"         Severe annular enlargement",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Secondary MVP",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Associated with connective tissue disease*",
"       </td>",
"       <td>",
"        <p>",
"         Diffusely thickened, redundant mitral leaflets",
"        </p>",
"        <p>",
"         Chordal elongation/rupture",
"        </p>",
"        <p>",
"         Severe annular enlargement",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Associated with congenital heart disease",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        <p>",
"         Thickened, redundant mitral leaflets",
"        </p>",
"        <p>",
"         Chordal elongation/rupture possible",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Acute myocardial ischemia",
"       </td>",
"       <td>",
"        Papillary muscle dysfunction with secondary prolapse/papillary muscle rupture",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Acute rheumatic fever",
"       </td>",
"       <td>",
"        Chordal and leaflet destruction by acute inflammatory process",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Endocarditis",
"       </td>",
"       <td>",
"        Chordal and leaflet destruction by infectious process; vegetations",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Other (trauma, severe mitral annular calcification, hypertrophic cardiomyopathy)",
"       </td>",
"       <td>",
"        Ruptured chordae, no myxomatous changes of mitral valve leaflets",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Associated with Marfan and Ehlers-Danlos syndromes, osteogenesis imperfecta, and pseudoxanthoma elasticum. Macroscopical and microscopical appearance similar to primary Barlow disease.",
"     <br/>",
"     <span class=\"bullet\">",
"      &bull;",
"     </span>",
"     Most common congenital disease associations are Ebstein's anomaly and atrial septal defect.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_57_25500=[""].join("\n");
var outline_f24_57_25500=null;
var title_f24_57_25501="Motor unit loss in ALS";
var content_f24_57_25501=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F50926&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F50926&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 510px\">",
"   <div class=\"ttl\">",
"    Motor unit loss revealed by incremental motor unit number estimation (MUNE) in patients with amyotrophic lateral sclerosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 490px; height: 290px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Average motor unit decline in a group of ten ALS control subjects receiving placebo in a therapeutic trial, as measured by multiple point stimulation MUNE in the thenar muscle group. Patients were tracked at one to two month intervals over 18 months. Motor unit loss averaged 30 to 40 percent for every six months of disease progression.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Clifton Gooch, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_57_25501=[""].join("\n");
var outline_f24_57_25501=null;
var title_f24_57_25502="Changes in wheezing prevalence in children";
var content_f24_57_25502=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F71920&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F71920&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 569px\">",
"   <div class=\"ttl\">",
"    Changes in the percent of children wheezing in different countries 1960-2000 from ISAAC and ECRHS data",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 549px; height: 426px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     ISAAC: International Studies of Asthma and Allergies in Children; ECRHS: European Community Respiratory Health Survey.",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Drs. Thomas Platts-Mills and Scott Commins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_57_25502=[""].join("\n");
var outline_f24_57_25502=null;
var title_f24_57_25503="Bleeding esophageal varix";
var content_f24_57_25503=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F87067&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F87067&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Actively bleeding esophageal varix",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 271px; height: 236px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Endoscopic view of an actively bleeding esophageal varix. The varix was banded successfully, and the bleeding stopped.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_57_25503=[""].join("\n");
var outline_f24_57_25503=null;
